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ABSTRACT: 
 
TITLE: Analysis of Management of ITP: Single Centre Retrospective Comparison of Dapsone       
             and Azathioprine as second line  therapeutic agents 
DEPARTMENT   : Clinical Hematology, Christian Medical College, Vellore. 
  
DEGREE AND SUBJECT  : D.M. Clinical Hematology 
 
NAME OF THE GUIDE  : Dr. Biju George, Professor, Dept. of Clinical Hematology. 
 
Aims and Objectives of the study: To assess efficacy of dapsone and azathioprine children and 
adults with steroid refractory or steroid dependent ITP and relapsed ITP treated in our institute. 
Methodology: We included patients treated with either dapsone or azathioprine for steroid 
refractory/dependent or relapsed ITP during 5 year period (March 1st 2007 to March 1st 2012).  
Results: Three hundred patients were included in the study; 104(34.7%) children & 196(65.3%) 
adults. Median ITP duration was 5 months (1-262). Overall response over median treatment 
duration of 10 months (1-61) was 58.6%, with equivalent response (58.8% and 58.5%) with 
dapsone and azathioprine respectively. In children with steroid refractory/dependent ITP, 
dapsone exhibited significantly better response than azathioprine (p=0.023). Median response 
duration was significantly longer with azathioprine-60 months (2-60) than with dapsone 
(p=0.015). Relapses on therapy was higher with dapsone than azathioprine (p=0.007). Response 
less than CR & steroid refractory/dependent ITP were significant predictors of relapse on 
therapy.  There were no deaths and event free survival was significantly better with azathioprine.  
Conclusion: Present study confirms comparable efficacy of dapsone and azathioprine, although 
azathioprine produced more durable responses than dapsone. The findings of our study need to 
be validated in prospective randomized control setting. Keywords: ITP, dapsone, azathioprine. 
 
Introduction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction: 
Idiopathic thrombocytopenic purpura (ITP), also known as autoimmune thrombocytopenic 
purpura, is an entity characterized by isolated thrombocytopenia often occurring in the absence 
of identifiable and specific precipitants(1). It is an acquired disease that affects both children and 
adults and causes a transient or persistent decrease in platelet count. Depending upon the degree 
of thrombocytopenia it is associated with an increased risk of bleeding(2).  
Definition and Nomenclature: 
The definition and nomenclature of ITP has evolved since the first ever practice guideline was 
published in 1996 by the American Society of Hematologists(3) which used the acronym ITP for 
“idiopathic thrombocytopenic purpura”, emphasizing that it is a diagnosis of exclusion with no 
specific criteria for diagnosis. Thus the earliest definition of ITP is an isolated thrombocytopenia 
with no clinically apparent associated conditions or other causes of thrombocytopenia. The other 
causes of thrombocytopenia that were addressed were: HIV infection, systemic lupus erythe-
matosus, lymphoproliferative disorders, myelodysplasia, agammaglobulinemia or hypogamma-
globulinemia, drug-induced thrombocytopenia, alloimmune thrombocytopenia and congenital 
hereditary or non-immune thrombocytopenia(3). Subsequently in 2003, the British Committee 
for Standards in Hematology (BCSH) brought out a similar definition(4). In addition, the 
definition used peripheral blood platelet count of less than 150 x 109⁄l as threshold for diagnosis. 
In the most recent guidelines published by 2009 International Working Group (IWG)(2), the 
panel of investigators decided to persist with the widely used acronym ‘ITP’ but instead of 
“idiopathic” in ITP, proposed use of “immune”, to emphasize upon immune-mediated 
mechanism involved, and qualified it further by replacing “idiopathic” by “primary” to denote 
the absence of any obvious initiating and/or underlying cause. Further the panel acknowledged 
that it is inappropriate to use the term ‘pupura’ since review of literature showed that in large 
proportion of cases, bleeding symptoms were absent. Thus the acronym ITP would expand 
henceforth to “Immune ThrombocytoPenia” according the 2009 IWG guidelines(2).  
In their guidelines, the IWG panel came to a consensus of using peripheral blood platelet count 
of less than 100 x 109⁄l as opposed to the previous cut off of less than 150 x 109⁄l to define 
individuals who can be considered thrombocytopenic. The recommendations cite the following 
considerations as basis: Stasi et al(5) showed that patients presenting with platelet count between 
100 & 150x109⁄l have very low (6.9%) risk of persistent platelet count less than 100 x 109⁄l over 
10 years of follow-up(5); in ethnicities other than the Western, normal healthy individuals may 
have platelet counts ranging from 100 to 150x109⁄l. The present cutoff value of 100x109⁄l is also 
based on the hypothesis this would reduce concern over mild “physiologic” thrombocytopenia 
associated with pregnancy. 
The 2009 International Working Group(2) recognized that various trials evaluating patient 
characteristics, determine responses, and report clinical outcomes, used widely discrepant criteria 
of assessment(6). In their opinion, this heterogeneity had lead to uneven and therefore unreliable 
comparison, of the results of clinical trials or cohort description. In order to harmonize and 
standardize disease definitions for better application of practical guidelines, they proposed the 
following definitions(2). 
 
 
 
Table 1 Summary of Recommendations : Adapted from 2009 IWG criteria(2):  
Definitions Proposed by the International Working Group on ITP:(2) 
Primary ITP It is defined as an “autoimmune disorder”. There is isolated 
thrombocytopenia (peripheral blood platelet count <100 x109/L).  
Characteristically, other causes of isolated thrombocytopenia have to be 
excluded. Currently, there is lack of clinical or laboratory parameters for 
establishing diagnosis of ITP. ITP thus remains a diagnosis of exclusion. 
Secondary ITP All patients of ITP not satisfying criteria for primary ITP: The associated 
disease/disorder should be specified (SLE, Drug induced, pregnancy related, 
HIV associated) after the acronym of “secondary ITP”. 
Phases Newly diagnosed ITP: ITP duration is within 3 months of diagnosis 
Persistent ITP: ITP duration is between 3 to 12 months of diagnosis. This is 
new category in present guidelines proposed to include ITP within 12 
months of diagnosis since incidence of spontaneous remission is still 
significant. It includes patients who have not reached spontaneous remission 
or not maintaining complete response off therapy.  
Chronic ITP: Any ITP lasting beyond 12 months from diagnosis. 
Severe ITP: Any ITP with bleeding symptoms at onset of magnitude that in 
itself is an indication for treatment. Also includes bleeding requiring 
additional therapy with different platelet-enhancing agent or increased dose. 
Review of Literature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature: 
Epidemiology and Natural History: 
Adult chronic ITP has an incidence of 58–66 new cases per million population per year or nearly 
5.8–6.6 per 100,000 in the US(7) with a similar incidence in the UK. This form of ITP affects 
mainly women of childbearing age (Male: Female-1:3)(8). Adult patients with ITP are more 
likely to manifest disease with a chronic course. Overall, approximately 15% of patients remit 
within 1 year after disease onset, but rare late remissions occur, even among patients who have 
failed splenectomy (9). Symptomatic bleeding is to a degree related to the platelet count, with 
literature suggesting that almost all major bleeding occurring with platelet counts < 30 x109/L. 
The risk of bleeding was analyzed in a pooled analysis of published clinical series comprising 
1800 patients. Severe chronic ITP in adults was defined as platelet count < 30x109/L at least with 
1 year after diagnosis, The annual incidence of fatal hemorrhage was 1.6-3.9 cases per 100 
patient years, with a lower risk in patients < 40 years of age (0.4% per year) compared with 
patients > 60 years of age (13% per year)(9). Risk of nonfatal hemorrhage was estimated to be 
3% per year in patients 40 years of age and 71% per year for patients > 60 years of age(9).  
Childhood ITP has an incidence of between 4.0 and 5.3 per 100 000(10)(11). The peak age of 
presentation of ITP in children is between 5 and 6 years, with 70% of cases presenting between 
ages of 1 and 10 years. Approximately 50%-60% of children will have a febrile illness that 
preceded the discovery of thrombocytopenia(12). In a study of 863 children with newly 
diagnosed ITP13: a) none or mild bleeding manifestations in 77% patients, b).moderate bleeding 
occurred in 20%, and c).severe bleeding in 3%.13 d).Life-threatening bleeding is rare and the 
estimated risk of intracranial hemorrhage is between 0.1% & 0.5% in newly diagnosed cases(13). 
Approximately 65%-70% of children remit by 6 months and another 15%-20% by 12 months. 
The 5%-10% of children who develop chronic ITP tend to be older, are more often female and 
usually present with a higher platelet count(9).  
Medical Management of ITP: 
Goals of therapy(1): 
a) In children: For children with ITP, when treatment is given, it is initially aimed at 
rapidly increasing the platelet count to a safe level, then maintaining an adequate and safe 
count while awaiting as spontaneous remission(1). 
b) In adults: For adults, most of whom will have chronic ITP, therapies are used to increase 
the platelet count to a safe level and/or to prevent further bleeding with minimal 
toxicities. Maintenance of platelet count> 30 x 109/L is considered an appropriate goal(1). 
Table 2 : Options for Therapy: Adapted from International Consensus Report 2010 (14):  
First line Therapy 
 (Newly diagnosed ITP)  
Corticosteroids: dexamethasone, methylprednisolone, prednis(ol)one 
Anti-D, IVIg 
Second Line Therapy 
(Persistent/Chronic ITP) 
Surgical: Splenectomy 
Medical Therapy: Cyclosporin A, Cyclophosphamide, Danazol, 
Dapsone, Mycophenolate mofetil, Vinca alkaloids 
Rituximab 
TPO receptor agonists 
Treatment  Options for 
patients who have 
failed first- and 
second-line therapies 
 
 
A: TPO receptor agonists; Supported by adequate data. 
B: Campath-1H, Combination of first and second-line therapies, 
Combination chemotherapy, HSCT.  The report acknowledges that 
category A is preferred over category B since data supporting the 
former is more substantial, whereas for the later, apart from 
inadequate supportive data, there is considerable toxicity associated 
with the later approach.  
 
Steroids as First Line Therapy in Immune Thrombocytopenia(14) 
Corticosteroids (prednisolone, methylprednisolone or dexamethasone) are the standard initial 
treatment14. Investigators have also noted that they may reduce bleeding independent of the 
platelet count rise by means of a direct effect on blood vessels. The frequency of complete 
remission (CR) after a course of first-line therapy with corticosteroids, noted across various 
studies, ranges from 10%-30% with daily oral prednisone. Additionally, investigators claim 
responses of as much as 60%-80% with high-dose, pulsed dexamethasone (HDD).(15)(16)(17) 
However, the latter remains to be confirmed in controlled trials, and currently available evidence 
does not establish the superiority of HDD. Patients are at risk of developing corticosteroid-
related complications that vary with the dose and duration(14). Due to above reasons, it is not 
advisable to use multiple cycles of HDD to induce remission in patients who have failed a course 
of prednisone(18). 
 
Second line Therapy for Cortecosteroid refractory or relapsed ITP(14) 
The approach to treatment of steroid refractory and relapsed ITP hinges or two types of 
modalities of therapy: 
a) Medical management: These included the following agents: anti-CD20 therapy, Dapsone, 
Azathioprine, Cyclophosphamide, Cyclosporine, Combination Therapy 
b) Surgical Management: Splenectomy (Laparoscopic/Laparotomy). 
The 2003 BCSH guideline(4) maintains that the wide variety of treatments available for second 
line therapy reflects their relative lack of efficacy. In their view, these agents should be used in 
non-urgent or ‘semi-urgent’ cases where there is a need to elevate the platelet count. 
In 2010 the International consensus report for management of ITP guidelines(14), the goal of 
second-line therapy has been defined as the achievement of sustained increase of the platelet 
count that is considered hemostatic. The report lists more than 10 second line therapeutic 
options, including splenectomy, without indicating a preference. Azathioprine, danazol, 
cyclophosphamide, cyclosporine A, dapsone and mycophenolate mofetil have all shown limited 
efficacy in the treatment of ITP. No single agent induces un-maintained remission in >30% of 
refractory cases. This is particularly true in patients refractory to splenectomy(1).  
There is paucity of evidence-based medicine on this topic as noted by various groups across 
detailed reviews(19). Both the American Society of Hematology(14) and the British Committee 
for Standards in Haematology General Haematology Task Force(4) have issued “practice 
guidelines.” These are essentially a compilation of opinions from panels of experienced 
physicians who have agreed upon some but not all of the practices. Across all these reviews, 
there are many unresolved issues and the investigators also agree that the approach to treatment 
to these cases will change in future as more and more data emerges to answer these question(20).  
Dapsone and Azathioprine as Second Line Therapeutic Agents: 
The 2003 BCSH guidelines(4) comment that in patients treated with dapsone, half of all patients 
with chronic ITP will show some response within 3 weeks, but it appears to be less effective in 
severe cases of ITP. They cite the series of 66 adults with chronic ITP that included patients with 
platelet counts < 50 x109 ⁄ l and treated them with dapsone at 75–100 mg orally(21). Responses 
were observed in 33 of 66 patients (50%), with a median duration of treatment required to 
achieve a response of 21 days. Sustained responses were observed in 19 patients(21). Treatment 
with azathioprine (2 mg ⁄kg, usually up to a maximum of 150 mg ⁄d) as single agent may also be 
considered and up to 25% of patients may have a sustained response. Azathioprine is slow-
acting, and should be continued for up to 6 months before being deemed a failure(4). 
The 2010 International consensus report for management of ITP(14) comments that dapsone as 
second-line therapy in doses of 75mg/day to 100mg/day, has moderate corticosteroid effects. The 
report notes that response may be observed in up to 50% of patients treated with dapsone.  
The appropriate time to response is usually 3 weeks. Sustained response may be noted in up to 
two-thirds of responders to therapy. Guidelines have also noted that dapsone may delay 
splenectomy for up to 32 months in corticosteroid refractory patients but splenectomized patients 
have a low response rate (evidence level IIb)(14).  
 
 
Regarding azathioprine the 2010 International Consensus report takes into account that despite 
few new data, this agent is still useful(14). Investigators have reported complete responses in 
45% of 53 patients (40 splenectomized) treated with azathioprine (150 mg/day) for a median of 
18 months(22). Although continued therapy is generally required, often a reduced dose suffices. 
Leukemia has only rarely been associated with azathioprine in other disorders but has not been 
described in ITP patients (evidence level III)(23) 
The 2011 American Society of Hematology(24) evidence based practice guidelines note that in 
children with ITP unresponsive to steroids, the recommendation regarding second line agents 
steroid sparing agents is not possible due to lack of data on any single agent. The only exception 
to this is dapsone. In this regard, the guideline cites  retrospective analysis of dapsone in chronic 
or persistent ITP that included 35 children from Christian Medical College Vellore(25), with a 
response rate of 66% and continuous complete response rate (platelet count > 50 x 109/L with or 
without dapsone) of 31%(25). The 2010 International consensus report(14) acknowledges that 
choice of second-line therapy in newly diagnosed patients who fail corticosteroids is 
controversial, as there are no comparative trials of treatment options in this setting. The 2011 
evidence based practice guideline by American Society of Hematology(24) also acknowledges 
inadequate research in the area since 1996 guideline(3). It thus maintains that it is not possible 
for investigators to include formal evidence based recommendations for indications and timing 
of use of second line therapy for ITP.  
 
 
 
 
Preliminary studies from Christian Medical College, Vellore in this context; 
 In 2005, Sharat Damodar et al(25)published data of 90 patients (55 adults and 35 children) of 
chronic ITP from Department Of Hematology ,Christian Medical College Vellore (platelet count 
of <50 x 109/L). It primarily included patients with more than 6 months of duration of ITP that 
were treated with dapsone (at a dose of 1–2 mg/kg/d) as second line therapy. A response was 
observed in 57 (63.3%) patients with complete response (CR) of 48.9%. The mean time to 
response was 3.5 months (range 1–9). The average duration of treatment with dapsone in this 
cohort of patients was 10.4 months (range 4–14).  Overall response rates of 65.7% and 61.8% 
were observed in children and adults respectively. Side effects requiring discontinuation of 
therapy were observed in three (2%) patients(25).  
These results demonstrate that dapsone is an effective, inexpensive and well-tolerated treatment 
for chronic ITP, in both children and adults. Hence it could be considered for patients who fail 
steroid therapy(25). 
Subsequently, in 2006 Rajsekhar et al (ISHTM Abstract 2006)(26) conducted a randomized 
control study comparing response of dapsone with azathioprine in patients with ITP who have 
failed steroids – defined as platelet counts <30 x 109/l after one month of steroid therapy. A total 
of 103 adult patients with idiopathic thrombocytopenic purpura (ITP) who failed steroids were 
randomized to receive either azathioprine or dapsone. In all, 79 (76.7%) patients were available 
for evaluation of response of which 37 received azathioprine and 42 received dapsone26. Results 
of the study that was presented as abstract in ISHTM 2006 are outlined in TABLE 3. 
 
 
Table 3: Comparison between Dapsone and Azathioprine as Second Line agents: 
Parameter Overall- (%) 
N=79/100  
Azathioprine (%)  
(N= 37) 
Dapsone (%) 
(N=42) 
P value  
Response 43 (53.8%)  21 (56.8%)  22 (52.4%)   0.69  
Complete Response  23 (53.5%)   9 (24.3%)  14 (33.3%)   0.23  
Partial Response  20 (46.5%)   NR  NR  NA  
Time to Response  NR  NR  NR  NR  
Response Duration  NR  NR  NR  NA  
Relapse  12 (27.9%)  8  4  0.20  
  Re T/T- Dapsone  
(including NR)  
17 NA  R – 8 (43.8%)  
  ReT/T Azathioprine  
(Including NR)  
9  R -- None  NA   
Total Response   30/59 (50.8%)   21/46 (45.7%)  0.60  
 
The investigators Rajsekhar et al concluded that dapsone therapy is as effective as azathioprine 
in the treatment of chronic ITP but at a significantly lower cost(26).  
In view of these observations and the fact that there is limited long term data on second 
line therapy in Indian patients with ITP, we intend study response to Dapsone and 
Azathioprine in patients diagnosed with relapsed or steroid refractory/dependent ITP 
therapy and in Department of Clinical Hematology Christian Medical College Vellore. 
Aims and Objectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Aims and Objectives: 
To assess efficacy of Dapsone and Azathioprine in treatment of patients with relapsed ITP and 
ITP refractory to steroid therapy treated in Department Of Hematology. 
 
Hypotheses:  
1. The overall treatment outcome of children with ITP in India is similar to that reported in 
the international literature. 
2. Using current treatment regimens, the outcome in the adults with ITP in India is similar 
to that as reported in literature. 
3. In both children and adults, dapsone therapy is as effective and as well tolerated as 
azathioprine in the treatment of both steroid dependent/steroid refractory ITP and 
relapsed ITP. 
 
 
 
 
 
 
Patients and Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Design: 
In this retrospective observational study, we compared efficacy of two second line agents, 
dapsone and azathioprine for treatment of patients with immune thrombocytopenia (ITP) who 
were either refractory to first line therapy (steroid therapy) or had relapse after achieving initial 
response. In order to identify patients with steroid refractory/dependent ITP or relapse of ITP, 
medical records of patients treated for ITP in Department of Hematology during the 5 year 
period between March 1st 2007 and March 1st 2012 were reviewed. Further analysis was done 
using data from medical records of patients who fulfilled inclusion criteria. Standard format of 
recording data was used for all patients included in the study. At the time of recording data, 
appropriate care was taken so that neither any direct or indirect identification of patient are 
mentioned. 
This study was conducted over 1 year – from 1st February 2013 to 31st January 2014.  
The study was approved by Institutional Review Board. 
 
 
 
 
 
 
 
Patients: 
Inclusion Criteria: All patients who underwent treatment in Department of Hematology during 
the five year period between March 1st 2007 and March 1st 2012 with either dapsone or 
azathioprine for steroid dependent/refractory ITP or relapsed ITP were included in the study: 
1. ITP refractory to steroids was defined as ITP patients who continued to have platelet count 
<30,000/cumm at 1 month of treatment with 1mg/kg daily prednisolone  
2. Steroid dependent ITP was defined as is ITP requiring treatment with corticosteroids 
repeatedly for   two months to prevent bleeding or maintain platelet count >30,000/cumm, and  
3. Relapsed ITP was defined as recurrence of low platelet count (< 30 × 109/L) or a 2-fold or 
greater decrease in platelet count from baseline or the presence of bleeding. Platelet count must 
be measured on 2 occasions more than a day apart. 
For purpose of analysis, we combined 1. steroid refractory ITP and 2. steroid dependent ITP 
patients since the duration of ITP in both the subsets of patients is within 12 months of 
diagnosis(persistent ITP), when chances of spontaneous remissions are  still significant(2). 
Exclusion Criteria: Patients with ITP for whom data from medical records are not retrievable, 
were excluded from the study. 
 
 
 
 
Method: 
a) Sample Size Calculation: On review of comprehensive Hematology Database for cases 
of ITP diagnosed since 2007, there were more than 1200 cases in all. Assuming that 
approximately 50% of ITP patients fail to either show response or will have relapsed ITP 
and further, assuming 10% attrition rate at level of medical records, we decided to 
include at least 300 patients for retrospective analysis. 
b) All patients with 1. Steroid refractory ITP, 2. Steroid Dependent ITP or 3. Steroid 
dependent ITP; who underwent treatment in Department of Hematology during recent 5 
year period (March 1st 2007 to March 1st 2012) were identiﬁed by our comprehensive 
Hematology database.  
c) Their medical records will be reviewed to gather the following data: age at diagnosis, 
gender, platelet count at diagnosis of ITP. Information regarding bleeding manifestations, 
both at time of diagnosis and at time of relapse or steroid failure, was recorded. 
d) “Mild bleeding” will be defined as involving skin manifestations only (bruising and    
  petechiae) without any mucosal bleeding(24).  
e) Clinically important or major hemorrhage:  deﬁned as presence of 1 or more of the    
following occurring at any time during the course of ITP: (1) Intracranial hemorrhage,  
(2) epistaxis requiring cautery or nasal packing, (3) gross hematuria, or (4) other mucosal 
or cutaneous hemorrhage severe enough to cause a decline in patient’s hemoglobin 
concentration to ≤10 g/dL or ≥2 g/dL below patient’s baseline haemoglobin value(27). 
Disease definitions:  The disease definitions outlined in TABLE 4 are adapted from criteria laid 
down by International Working Group for Immune Thrombocytopenia(2). 
Table 4: Definitions of disease(2) 
 
 
Primary ITP It is defined as an “autoimmune disorder”. There is isolated 
thrombocytopenia (peripheral blood platelet count <100 x109/L).  
Characteristically, other causes of with isolated thrombocytopenia have to be 
excluded. Currently, there is lack of clinical or laboratory parameters for 
establishing diagnosis of ITP. ITP thus remains a diagnosis of exclusion. 
Secondary ITP All patients of ITP not satisfying criteria for primary ITP: The associated 
disease/disorder should be specified (SLE, Drug induced, pregnancy related, 
HIV associated) after the acronym of “secondary ITP”. 
ITP : Phases Newly diagnosed ITP: ITP duration is within 3 months of diagnosis 
Persistent ITP: ITP duration is between 3 and 12 months of diagnosis. This 
is a new category in present guidelines proposed to include ITP within 12 
months of diagnosis since incidence of spontaneous remission is still 
significant. It includes patients who have failed to reach spontaneous 
remission or are not maintaining complete response off therapy.  
Chronic ITP: Any ITP lasting beyond 12 months from diagnosis. 
Severe ITP: Any ITP with bleeding symptoms at onset of magnitude that in 
itself is an indication for treatment. Also includes bleeding requiring 
additional therapy with different platelet-enhancing agent or increased dose. 
Dapsone  and Azathioprine Therapy: 
At our centre, dapsone and azathioprine are used as second line therapeutic agents for inducing 
response in steroid dependent/steroid refractory patients and also in relapsed ITP. The selection 
of particular therapeutic agent is based on physician preferences and affordability of the patient.  
The initial dose of dapsone in children is 1.5mg/kg/d and that in the adult is 50mg per day for 
first 2 weeks. Patients are counseled regarding side-effects such as hemolytic anaemia, dermatitis 
and methemoglobinemia. They are electively re-assessed at the end of 1 week for intolerance. In 
patients without any intolerance to dapsone, the side effect profile and need for follow up for the 
same either with our centre or with a local physician is re-enforced at that visit. Patients are not 
tested for G6PD deficiency prior to initiation of therapy with dapsone. In case of compensated 
hemolysis, therapy is continued with bi-weekly monitoring of hemoglobin and bilirubin levels 
and a drop in hemoglobin>1g/dl is an indication to discontinue dapsone. Dermatitis, leucopenia 
hypersensitivity syndrome and methemoglobinemia are absolute indications for discontinuation 
of therapy. In absence of above, dose is increased to maximum dose of 2mg/kg/d in children and 
100mg to 150mg in adults. 
The initial dose of azathioprine therapy in children and adults is 1.5mg/kg/d. The patients are 
counseled regarding side effects such as cytopenia and dermatitis. Patients are re-assessed for the 
same at the end of 15 days. Thereafter the dose is increased over subsequent visits to reach a 
maximum dose of 2.5mg/kg./d.  
Stable patients on treatment with dapsone or azathioprine are followed up at least once every 
three months for assessment of response. In patients achieving complete response, azathioprine 
was tapered and eventually stopped while dapsone therapy was stopped without prior tapering.  
Primary Outcome: This included:  
 Overall response and complete response rates in ITP patients treated with dapsone and 
azathioprine  as second line therapy therapy.  
Secondary Outcome measures : These included:  
1. Time to initial response, median dose for initial response, duration of response on therapy 
and comparative rates of relapse while on therapy. 
2. Sustained response rates after stopping therapy, duration of sustained response and 
relapse rates after stopping second line therapeutic agents dapsone and azathioprine.  
3. Comparison of overall survival and event free survival rates in patient who received 
dapsone and azathioprine. 
4. Bleeding at diagnosis and at time of relapse or failure of steroid therapy in entire cohort. 
Definition of Outcomes:  In analysis of both arms, the assessment of response was based on 
recommendations of 2009 International Working Group Guidelines(2), as follows:  
• Complete response (CR):  Patients were defined to be in CR when they achieved 
platelet count ≥ 100 × 109/L measured on 2 occasions at least 7 days apart and the 
absence of bleeding. 
• Response (R): Response to second line therapy was defined as achievement of platelet 
count ≥ 30 × 109/L or achievement of at least a 2-fold increase in platelet count from 
baseline measured on 2 occasions at least 7 days apart and in the absence of bleeding. 
• No response (NR): A platelet count < 30 × 109/L or a less than 2-fold increase in platelet 
count from baseline or bleeding. Platelet count must be measured on 2 occasions more 
than a day apart. 
• Loss of complete response: A platelet count < 100 × 109/L measured on 2 occasions 
more than a day apart and/or the presence of bleeding. 
• Loss of response: A platelet count < 30 × 109/L or a less than 2-fold increase in platelet 
count from baseline or the presence of bleeding. Platelet count must be measured on 2 
occasions more than a day apart. 
• Time to response: It was measured from start of treatment until the time that patient 
either achieved complete response or at least a response. 
• Duration of response: The 2009 Guidelines by International Working Group on ITP 
defined duration of response in two ways. A) Time from complete response or response 
until loss of complete response or response. B) Duration of response can also be 
measured as the proportion of the cumulative time spent in complete response or 
response during the period under examination as well as the total time observed from 
which the proportion is derived. 
Statistical Analysis:  
Descriptive Statistics (mean, median and mode) were used for all variables. For dichotomous 
variables, the difference in proportions were assessed using Chi Square Test or Fisher’s Exact 
Test. Difference in mean was assessed using T test or Mann Whitney “U” Test.  
For purpose of analysis, it was decided to combine variables from steroid dependent ITP and 
steroid refractory ITP since the duration of ITP in both these categories was less than 12 months. 
There is evidence to suggest that there is still significant chance of remission during initial 12 
months from time of diagnosis. 
Children were defined as patients less than 15 years of age and adults were defined as 15 years or 
more in age, in accordance with previous study from our centre published by Damodar et al (25). 
Overall survival was defined as time from initiating second line therapy to last follow up or 
death. 
Event free survival was calculated from the time of initiation of second line therapy to time of 
last follow up or an event. 
Events were defined as follows:  
1. Death while on second line therapy,  
2. Lack of response to second line therapy at 6 months,  
3. Severe adverse effects of therapy necessitating discontinuation,  
4. Relapse while on therapy, and 
5. Relapse after stopping therapy. 
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Results: 
A total of 300 patients satisfied inclusion criteria. This included two patients who already had 
splenectomy for ITP elsewhere. Majority (98%) of patients included in study cohort had primary 
(ITP). Only 6 patients (2.0%) satisfied criteria for secondary ITP: it included two patients 
diagnosed with ITP associated with pregnancy, 3 patients with systemic lupus erythematosus and 
one patient with rheumatoid arthritis. Three patients (1.0%) with primary ITP had associated 
autoimmune hemolytic anaemia (Evan’s Syndrome). The median age of entire cohort was 22 
years (range 1-80 years). There were 104(34.7%) children and 196(65.3%) adults. The male to 
female ratio in the present cohort was 0.56:1. Median platelet count at diagnosis was 12 x 109/l 
(range 10-56 x 109/l). There were 144 patients (48%) who had steroid refractory/dependent ITP 
and 156 patients had relapsed ITP in the present cohort of patients (TABLE 5A). 
Table 5A: Comparative Patient Characteristics: Dapsone & Azathoiprine (N=300) 
Characteristics Total (%) 
N = 300 
Dapsone (%) 
n = 170 
Azathioprine (%) 
n = 130 
P 
value 
Children 104 (34.7) 64(37.7) 40(30.7) 0.224 
Adults 196 (65.3) 106(62.3) 90(69.3) 0.224 
Male:Female Ratio 0.56:1 0.68:1* 0.42:1* 0.069* 
Platelet<10x109/l at Diagnosis 129 (43.0) 74 (43.5) 55(42.3) 0.906 
Platelet>10x109/l at Diagnosis 171(57.0) 96(56.5) 75(57.7) 
Median ITP Duration 
(months) 
5 (1–262) 4(1-262) 6(1-146) 0.149 
 
The adults included in the study had significantly lower male to female ratio (p=0.005) than 
adults. Median duration of was comparable between children and adults (TABLE 5B). 
Table 5B: Comparative characteristics between children and adults (N = 300) 
Characteristics Total (%) 
N = 300 
Children (%) 
n =104 
Adults (%) 
n = 196 
P value 
Patients 300 104(34.7) 196(65.3) --- 
Male : Female Ratio 0.56:1 0.89:1* 0.43:1* 0.005* 
Median Platelet Count at Diagnosis 12 x 109/l 12 x 109/l 12.5 x 109/l 0.112 
Median ITP Duration 5(1-262) 5(1-64) 5.5(1-262) 0.346 
 
Table 6: Comparative Indication of Second line Therapy For Entire Cohort (N=300):  
Variable Dapsone (%) 
n = 170 
Azathioprine (%) 
n =130 
P Value 
Steroid Refractory/ Dependent ITP 
n = 144  
90 (52.9) 54 (41.5) 0.062 
Relapsed ITP  
n = 156 
80 (47.1) 76 (58.5) 0.062 
 
We observed that in present cohort of ITP patients, patients with steroid refractory/dependent 
ITP were more often treated with dapsone than azathioprine (TABLE 6). Patients with relapsed 
ITP were more often treated with azathioprine than dapsone. Thus, there were more steroid 
refractory/dependent ITP patients on dapsone therapy and more relapsed ITP patients on 
azathioprine in our study cohort, with trend towards significance (p=0.062).  
On further subgroup analysis of children and adults treated with dapsone and azathioprine in the 
study cohort, the difference in treatment preference was found to be statistical significant only in 
adults (p=0.045) (TABLES 7A and 7B). 
Table 7A: Comparative Indication of Second line Therapy in Children (N=104):  
Variable Dapsone (%) 
n = 64 
Azathioprine (%) 
n = 40 
P Value 
Steroid Refractory/ Dependent ITP  33(51.6) 19(47.5) 0.840 
Relapsed ITP 31(48.4) 21(52.5) 0.840 
 
Table 7B: Comparative Indication of Second Line agents in Adults (N = 196): 
Variable Dapsone (%) 
n = 106 
Azathioprine (%) 
n = 90 
P Value 
Steroid Refractory/ Dependent ITP  49 (46.2) 35 (38.9) 0.045 
Relapsed ITP 57 (53.8) 55 (61.1) 0.045 
 
Bleeding Manifestations: 
Major Bleeding: In the present cohort of patients, at least one episode of major bleeding at 
diagnosis was documented in 44 (14.7%) of cases (Table 8A). These included 9 patients (3%) 
who had intracranial hemorrhage at diagnosis and 34 patients(11.3%) who had mucosal bleeding 
(hematuria, menorrhagia, or recurrent gum bleeding) that caused decline in hemoglobin to 
<10g/dl or >2g/dl below the patient’s baseline hemoglobin levels. One patient also had epistaxis 
that required nasal packing. In contrast, only 16 patients (5.3%) had major episode of bleeding at 
the time of relapsed ITP or failed response to steroid. Only 1 patient had new onset intracranial 
hemorrhage at the time of relapse. 
Table 8A: Bleeding Manifestations in Entire Cohort of Patients: 
Characteristics  Total (%)  Dapsone (%)  Azathioprine (%)  P value  
Bleeding 
at 
Diagnosis 
Major 
Minor 
None  
44 (14.6) 
252 (84) 
4 (1.3)  
21(12.4) 
149 (84.7) 
0  
23 (17.7) 
103 (79.2) 
4 (3.07)  
0.066* 
Bleeding  
at  
Steroid Failure* 
or Relapse 
Major 
Minor 
None  
16 (5.3) 
249 (83) 
35 (11.7)  
7 (4.1) 
144 (84.7) 
19 (11.2)  
9 (6.9) 
105 (80.8) 
16 (12.3)  
0.544  
* included Steroid refractory/dependent ITP.  
Table 8B: Bleeding Manifestations in Children and Adults: 
Characteristics  Total (%)  Children (%)  Adults (%)  P value  
Bleeding 
at 
Diagnosis 
Major 
Minor 
None  
44 (14.7)  
252 (84) 
4 (1.3)  
3 (2.9) 
100 (96.2) 
1 (1)  
41 (20.91) 
152 (77.5) 
3 (1.5)  
0.001  
Bleeding 
at 
Steroid Failure* 
or  Relapse 
Major 
Minor 
None  
16 (5.3) 
249 (83) 
35 (11.7)  
1 (1) 
91 (87.5) 
12 (11.5)  
15 (7.65) 
158 (80.6) 
23 (11.7)  
0.106  
* included Steroid refractory/dependent ITP.  
Major hemorrhagic episodes in children (Table 8B) at diagnosis (2.9%) were significantly less 
among children than in adults - (20.91%) – p=0.001. None of the children included in the study 
had intracranial hemorrhage. All 10 patients with intracranial hemorrhage (9 patients at diagnosis 
and 1 additional patient at time of steroid failure) were adults. Thus 20.91% (41/196) adults had 
“severe ITP” compared to only 2.9% (3/104) in children. Although the same trend of bleeding 
manifestations was seen at time of steroid failure or at time of relapse of ITP, the difference was 
not statistically significant (Table 8B).  
As compared to ITP at diagnosis, the proportion of “severe ITP” decreased from 14.7% to 5.3% 
in steroid refractory ITP/ dependent ITP and at relapse. The decrease in bleeding manifestations 
was seen both in children -2.9% to 1% and adults – from 20.9% to 7.65% (Table 8B). 
Minor Bleeding: Majority of patients had minor episodes of bleeding in the form of petechial 
and purpuric rashes, both at diagnosis (84%) and at the time of relapse (83%). There were 4 
patients that did not have bleeding manifestations at diagnosis. Further, the number of patients 
without any bleeding manifestations increased to 35 when it came to bleeding at time of 
relapse/steroid failure. Compared to adults (77.5%), significant majority of children (96.2%) had 
minor bleeding episodes at diagnosis (Table 8B). Although a similar trend of bleeding 
manifestations was seen at time of steroid failure, the difference was not statistically significant. 
 
 
 
 
Primary Outcome: Response to Second Line Therapy: (TABLE 9A) 
There were 170 patients who were treated with dapsone as second line therapy and 130 had 
received azathioprine as second line therapy. Of these, 2 patients had already undergone 
splenectomy for steroid refractory ITP before they received second line medical therapy. Overall 
response rate to second line medical therapy in the present cohort was 58.6%. In all 124 patients 
(41.3%) failed to show response to either dapsone or azathioprine. The median time to response 
for entire cohort was 3 months (range 1-12 months). The time to initial response was identical 
for patients treated with both dapsone and azathioprine months (p=0.827). The median duration 
of treatment for entire cohort was 10 months (range 1–61 months).  
Table 9A: Primary Outcome - Overall Comparison between Second Line Therapy. 
Variables Dapsone(%) Azathioprine(%) P value 
Overall Response 100 (58.8) 76 (58.5) 1.000 
Complete Response 78 (45.9) 60 (46.2) 1.000 
Time To Response (months) 3 (1-12) 2.8 (1-11) 0.999 
Dose Of Response: 
Children 
 
1.5 (1-3 mg/kg/d) 
 
2.0 (1-3 mg/kg/d) 
 
--- 
Adults 100mg (50 -150mg) 2.0 (1-3 mg/kg/d) --- 
Median T/t Duration (months) 10 (1-61) 10.5 (2-47) 0.857 
Median Response Duration (months) 27 (5-74) 60 (2-60) 0.015 
 
Overall response to dapsone therapy was 58.8%, whereas it was 58.5% in patients treated with 
azathioprine therapy (p=1.000). Both therapies showed comparable rates of complete response.  
Patients who had steroid refractory/dependent ITP showed overall response rates of 55.6%, 
comparable to response in patients with relapsed ITP  61.5% (p=0.348).  Patients with relapsed 
ITP achieved complete response rates of 50% compared to steroid refractory ITP, who achieved 
complete response rates of 41.7% (p=0.165).  
In steroid refractory/dependent ITP dapsone showed overall response of 58.9% which was 
comparable to 50% response rate in patients treated with azathioprine (p=0.299). Similarly, 
complete response (CR) rate for dapsone (44.4%) was comparable to CR rate (37%) for 
azathioprine (p=0.383).  
In patients treated for relapsed ITP, azathioprine showed overall response rate of 64.4% that was 
comparable to 58.8% overall response rate for dapsone (p=0.463). Similarly the complete 
response rate for azathioprine (52.6%) was comparable to that with dapsone (42.5%) (p=0.522). 
The median duration of response to second line therapy was 35 months (2-74 months). Median 
duration of response was significantly more - 60 months (2 to 60 months) in patients treated with 
azathioprine therapy compared to patients on dapsone therapy where it was 27 months (5 to 74 
months) (p=0.015).  
Nature of Response: (Table 9B) 
In the present retrospective analysis, median duration of treatment with dapsone was 10 months 
(range 1-61 months) and with azathioprine was 10.5 months (range 6-47months). 
At a median time to initial response of 3 months (range 1-12 months), of 176 patients responding 
to therapy, 96(54.5%) showed complete response and 80(45.5%) patients showed “response”.  
Of these 80 initial ‘responders’ 46(57.5%) patients went on to achieve complete response – 
platelet counts >100x109⁄l, whereas 34 patients (42.5%) remained in “response” – platelet count 
>30x109⁄l and absence of bleeding manifestations. Also, of the 96 patients who showed complete 
response to initial therapy, only 3 patients (3.125%) went on to lose their complete response 
while on therapy and proceeded to maintain only partial response thereafter.  
In all there were 139(46.3%) patients who achieved CR and 37(12.3%) patients who achieved 
‘response’ on second line therapy. 
The median time to achieve complete response for entire cohort was 3 months with dapsone 
(range 1-15 months) and 5 months with azathioprine (range 1-12 months) (p=0.28). In the subset 
of patients with initial partial response who went on to achieve complete response, median time 
to achieve CR was a further of 4 months (range 1-20 months) from the time of initial response. 
Table 9B: Nature of Response to Second line Agents In Present cohort of Patients: 
Variables CR Response NR 
Number (%) 139 (46.3) 37 (12.3) 124 (41.3) 
ITP Duration (months)  6 (1-210) 5.5 (1-85) 4 (1-262) 
Time to Response (months) 2 3  NA 
Median Duration of T/t (months) 16 (1-47) 13 (3-44) 6 (2-61) 
Median Response Duration (months) 20 (1-76) 14.5 (3-86) NA 
 
 
 
Response to Second Line Therapy in Children: TABLE 10A 
There were 104(34.7%) children in present cohort. Of these, 64 children (61.5%) were treated 
with dapsone and 40 children (38.46%) were treated with azathioprine.  Fifty two children each 
had steroid refractory ITP and relapsed ITP. Overall response to both second line agents in 
children was 52.9%, with complete response of 45.2% of children. It was comparable to overall 
response and complete response rates in adults. Response in patients treated with dapsone was 
59.3% whereas it was 42.5% in patients treated with azathioprine (p=0.062). The overall median 
duration of response in children was 28 months (6 to 64 months). 
Table 10A: Comparative Data In Children – Second line therapy: 
Variable  Dapsone 
(64 children) 
P 
value 
Azathioprine 
( 40 children) 
P Value 
Steroid 
Refractory 
or 
Dependent 
(n=33) 
Relapsed   
 
 
 
(n=31) 
 Steroid 
Refractory 
or 
Dependent 
(n=19) 
Relapsed 
 
 
 
(n=21) 
Overall 
Response  
20 (60.6)  18 (58.1)  1.000  5 (26.3)  12 (57.1)  0.062  
Complete 
Response  
17 (51.5)  16 (51.6)  1.000  5 (26.3)  8 (38.1)  0.511  
                                                            Dapsone               Azathioprine  
Time to Response (months) 3 (1-7) 3 (1-10) 0.542  
Median Dose to Response (mg/kg/d)  1.5 (1-3) 2.0 (1.5-3.0) ---  
Mean Response Duration months 35.3* 44** 0.257 
*(SE=4.526, 95% CI 26.474 – 44.215), **(SE=5.993, 95% CI 32.5 -55.992) 
 
The median time to response and mean duration of response were similar to dapsone and 
azathioprine in children in the present cohort. Median response dose was comparable between 
dapsone and azathioprine. TABLE 10A outlines comparison of response to dapsone and 
azathioprine in children in the present cohort of ITP patients. 
Children treated for steroid refractory/steroid dependent ITP showed overall response of 20/33 
(60.6%) to dapsone, which was significantly better than azathioprine, with response rates of 5/19 
(26.3) – (p=0.023). The CR rates also showed trend favoring dapsone (p = 0.090). In relapsed 
ITP the response to dapsone (58.1%) was comparable to azathioprine (57.1%).  
The median duration of response was not reached in children treated with azathioprine, while it 
was 26 months (range 6-64 months) in children treated with dapsone (p=0.257). The mean 
duration of response was 35.3 months (SE=4.526, 95% CI 26.474 – 44.215) in children treated 
with dapsone, whereas it was 44.25 months (SE=5.993, 95% CI 32.5 -55.992) in children treated 
with azathioprine, although difference was not statistically significant (p=0.257). 
Response to Second Line Therapy in Adults: TABLE 10B: 
The present ITP cohort had 196 adults, 106(54.08%) of which received dapsone therapy and 
90(45.91%) received azathioprine.  Ninety two adults had steroid refractory ITP (46.93%), 
whereas 104 (53.06%) had relapsed ITP. The overall response rate in adults treated was 61.7%, 
with complete response rates of 47.95%. The overall median duration of response in adults to 
second line therapy was 33 months (2-74 months).  Overall response in adults to dapsone was 
59.6% (CR=42.5%) comparable to response rate of 64.4% (CR=52.2%) to azathioprine 
(p=0.376) (TABLE 10B). 
 
Table 10B: Comparative Data In Adults – Second line therapy: 
Variable  Dapsone 
N = 106 adults 
P 
value 
Azathioprine 
N = 90 adults 
P 
Value 
Steroid 
Refractory  
or 
Dependent 
(n = 57) 
Relapsed  
 
 
 
(n=49) 
 Steroid 
Refractory 
or 
Dependent 
(n=35) 
Relapsed 
 
 
 
(n=55) 
Overall 
Response  
33 (57.9)  29 (62.9)  1.000  22 (60)  37 (67.3)  0.820  
Complete 
Response  
23 (40.4)  22 (44.9)  0.696  15 (42.9)  32 (58.2)  0.196  
 Dapsone Azathioprine 
Median Time to Response 2 (1-12months) 2 months (1-11months) 0.957  
Median Dose to Response  100mg (50-150) 2.0mg/kg (1-3mg/kg/d) --  
Median Response Duration  24 months(3-39months) 44 months (1-48months) 0.037  
 
The median duration of response of 44 months (range 2-60 months) achieved with azathioprine 
was longer than that with dapsone – 24 months (range 5-74 months) – p value = 0.037.  
Complete response to dapsone was achieved in 47/106 (44.33%), whereas it was 47/90 (52.2%) 
in adults treated with azathioprine (p value = 0.325). In relapsed ITP, azathioprine showed better 
overall response of 67.7%, compared to dapsone as for relapsed ITP (59.18%)  (p=0.425). 
Patients treated with azathioprine also included 6 secondary ITP patients, and 3 patients with 
Evan’s syndrome. Seven patients (77.7%) of the 9 patients responded to azathioprine therapy, 
with complete response seen in 6 patients (66.6%). Of these, one patient relapsed while on 
therapy and another patient relapsed after stopping treatment. 
Secondary Outcome: Relapse while on Therapy:  
Of the 176 patients who showed response to second line therapy in present cohort of ITP 
patients, 166 were evaluable for secondary outcome. The remaining 10 patients were excluded 
due to inadequate follow up (< 6 months on therapy). Of the 166 patients, 49 patients (28.5%) 
relapsed while on therapy. Relapses (38%) were significantly higher in patients on dapsone 
therapy compared to azathioprine therapy (18.9%) (p=0.007)(Fisher’s Exact Test). The median 
time to relapse was 14 months in case of both dapsone and azathioprine. 
TABLE 11A shows comparative data for secondary outcome in present ITP cohort. 
Variables  Dapsone (%) Azathioprine (%) P value  
Relapses On Therapy: 49/166   
                                   (28.5%) 
35/92 
(38.0) 
14/74  
(18.9) 
0.007  
Relapse on          : 18/46 (39%) 
stopping therapy 
13/27 (48.1)  5/19 (26.3)  0.075  
Sustained Response Off 
Therapy  
14/27  (51.8)  14/19 (73.7)  0.165  
Duration Of Response Off 
therapy (months) 
12 (1-74)  11.2 (2-48)  0.451 
 
Analysis for predictors of relapse while on therapy (TABLE 11B) showed that: 
1. Achieving anything less than complete response to second line therapy was significantly 
associated with higher risk of relapse while on therapy (p = 0.030)  
2. Primary steroid refractory/steroid dependent ITP was significantly associated with 
increased risk of relapse while on second line therapy. (p value =0.042).  
Neither age (<15 or >15 years), gender nor platelet counts at diagnosis were predictive. 
Table 11B: Analysis of Predictors of relapse while on Therapy: 
Variables No Relapse On 
Therapy (%) 
Relapse on 
Therapy (%) 
P value 
Age at diagnosis <15 years 38 (32.8) 16 (32.7) 1.000 
> 15 years 78 (67.2) 33 (67.3) 
Platelet count at 
diagnosis 
< 10,000 51 (44) 23 (46.9) 0.735 
          >10,000 65 (56) 26 (53.1) 
Gender Male 38 (32.8) 22 (44.9) 0.158 
Female 78 (67.2) 27 (55.1) 
Indication of 
Second Line 
Therapy 
Steroid Failure* 46 (39.7) 28 (57.1) 0.042 
Relapsed ITP 70 (60.3) 21 (42.9) 
Nature of Response CR 105 (75.5) 34 (24.5) 0.030 
‘Response’ 18 (54.5) 15 (45.5) 
* includes steroid dependent and steroid refractory ITP 
Secondary Outcome: Response and relapse rates after stopping second line therapy: 
In addition, second line therapy was stopped in 65 of remaining 122 (53.3%) evaluable patients. 
Further analysis could only be carried out with 46 of 65 patients, since 19 patients, were lost to 
follow up after stopping therapy. Of the 46 evaluable patients off therapy, 27 (58.7%) patients 
were on dapsone and 19 (41.3%) patients were on azathioprine.  
Overall, 28(61%) of 46 evaluable patients had sustained response off therapy. Thus, half of 
patients treated with dapsone - 14/27(51.8%) maintained response off therapy. Similarly, two-
thirds of patients treated with azathioprine - 14/19(73.7%) maintained response after stopping 
therapy (p= 0.165).  
The median duration of sustained response off therapy was 12 months (1-72 months) in dapsone 
group and was 11.2 months (2-48 months) in azathioprine group. Eighteen patients (39%) 
patients relapsed after stopping therapy. These included 13(48.1%) patients treated with dapsone 
and 5/19 (26.3%) patients in azathioprine (Table 11A). 
Thus in all, 40% (67/166) of evaluable patients had relapse in present cohort of patients. Fifty 
two patients - 31% (51/166) are still on therapy and maintaining response at last follow up. There 
are also the additional 28 patients (16.4%) patient who maintained response for median of 12 
months duration even after stopping of therapy. These are apart from 19 patients (11%) who had 
been advised to stop therapy at last follow up. 
Figure 1: Secondary Outcome Measures in Responders in Present cohort of Patients: 
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Overall Survival And Event Free Survival: 
There were no deaths in present cohort of patients with ITP. The estimated mean overall survival 
duration for the entire cohort was 24.5 months (S.E = 1.817, 95% CI: 20.89 – 28.01 months) and 
the estimated median overall survival time for the entire cohort was 14 months (S.E: 1.575, 95% 
CI: 10.87 – 17.127). 
Event Free Survival: Three year estimated event free survival was 26.2% (+3.2%)  
Figures 2(A) depicts Event Free Survival for entire cohort of patients. 
 
Figure 3(a): Kaplan Meier curves: event free survival for entire study cohort (N=300): Over 
median treatment duration of 10 months (range 1-61 months), estimated 3 year EFS of patients 
on second line therapy was 26.2% (+3.2%). 
3 year EFS: 26.2%(+3.2%) 
In patients treated with dapsone as second line therapy, estimated 3 year event free survival was 
20.6% (+ 3.9%). With with azathioprine, it was 35.2% (+ 5.1%)  
{X2 = 1.996, df – 1, significance 0.158). 
Figure 2(B) Comparative 3 year EFS (Dapsone and Azathioprine) For Entire Cohort:   
 
Figure 2(B): Kaplan Meier curves: event free survival comparison dapsone and 
azathioprine (N=300): Over median treatment duration of 10 months (range 1-61 months), 
estimated three year EFS was better in patients treated with azathioprine than dapsone, although 
difference was not statistically significant (p=0.158). 
p=0.158 
Azathioprine: 35.2% (+5.1%) 
Dapsone: 20.6% (+3.9%) 
In the patients who responded to second line therapy, 3 year event free survival was significantly 
better - 48.7% (+ 4.9%) than those who failed to respond to therapy where it was 0%. 
{X2 = 284.131, df – 1, significance <0.001). 
Figure 3(A) shows EFS Comparison between Responders and Non-Responders.  
 
Figure 3(A): Kaplan Meier curves: event free survival comparison of responders and non-
responders to second line therapy (N=300): Over median treatment duration of 10 months 
(range 1-61 months), estimated 3 year EFS of patients responding to second line therapy was 
significantly better (p<0.001) than patients who failed to respond to therapy. 
p <0.001 
CR+PR: 48.7% (+ 4.9%) NR:  0%  
Amongst patients who responded, estimated 3 years event free survival for azathioprine was 
significantly better - 61.0% (+ 7.6%) than with dapsone – 36.1% (+6.4%).  
{X2 = 5.571, df – 1, significance - 0.018). 
Figure 3(B): Estimated 3 year EFS Responders (CR+PR) : Dapsone versus Azathioprine 
 
 
Figure 3(B): Kaplan Meier curves: event free survival comparison of dapsone and 
azathioprine in responders (N=176): Over median treatment duration of 10 months (range 1-61 
months), estimated 3 year EFS of patients treated with azathioprine was significantly better 
(p=0.018) than patients treated with dapsone. 
Azathioprine: 61.0% (+ 7.6%) 
Dapsone: 36.1% (+6.4%). 
p = 0.018 
Third Line Therapy: 
Data regarding various third line therapeutic agents was available in 150 (50%) of patients of the 
present cohort. These included 94 patients (62.66%) who had failed to respond to both second 
line therapeutic agents (dapsone and azathioprine), and 56 patients (37.1%) who had shown 
initial response to second line therapy. Of these patients, going 43 patients had relapse while on 
therapy. Another 9 patients had relapse after withdrawal of second line therapeutic agents. 
Additionally, 3 patients were changed over to third line therapy since they had achieved only 
partial response to second line therapeutic agents, 1 in dapsone arm & 2 in azathioprine arm. 
Also, 1 patient developed azathioprine induced dermatitis at 6 months of achieving response 
hence therapy was changed to dapsone therapy. 
Table 12 shows various third line modalities of therapy & indications in the present cohort.  
Third Line 
Therapy 
      N = 150  
Dapsone (n=99) Azathioprine (n=51)  
Non 
Response 
Relapse / PR / 
Others 
Non 
Response 
Relapse / PR / 
Others 
Total 
Dapsone  1(1.9%) 10(19.6%) 26(51%) 14(27.45%) 51 
      
Azathioprine  51(62.2%) 28(34.1%) 3(3.6%) 0 82 
      
Splenectomy  4 1 4 0 9 
      
*Others  2 2 3 1 8 
*Others includes: Dexa + Azathioprine, Dexa + Dapsone, Prednisolone+dapsone, 
Cyclophosmide-Vincristine-Prednisolone, Eltrombopag, Cycloporine, Mycophenolate. 
 
 
 
 
Response to Dapsone and Azathioprine as “Third Line” Therapeutic Agents: 
Patients who were treated with third line dapsone after failed response to azathioprine showed 
response rate of 45.8%. In contrast, patients who received azathioprine as third line therapy after 
failing to respond to dapsone had response of 21.2% (p = 0.168). 
On re-challenging patients who had relapsed while on dapsone therapy, dapsone produced 
response in 7 out of 8 patients. Two of these patients subsequently relapsed, thus overall 
response rates to third line dapsone was 62.5% in this group of patients. In contrast, only 30% of 
patients who had relapse on therapy with azathioprine – showed response to re-treatment with 
azathioprine (p= 0.168). Table 13 shows comparative response rates between dapsone and 
azathioprine as third line therapeutic agents in the present cohort.  
Table 13: Comparison Of Dapsone and Azathioprine as Third Line Agents: 
Third Line 
Therapy 
Dapsone Azathioprine 
Non 
Response 
Relapse 
on 
therapy 
Relapsed 
on 
stopping 
Therapy 
Non 
Response 
Relapse on 
Therapy 
+ 
Side effects 
Relapse 
on 
stopping 
therapy 
Dapsone 
(48/51) 
P = 0.168 
0/1 7*/8 
(87.5%) 
1/1  11/24  
(45.8%) 
6/9  
+ 
1/1 
(dermatitis) 
2/3  
Azathioprine 
(75/82) 
P = 1.000 
10/47 
(21.2%) 
6/20 
(30%) 
+ 0/1 (R) 
2/4 0/3 0 -- 
*2 of these patients relapsed. (R) – Patient with response that was less than CR. 
 
 
Splenectomy:  
In the present cohort, 41 of 298 patients eventually underwent splenectomy, subsequent to 
initiation of second line therapy. The analysis excluded the 2 patients who had already 
undergone splenectomy prior to being given second line medical therapy (dapsone or 
azathioprine) Table 14 shows splenectomy rates in various groups of patients in study cohort.  
Table 14: Comparison between rates of Splenectomy in present cohort. 
Splenectomy CR +PR Non responders P value 
Yes 10 (5.7%) 31 (25%) <0.001 
No (164) (93) 
 
Splenectomy Steroid Refractory/ 
Dependent ITP 
Relapsed ITP P value 
Yes 30 (21%) 11(7.1%) <0.001 
No (113) (144) 
 
In all, there were 10 patients who had initial response to second line therapy but either relapsed 
while on therapy (9 patients) or had relapse after stopping therapy 1 patient. The other 31 
patients were the ones who had failed to show any response to second line therapeutic agents, 
dapsone and azathioprine. The failure to respond to second line therapy was significantly 
associated with increased incidence of splenectomy, exhibiting splenectomy sparing role of 
second line therapeutic agents (TABLE 14).  In the present study we observed that patients who 
had steroid refractory or steroid dependent ITP had significantly higher rates splenectomy (21%) 
as compared to patients who received second line therapy for relapsed ITP, where splenectomy 
rate was 7.1% (p=0.001). These findings suggest “splenectomy sparing” role of both second line 
therapeutic agents. Moreover, in those who eventually underwent splenectomy, we observed that 
median time to splenectomy in patients showing response to second line therapy was 26 months 
(13-47 months), which was significantly longer than median time to splenectomy of 14 months 
(3-65 months) in patients not responding to second line therapy (p=0.047). Over median post-
splenectomy follow-up of 7 months (1-62 months), 83% (34/41) patients responded to 
splenectomy with complete response rate of 71%  
Side Effect Profile: Dapsone:  
Table 15A summarizes incidence of various side effects in patients on Dapsone Therapy: 
Dapsone (Pts =170) N Percentage 
Compensated Hemolysis 6 pts 3.5% 
Dermatitis 2  1.1 % 
Side Effect Requiring Discontinuation: 
Methemoglobinemia 1  0.5% 
Agranulocytosis 1  0.5% 
Dapsone Syndrome 2  1.1% 
Uncompensated Hemolysis 1  0.5% 
Overall Discontinuation 5 2.6% 
 
In present cohort of patients, dapsone was found to be well tolerated. The most common side 
effect observed was compensated hemolysis (3.5%) as adjudged by presence of mild indirect 
hyperbilirubinemia, polychromasia, mild reticulocytosis, presence of “bite cells & blister cells” 
without significant fall in hemoglobin. Dapsone was continued without any further worsening of 
hemolysis. There were 2 patients who had self limiting dermatitis while on dapsone, which 
subsided with temporary discontinuation. Re-challenge with dapsone did not result in recurrence.  
Significant side-effects (2.6%) that required stopping dapsone were: a) Dapsone Syndrome - 
Triad of fever with rashes and hepatitis was observed in 2 patients, b) Methemoglobinemia – 
occurred in 1 patient, c) Agranulocytosis seen in 1 patient, and d) Uncompensated hemolysis was 
seen in 1 patient. 
Azathioprine Side effect Profile: 
Azathioprine was well tolerated as second line therapy in present cohort of patients. The most 
common side effect was borderline uni-lineage cytopenia (Total WBC count <3000/cumm) that 
was observed in 6.1% of patients. Mean azathioprine dose in the 8 patients was 2.16mg/kg/day. 
Patients recovered baseline WBC counts after dose reduction. There were 2 patients (1.5%) who 
required discontinuation of azathioprine therapy on account of side effects; one patient had 
agranulocytosis and another patient had generalized erythroderma.  
Table 15B summarizes the side effect profile of Azathioprine Therapy: 
 
 
 
 
Azathioprine: (Pts = 130) N Percentage 
Borderline Cytopenia 8  6.1% 
Alopecia 2  1.5% 
Dermatitis 2 1.5% 
Side effects Requiring Discontinuation: 
Agranulocytosis 1 0.7% 
Dermatitis 1  0.7% 
Overall Discontinuation 2   1.5% 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion: 
The present study is a single centre retrospective analysis aimed at assessment of efficacy of two 
second line agents – dapsone and azathioprine in the treatment of steroid refractory/dependent 
ITP as well as relapsed ITP. Both children and adults were included in the study. Children were 
defined as patients between ages of 3 months to 15 years, and adults by an age of 15 years and 
above – in accordance with similar study published from our centre by Damodar et al(25). 
Standard definitions of ITP laid down by the International Working group on ITP (14) for steroid 
dependent ITP, steroid refractory ITP and relapsed ITP were used at the time of inclusion of 
patients in the study. Although the study aimed at assessing patients for response to dapsone and 
azathioprine as second line agents prior to splenectomy, two patients who had splenectomy prior 
to administration of dapsone or azathioprine were also included in the study. There were 106 
children and 194 adults who satisfied the inclusion criteria of the present study.  Majority of 
patients in the present study (98%) had primary ITP. Six patients (2%) had secondary ITP. There 
was female predominance in entire cohort - (M:F ratio 0.56:1), similar to that reported in various 
epidemiological studies across literature(8). The female predominance of ITP was more 
pronounced in adults (M:F ratio 0.42:1) than in children (M:F ratio 0.86:1). Similar findings are 
reported in prospective study conducted by Intercontinental Co-operative Thrombocytopenia 
study group(28). Kuhne et al has reported  male:female ratio of 0.85:1 in children and 0.47:1 
ratio in adults(28). The mean platelet count at diagnosis in children of our study was also similar 
(14.25 x109/l) between our study and that reported by ICIS study for children – which reported 
mean platelet counts of children of (18.1 x109/l). In adults, our study cohort had lower mean 
platelet counts - 12.5 x109/l at diagnosis, as compared to the ICIS study which reported mean 
platelet counts of 25.4x109/l for adults at diagnosis(28). 
 Investigators from All India Institute of Medical Sciences retrospectively analyzed 1230 patients 
of ITP diagnosed at their centre. These included both children and adults(29). The median age at 
diagnosis was reported as 19.6 years (range 0.9-80years) with slight female preponderance 
(51.1%). The median platelet count at diagnosis was 34 + 18.3 x109/l.  The patient population of 
our present study was also similar, with a median age of diagnosis at 22 years, showing female 
preponderance at 64%, although median platelet count at diagnosis was lower (12+9.3 x109/l). 
This is probably due to fact that analysis reported by Choudhary et al(29) was conducted in 
2004, prior to International Working Group guidelines(2) that are in vogue only since 2009. 
 In the present cohort of study, there were 19 patients in the present study cohort who received 
treatment for ITP at platelet counts of >30 x109/l. Of these, 9 patients were treated at our centre 
prior to 2009. Five other patients had been diagnosed and treated elsewhere, before they were 
seen at our centre. One additional patient had significant bleeding in the form of menorrhagia 
causing anaemia that required blood transfusions.  
Bleeding Manifestations: 
Thus far, there is no consensus definition of significant bleeding in patients with ITP. In present 
study cohort, we used criteria reported previously by Medeiros et al (27), as presence of 1 or 
more of following occurring at any time during the course of ITP:  
(1) Intracranial hemorrhage, (2) epistaxis requiring cautery or nasal packing, (3) gross hematuria, 
or  
(4) other mucosal or cutaneous hemorrhage severe enough to cause a decline in patient’s 
hemoglobin concentration to ≤10 g/dL or ≥2 g/dL below patient’s baseline haemoglobin. 
Minor bleeding was defined as involving skin manifestations only (bruising and petechiae) 
without any mucosal bleeding in accordance with the American Society of Hematology 
management guidelines(24). Using these criteria, 44 patients (14.7%) had at least one episode of 
major bleeding – thus satisfying criteria for “severe ITP”.  Major bleeding at diagnosis was seen 
significantly more in adults (20.91%) as compared to children (2.9%) – p = 0.001. In children, 
proportion of patients with minor bleeding was significantly higher (96.2%) compared to that in 
adults (77.5%).  
Table 16: Bleeding at Diagnosis: Comparative Literature: 
Bleeding at diagnosis 
In Children 
ICIS 
Registry II 
(n =863) 
Bolton-Maggs and 
Moon 
(n=427) 
Present Study 
 
(n =300) 
No or Mild 77% 76% 84% 
    Moderate 20% 21% NR 
Severe 3% 3% 2.9% 
 
These results compare favorably with two other large scale prospective epidemiological 
studies(13)(30) that addressed the question of bleeding manifestations in childhood ITP at 
diagnosis. In both these studies, investigators categorized severity of bleeding into three 
categories – 1. none or mild – defined similar to that used in our study, 2. moderate bleeding – 
defined as more severe skin manifestations and more troublesome epistaxis and or menorrhagia, 
and 3. severe bleeding – again defined similar to used in our present study. Using the above 
severity scale, Bolton-Maggs and co-workers reported 3% incidence of major bleeding and 76% 
of no or minor bleeding manifestations at diagnosis in prospective analysis of 423 cases of 
childhood ITP(30).  
Similarly, in the study on behalf of ICIS (13), investigators reported that 77% of children had no 
or mild bleeding manifestations and only 3% children had severe bleeding at diagnosis, findings 
that are virtually identical to those of our study. None of the children in our study cohort had 
intracranial hemorrhage, similar to only one patient (0.15%) in the ICIS prospective analysis and 
0.6% incidence in subsequent study by the same group(28).  
In order to maintain more objectivity in assessment of bleeding, our study did not use the more 
category of “moderate bleeding” that has definitions that are subjective. This accounts for the 
fact that there were more children (97.1%) with no or mild bleeding manifestations reported in 
our study, compared to 77% reported by Bolto-Maggs and Neunert and co-workers for ICIS. 
Thus, in part, our retrospective analysis supports the conclusion arrived at by the above studies 
that severe bleeding, in particular intracranial hemorrhage is uncommon in childhood ITP at 
diagnosis. 
Bleeding manifestations at diagnosis were significantly higher in adults than in children in 
present study cohort.  In contrast, the recently published prospective analysis by ICIS(28) 
reported higher bleeding rates in children (91%) than adults (69%) – (p <0.0001) on comparing 
incidence of bleeding at any site. This observation was consistent both in treated and untreated 
group of patients in ICIS study(28). Also, in adults included in our study cohort incidence of 
intracranial hemorrhage at diagnosis was higher in patients (4.5%). Although the ICIS study(28) 
does not categorize bleeding manifestations according to severity, this difference in bleeding 
manifestations between our study and ICIS results could be due to the fact that mean platelet 
counts in our cohort of patients was less than 20 x109/l (12.5 x109/l) whereas in ICIS study it was 
more than 20 x109/l (25.4x109/l)(28).  
Bleeding in relapsed and steroid refractory/dependent ITP: 
In our study, majority of patients had mild bleeding, both at diagnosis (84%) and at in steroid 
refractory or relapsed ITP or (83%). Also, number of patients presenting with major bleeding 
manifestations declined significantly (14.7% to 5.3%) from time of diagnosis to when bleeding 
rates were analyzed for relapsed or steroid refractory ITP in the same cohort of patients. We 
observed no difference in incidence of bleeding in children and adults with diagnosis of steroid 
refractory/steroid dependent and relapsed ITP. The only prospective analysis which has 
addressed the question of bleeding in children with persistent ITP comes from ICIS group(31), 
which reported no intracranial hemorrhages in the study, a finding similar to our study. 
Investigators also summarized that the study was unable to arrive at predictors of subsequent 
bleeding due to infrequency of severe bleeding manifestations even at diagnosis. Thus, our study 
confirms the conclusion of the study(31) that ITP in children is a benign disease and is not 
associated with major hemorrhage even in patients with prolonged thrombocytopenia.  
Response to Second Line Therapy:  
Between the two agents, the patient characteristics are comparable between dapsone and 
azathioprine in most aspects. We acknowledge the fact that there are two major differences in 
patients treated with dapsone and azathioprine:  
1. Patients with secondary ITP were treated only with azathioprine (p = 0.002) and  
2. There are more steroid refractory patients in dapsone group and more relapsed patients were 
treated with azathioprine. The difference is statistically significantly in adults (p=0.045) 
Overall response rates to second line medical therapy in the present cohort is 58.6%. Both 
dapsone and azathioprine showed comparable response rates as second line agents. In all, 125 
patients (41.3%) failed to show response to either dapsone or azathioprine. These findings 
compare favorably with those reported in literature(14)(24). International consensus report 2010 
on ITP (14) quotes response rate of up to 50% for dapsone – identical to 58.8% in the present 
study. The consensus report(14) also mentions that up to two-thirds patients treated with 
azathioprine show response – findings that are similar to overall response rates of 58.5% in to 
azathioprine in the present study that included patients with ITP refractory to steroid therapy or 
steroid dependent ITP and relapsed ITP.  
The median time to response for the entire cohort of patients was 3 months. It was identical 
between dapsone (3 months) and azathioprine (2.8 months). The International consensus 
report(14) comments that response to azathioprine is slow and may take 3 to 6 months. In 
contrast, results of our study show that time to initial response was just 2.8 months in patients on 
azathioprine therapy. These findings compare favorably to the expected time to initial response 
(1 to 3 months) for azathioprine as per the American Society of Hematology evidence based 
guidelines(24). For dapsone, the time to initial response is quoted by International consensus 
report as 3 weeks – much lower than the 3 months noticed in our study. In a meta-analysis of 
patients treated with dapsone as second line agent, Rodrigo et al(32) reports a time to response 
between 3 weeks to 3 months. 
 
 
 
Response to Second Line Therapy Dapsone in Adults: 
There are no randomized control studies comparing efficacy of second line agents. Present study 
results compare favorably with all studies reviewed by Rodrigo et al(32) as outlined in 
(TABLE17). These included single arm prospective (Godeau et al, Hernandez et al, Zaja et al, 
Sharma et al) as well as retrospective studies (Audia et al, Damodar et al, Vancine-Califani et al). 
Table 17: Dapsone As Second Line Therapy: Comparative response in Literature: 
Author  Design  Pts  ITP 
Duration  
months 
Overall 
RR  
Time to 
response 
(months)  
Duration  
(months) 
Dose  
Godeau Prospective  66  52 (3-240)  50%  1 12  75-100mg  
Hernandez Prospective  15  29(12-131)  40%  1 NR  100mg  
Le Louet Prospective  19  NR  47%  NR  NR  100mg 
Audia Retrospective  40  40(2-249)  42%  1½ NR  100mg 
Zaja Prospective  20  46 (2-274)  55%  1 42  50 to 
100mg  
Damodar Retrospective  90  24(6-132)  63.3%  3.5 12  1-2mg/kg 
Vancine- 
Califani 
Retrospective  52  5 (1-30)  44.3%  NR  21   100mg 
Sharma Prospective  46  NR  80%  NR  32  50-100mg 
Present 
Study 
Retrospective  170  5 (1-262) 58.8%   3 27(5-74)   50-150mg 
 
The following are other notable comparisons: 
1. Before International working group guidelines on response criteria (2)  came into vogue, 
studies conducted prior to 2009 show lower overall response rates on account of response criteria 
that use higher platelet counts to define response. Godeau et al(21) defined complete response 
(CR) as platelet counts >150 x 109/l, and partial response as platelet counts >50x109/l. Although 
the overall response rates of 50%  are similar to our study results, complete response rates 
(13/66) of 19.7% appear markedly less compared to complete response rates of 45.9% to 
dapsone (and azathioprine) in the present study, probably as a result of underestimation of CR 
rates in accordance to their response criteria.  Le Louet et al(33) and Hernandez et al(34) using 
the criteria used by Godeau et al(21), have all reported similar response rates in their respective 
study population. In that respect, a previous study of 90 patients treated with dapsone from our 
centre by Damodar et al(25) that predates the 2009 guidelines, has reported response rates of 
63.3% using response criteria similar to International working group 2009 guidelines(2).  
2. On the other hand, Sharma et al (35) used ‘disappearance of purpura and rise in platelet count 
> 40x109/l’ as criteria of response. They have reported high response rates of 80% compared to 
58.8% reported in our study. We speculate that it is probably again due to the subjectivity in the 
response criteria used by their study, compared to that stated by International Working Group(2), 
which require platelet counts to be > 30x109/l or at least a 2 fold rise from baseline platelet 
counts measured on 2 separate occasions at least 7 days apart – criteria that we used in our study. 
3. Zaja et al(36) conducted prospective study of 20 patient unresponsive to or relapsing on 
treatment with combination of rituximab and dexamethasone. They have reported response rates 
of 55% using the International Working Group(2) criteria of response assessment, identical to 
our study. Again, our retrospective analysis showed higher complete response rates to dapsone – 
45.9% compared to 20% complete response rates to dapsone in their study. This is probably 
because responses in post splenectomy patients may be lower (14)(34). We had only 2 post-
splenectomy patients in our study cohort. Both received dapsone therapy, and none of them 
achieved complete response. 
4. The median duration of response was 27 months. This is lower from duration of response of 
42 months, reported by Zaja et al(36) in their prospective analysis.  This might be due to the fact 
that our study had higher incidence of relapse while patient was on treatment – 38% compared to 
0% in study by Zaja et al(36).  
5. In studies reviewed by Rodrigo et al(32), remarkably, there were very few relapses on therapy 
- 0% in study by Zaja et al(36) and 5% in study by Godeau et al(21) – compared to 38 % relapse 
rates on therapy with dapsone. Audia et al report relapse rates 37.5% in steroid refractory 
patients treated with dapsone – identical to our study findings.  In our analysis, the steroid 
refractory/dependent ITP (p=0.045) and achievement of response less than CR (p=0.030), were 
significant predictors of relapse while on therapy. 
6. In retrospective analysis of 52 patients of steroid refractory/steroid dependent ITP, 
investigators Vancine-Califani et al(37) reported an overall response rate of 44.2%. In our study, 
the overall response in steroid refractory/steroid dependent adult patients to dapsone is 58.9% 
with complete response rates of 44.4%, which compares favourably with that reported by 
Vancine-Califani et al (37) in their study.  
 
 
Table 18: Dapsone: Secondary Outcome Measures across Various Studies in Literature: 
Author  Design  Pts  Relapse 
on 
Therapy  
Relapse 
on  
Stopping 
Therapy  
Sustained 
Response  
OFF 
Therapy  
Sustained 
Response  
Duration 
(months)  
Splenectomy 
after Second 
Line 
Therapy  
Godeau Prospective  66  5%  92%  8%  NA  NR  
Zaja Prospective  20  0%  0%  50%  NA  NR  
Damodar Retrospective  90  NR  15.5% 50%  17  NR 
Audia Retrospective  40  37.5%  NR  NR  NR  NR 
Vancine- 
Califani 
Retrospective 
Primary-40, 
Secondary-
12  
40 NR  27.7%  83%  NR  Responders- 
0% 
NR - 68.9% 
(OR–0.01, 
95%CI= 
0.01 – 0.11)  
Present 
Study 
Retrospective 
(All primary)  
170  37.5%  48.1%   51.82%  12(1-74) 
 
Responders– 
5.7% 
NR – 25% 
(p <0.001)  
 
Present study had 46 patients evaluable after stopping therapy. Twenty eight (61%) patients had 
sustained response off therapy for median duration of 1 year. With dapsone - 14/27(51.8%) 
maintained response off therapy. Similarly,with azathioprine - 14/19(73.7%) maintained 
response after stopping therapy (p=0.165). The results are comparable to sustained response rates 
reported in retrospective study by Vancine-Califani et al (37) and Damodar et al (25). 
Response to Second Line Therapy Dapsone in Children: 
There is scanty literature on response of dapsone as second line agent in children with ITP, partly 
because the persistent and chronic ITP is rarer in children than in adults(9)(32). In the 104 
children included in present study cohort showed overall response of 52.88% with complete 
response rate of 45.2% - comparable to adults in study cohort. These responses are comparable 
to 65.7% overall response reported by Damodar et al(25) in a series of 35 children with chronic 
ITP and treated with dapsone at our centre. The complete response rates 48.5% were identical to 
our study. In another retrospective study by Meeker et al(38), 3 of 7 (43%) children responded.  
The time to initial response of 3 months was also comparable to adults, and identical in both 
dapsone and azathioprine therapy. There were 52 patients with steroid dependent/steroid 
refractory ITP in present study. Therapy with dapsone has shown a significantly better overall 
response - 60.6%, than azathioprine - 26.3% (p=0.023). In this respect it proved to be a better 
steroid sparing agent in this subgroup of patients.  
Response to Second Line therapy Azathioprine: 
Patients treated with azathioprine as second line therapy had more number of patients who had 
relapsed ITP and lesser number of steroid refractory/steroid dependent ITP, than those treated 
with dapsone therapy, with a trend towards significance (p – 0.062). As opposed to patients 
treated with dapsone, patients on azathioprine therapy also included secondary ITP (6/130 - 
4.6%) and Evans syndrome patients (2%) (p = 0.002).   
 Overall response to azathioprine was 58.5% with complete response in 46.2%. The response is 
similar to dapsone therapy. Median time to response and duration of response were also found to 
be similar to dapsone therapy, with equivalent responses in steroid refractory/steroid dependent 
ITP and relapsed ITP in adults. The lower dose of response in dapsone therapy patients was 
found to be statistically significant. Children with steroid refractory ITP had inferior response to 
azathioprine as compared to dapsone (p = 0.023), whereas children with relapsed ITP showed no 
difference in response rates between dapsone and azathioprine. 
Patients treated with azathioprine also included 6 secondary ITP patients, and 3 patients with 
Evan’s syndrome. Seven patients (77.7%) of the 9 patients responded to azathioprine therapy, 
with complete response seen in 6 patients (66.6%). Of these, one patient relapsed while on 
therapy and another patient relapsed after stopping treatment. 
Response rates in our study cohort compare favorably with response reported by other 
investigators (Table 19 and 20) with azathioprine for persistent and/or chronic refractory ITP. 
Table 19: Comparison Of Azathioprine Therapy Response For ITP in Literature: 
Author  Design  N ITP 
Duration  
(months)  
Response 
Rate  
Time to 
response  
 
Response  
Duration 
(months)  
Dose to  
Pizzuto Retrospective  
Multicentre  
41  NR 
(postsple-
nectomy)  
ORR 51% 
CR – 41%  
NR  NR  2mg/kg  
Quiquandon Prospective  53 19 
(6-350) 
ORR - 64% 
CR - 45%  
4.0 
months 
(7–180)  150mg  
Present 
Study 
Retrospective  130  6 (1-46) ORR 57.7% 
CR -  46.9%  
 2.8 
monhs 
(1-11) 
60 (2-60) 2mg/kg  
 
Table 20: Secondary Outcome In Patients on Azathioprine Therapy: Literature review 
Author Design Pts  Relapse 
on 
Therapy  
Relapse 
on  
Stopping 
Therapy  
Sustained 
Response  
OFF 
Therapy  
Sustained 
Response  
Duration  
Splenectomy 
after Second 
Line 
Therapy  
Quiquandon  Prospective  53  3/34 
(8.8%)  
5/34 
(14.7%)  
10/34 
(29.4%)  
7-182 
months  
NR  
Present 
Study 
Retrospective  130  14/73 
(19.6%)  
5/22 
(22.3%)  
 17/22 
77.3%  
11.2 
months  
Responders 
– 5.7% 
NR – 25% 
(p <0.001)  
 
Second Line Therapy: Splenectomy Sparing Effect: 
We observed that failure to respond to second line therapy was significantly associated with 
increased incidence of splenectomy, exhibiting ‘splenectomy sparing’ role of second line 
therapeutic agents (TABLE 10). In the present study we observed that patients who had steroid 
refractory or steroid dependent ITP had significantly higher rates splenectomy (21%) as 
compared to patients who received second line therapy on account of relapsed ITP, where 
splenectomy rate was 7.1% (p=0.001). There was trend towards increased rates of splenectomy 
in patients treated with dapsone as second line therapy (p = 0.061), probably accounted for by:  
a) Predominance of steroid refractory/steroid dependent ITP in dapsone therapy subgroup as 
compared to azathioprine therapy subgroup (p=0.069). This subset of patients has been 
shown to have significantly higher incidence of subsequently undergoing splenectomy in 
our analysis. 
b) There were significantly more relapses in the dapsone group after while on therapy than 
in patients treated with azathioprine. 
In a retrospective analysis of 40 primary ITP patients with steroid refractory/steroid dependent 
ITP treated with dapsone, investigators Vancine-Califani et al(37) noted that none of the patients 
who responded to dapsone required splenectomy, whereas 68.9% amongst non-responders 
required splenectomy. The relapse rates while on therapy was not reported in the study, whereas 
relapse on stopping therapy was 27.7%. Thus our results compare favorably with above study. 
Dapsone and Azathioprine Side Effects: Review of Literature: 
Dapsone was well tolerated in our study. There was only 2.6% chance of serious side effects 
requiring discontinuation of therapy. Similarly azathioprine was also well tolerated – with rates 
of discontinuation of only 1.5% on account of side effects.  
Table 21A: Dapsone Side Effects: Literature Review 
Author Pts Incidence 
of 
Hemolysis 
Incidence 
of 
Methemo-
globinemia 
Incidence 
of Other 
Reactions 
Serious side-effects 
requiring 
Discontinuation 
Zaja 20 0 0 0 0 
Godeau 66 2 1 6 9/66 (14%) 
Hernandez 15 7 2 0 3/15 (20%) 
Damodar 90 1 0 2 3/90 (3%) 
Vancine- Califani 40 11 0 0 3/52 (6% ) 
Present Study 170 6 1 5 5/170 (2.6%) 
 
 
Table 21B: Azathioprine Side Effects: Literature Review 
 
Limitations of the Present Study: 
The present retrospective analysis included ITP patients with median disease duration of 5 
months (range 1-262 months). The indication of treatment with second line agent was 
predominantly steroid refractory/dependent ITP in patients treated with dapsone and relapsed 
ITP in patients treated with azathioprine, indicating a physician preference in our practice. This 
preference towards particular drug for particular indication – dapsone for steroid dependent or 
steroid refractory ITP and azathioprine use for relapsed ITP was statistically significant in adults. 
Apart from retrospective nature, this bias is a limitation of our study.  
Another limitation of the study is that we had very few cases of secondary ITP (6/300) included 
in the study. Besides, all these cases were treated only with azathioprine. Hence it was not 
possible to make any comparisons of second line therapy efficacy in this group of patients. Due 
to the small number of patients of secondary ITP, we are also unable to draw any seperate 
conclusions in this category of patients. Hence, it was decided to include these in the analysis of 
entire cohort and thus we have not reported the outcome separately. 
 
Author Pts Borderline 
Cytopenia 
Agranulo -
cytosis 
Dermatitis Serious side-effects 
requiring 
Discontinuation 
Quiquandon 53 7 (3%) 0 0 0 
Present Study 130 8 (6%) 1 1 2/130 (1.5%) 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions: 
The following are salient features of our study that allow for robust conclusions: 
1. The high number of patients that we included in the study, with more than 100 patients in 
each arm and each subgroup. We also include more than 100 children in the study. 
2. Use of response criteria as laid down by 2009 International Working Group on ITP. We 
have shown that these criteria are robust and objective even in retrospective study setting.  
3. The response rates are comparable to contemporary literature for both agents. 
 
The second line therapy with dapsone and azathioprine showed identical response rates with 
limited side effects. The response rates of dapsone and azathioprine and side effect profile are 
comparable with contemporary published literature.  
Dapsone exhibited better response rates (overall response and complete response) than 
azathioprine in children treated for steroid dependent/steroid refractory ITP (p=0.023). In adults, 
azathioprine showed marginally better response rates than dapsone in relapsed ITP, but this was 
not statistically significant. Both these findings need confirmation in prospective setting. 
Azathioprine produced significantly more durable response rates than dapsone; median response 
duration 60 months (range 2-60 months) for azathioprine and 27 months (range 5-74 months) for 
dapsone (p=0.015) with lower relapse rates while on therapy (p=0.007). The prolonged response 
was significant in adults (p=0.037) treated with azathioprine but not in children. These findings 
require to be validated in prospective randomized control trial setting. 
An important finding of our study was higher relapse rates while on therapy. Steroid 
refractory/dependent ITP and any response less than complete response were significantly 
associated with relapse while on therapy. The bias towards treating steroid refractory/dependent 
ITP with dapsone that resulted in over-representation of these cases in dapsone arm, may explain 
the trend towards more relapses in the dapsone therapy patients when compared to azathioprine 
therapy patients. This finding requires confirmation in prospective randomized control setting. 
Similarly, although the splenectomy sparing effect could be demonstrated in responders of 
second line therapy, this needs validation in prospective randomized control study. We also need 
to confirm in prospective setting the finding of significant association of steroid dependent-
refractory ITP with increased incidence of splenectomy.  
There were no deaths in present study cohort. This demonstrated that with our approach of using 
second line (and even third line) therapy for persistent and chronic ITP, we could reduce the 
rates of splenectomy without subjecting patients to increased mortality. In those who eventually 
underwent splenectomy the median time to splenectomy was significantly longer amongst 
responders- 26 months, compared to non-responders, thus showing that our approach helps delay 
splenectomy by at least 1 year duration. It remains to be assessed in the setting of prospective 
randomized control study for validation. 
Finally our study confirmed that bleeding manifestations are rare in patients with persistent or 
chronic ITP.  The bleeding manifestations in adults though were more in our study cohort than 
that reported in literature. We acknowledge that there is need to assess bleeding manifestations 
with objective criteria in a prospective setting in both children and adults with ITP, in order to 
arrive at a firm conclusion.  
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Masterchart 
 
sno Hosp Age Gender Date_of_Diag Platelet_co Bleeding_aRefract Relapse Date_of_ReBleeding_@_Rel Dose Starting_Date Time f     First_Response Date_of_First_Time_to_response DATECR Time from      Time from      Response_ Response_ Response_ Response_ Response_ Starting_do
1 270887D 1 Male 01-21-2009 4,000 Minor Yes No 9                        Minor Dapsone 03-03-2009 1 PR 07-14-2009 4 10-13-2009 3 4 NR CR NA CR CR 2.00
2 382268D 3 Male 12-12-2008 11,000 Minor No Yes 1/30/09                  Minor Dapsone 02-13-2009 2 CR 03-03-2009 1 03-03-2009 0 1 CR CR NA CR NA 2.00
3 389987D 28 Male 12-18-2008 14,000 Minor Yes No 9                        Minor Azathioprine 02-03-2009 2 CR 03-31-2009 2 03-31-2009 0 2 CR CR NA NA NA 2.00
4 286872D 18 Male 12-18-2008 14,000 Minor Yes No 9                        Minor Dapsone 01-13-2009 1 CR 03-15-2009 2 03-15-2009 0 2 CR CR NA CR NA 100.00
5 386077D 40 Female 01-01-2008 11,000 Other No Yes 1/18/09                  Minor Azathioprine 01-20-2009 13 NR 01-09-1900 NR NR NR NA NA 1.30
6 383477D 10 Male 04-16-2008 14,000 Minor No Yes 1/3/09                   Minor Dapsone 01-16-2009 9 PR 05-19-2009 4 NR PR PR NA NA 1.50
7 391090D 17 Female 01-16-2009 8,000 Other No Yes 3/6/09                   Minor Dapsone 03-06-2009 2 PR 06-30-2009 4 10-20-2009 4 4 NR CR NA CR CR 100.00
8 381518D 3 Male 12-27-2008 17,000 None No Yes 6/5/09                   Minor Azathioprine 06-05-2009 5 PR 09-11-2009 3 01-27-2010 5 8 PR CR CR CR CR 1.50
9 386758D 7 Female 12-01-2007 20,000 Minor No Yes 3/1/08                   Minor Dapsone 01-27-2009 14 CR 05-08-2009 3 05-08-2009 0 3 CR CR CR NA NA 2.00
10 395656D 53 Male 11-01-2007 5,000 Minor No Yes 11/1/08                  Minor Dapsone 02-13-2009 16 CR 05-12-2009 3 05-12-2009 0 3 CR CR CR Relapse NA 100.00
11 400171d 29 Female 02-03-2009 7,000 Minor Yes No 9                        None Dapsone 03-20-2009 2 NR 01-09-1900 NR NR NA NA NA 50.00
12 403330D 9 Male 03-01-2004 15,000 Minor Yes No 9                        None Dapsone 06-02-2009 64 NR 01-09-1900 NR NR NR NR NA 1.50
13 409731D 17 Female 01-18-2009 4,000 Minor Yes No 9                        Minor Dapsone 02-17-2009 1 PR 10-07-2009 8 10-06-2009 3 8 NR CR CR Relapse CR 100.00
14 405384D 27 Female 01-01-2009 22,000 Minor Yes No 9                        None Dapsone 02-17-2009 2 PR 05-08-2009 3 NR PR Relapse NR NA 100.00
15 403332D 6 Female 01-24-2009 17,000 Minor No Yes 7/17/09                  Minor Dapsone 10-09-2009 9 PR 01-15-2010 3 11-30-2010 11 14 PR PR PR NA CR 1.50
16 410383D 5 Female 12-17-2008 5,000 Minor No Yes 2/16/09                  Minor Dapsone 02-20-2009 2 CR 05-19-2009 3 05-19-2009 0 3 CR CR CR CR Relapse 1.50
17 407779D 8 Male 01-25-2009 12,000 Other Yes No 9                        Minor Dapsone 03-27-2009 2 NR 01-09-1900 NR NR NR NR NR 1.50
18 315301D 32 Female 09-16-2008 20,000 Other Yes No 9                        Other Azathioprine 03-03-2009 6 CR 07-14-2009 4 07-14-2009 0 4 NR CR NA NA NA 1.50
19 413579D 26 Male 01-01-2009 20,000 None Yes No 9                        None Azathioprine 03-03-2009 2 NR 01-09-1900 NR NR CR CR NA 2.00
20 421944D 26 Female 10-01-2008 20,000 Other Yes No 9                        Other Dapsone 03-24-2009 6 PR 04-01-2010 12 NR NR NA PR NA 100.00
21 415464D 5 Male 02-10-2009 4,000 Minor Yes No 9                        Minor Dapsone 03-13-2009 1 PR 05-29-2009 3 PR PR NA Relapse NR 1.50
22 422165D 19 Female 11-01-2008 25,000 Intracranial Yes No 9                        Other Dapsone 03-27-2009 5 NR 01-09-1900 NR NR NA NA NA 100.00
23 424284D 53 Male 03-20-2009 12,000 Minor No Yes 5/5/09                   None Azathioprine 05-05-2009 2 PR 06-05-2009 1 07-09-2009 1 2 CR CR CR CR NA 1.50
24 422912D 4 Male 09-01-2008 29,000 Minor Yes No 9                        Minor Dapsone 03-13-2009 6 CR 05-29-2009 3 05-29-2009 0 3 CR CR NA Relapse PR 1.50
25 417226D 38 Male 02-01-2009 15,000 Minor Yes No 9                        Minor Azathioprine 03-13-2009 1 NR 01-09-1900 NR NR NR NR NR 1.50
26 423359D 33 Male 03-09-2009 14,000 Minor Yes No 9                        Other Dapsone 04-16-2009 1 NR 01-09-1900 NR NR NR NA NA 100.00
27 392297D 72 Female 01-21-2009 10,000 Intracranial Yes No 9                        Other Dapsone 04-03-2009 2 PR 05-08-2009 1 08-04-2009 3 4 CR CR PR NA PR 75.00
28 418506D 21 Female 01-21-2008 10,000 Minor No Yes 6/14/08                  Minor Azathioprine 06-20-2008 5 PR 11-27-2008 5 03-16-2009 4 9 NR PR CR CR NA 1.00
29 427871D 42 Female 01-19-2006 8,000 Intracranial Yes No 9                        Minor Dapsone 03-20-2009 39 PR 04-21-2009 1 07-20-2009 3 4 CR CR NA PR CR 100.00
30 427720D 20 Male 03-24-2009 8,000 Minor No Yes 2/1/09                   Minor Dapsone 08-04-2009 4 NR 01-09-1900 NR NR NR NA NA 100.00
31 427984D 28 Female 03-27-2009 5,000 Minor Yes No 9                        Minor Dapsone 05-15-2009 2 NR 01-09-1900 NR NR NA NA NA 100.00
32 436935D 5 Male 04-01-2009 3,000 Minor Yes No 9                        Minor Dapsone 05-08-2009 1 NR 01-09-1900 NR NR NR NR NR 1.50
33 436593D 3 Female 04-01-2009 8,000 Minor No Yes 7/21/09                  None Dapsone 07-21-2009 4 NR 01-09-1900 NR NR NR NR NA 1.50
34 422443D 9 Male 04-01-2007 10,000 Minor No Yes 3/20/09                  None Dapsone 03-20-2009 24 CR 06-19-2009 3 06-19-2009 0 3 CR CR Relapse NR NA 1.50
35 424586D 28 Male 01-01-2009 14,000 Minor Yes No 9                        Minor Dapsone 03-25-2009 3 PR 06-16-2009 3 PR Relapse NR NR NR 100.00
36 423049D 14 Female 01-03-2009 12,000 Minor Yes No 9                        None Azathioprine 04-24-2009 4 CR 07-03-2009 2 07-03-2009 0 2 CR CR NA CR CR 1.50
37 429535D 22 Female 10-01-2008 15,000 Minor Yes No 9                        Other Azathioprine 12-01-2008 2 NR 01-09-1900 NR NR CR NA CR 2.50
38 445240D 30 Male 06-27-2005 22,000 Minor No Yes 21/04/2009               Minor Dapsone 04-21-2009 46 CR 07-03-2009 2 07-03-2009 0 2 CR CR CR CR CR 100.00
39 450408D 28 Female 03-27-2009 35,000 Minor Yes No 9                        Minor Dapsone 05-01-2009 1 CR 06-03-2009 1 PR PR NA NA NA 50.00
40 451205D 28 Female 02-24-2009 10,000 Minor No Yes 5/5/09                   None Dapsone 05-05-2009 2 CR 08-14-2009 3 08-14-2009 0 3 CR CR NA CR CR 100.00
41 449279D 32 Female 04-05-2009 3,000 Other Yes No 9                        None Dapsone 06-02-2009 2 CR 06-02-2009 0 06-02-2009 0 1 CR CR CR CR NA 100.00
42 453997D 50 Male 04-15-2009 1,000 Minor Yes No 9                        Minor Azathioprine 05-15-2009 1 PR 04-23-2010 11 06-07-2011 14 25 NR NR NR PR CR 1.80
43 456183D 34 Female 05-22-2009 13,000 Minor Yes No 9                        Other Dapsone 11-09-2009 6 CR 05-11-2010 6 05-11-2010 0 6 NR CR Relapse NR NR 100.00
44 468847D 5 Female 04-01-2008 8,000 Minor No Yes 18/04/2009               Minor Azathioprine 06-12-2009 15 NR 01-09-1900 NR NR NR NR NA 1.50
45 446318D 21 Female 03-01-2009 7,000 Other No Yes 8/10/12                  Minor Azathioprine 10-09-2012 44 CR 11-06-2012 1 11-06-2012 0 1 CR CR CR CR NA 1.50
46 469672D 45 Female 05-01-1996 12,000 Minor No Yes 3/5/09                   Minor Dapsone 06-30-2009 160 CR 08-25-2009 2 08-25-2009 0 2 CR CR NA NA NA 100.00
47 476714D 36 Female 03-01-2007 10,000 Minor No Yes 10/6/09                  Minor Dapsone 06-12-2009 28 CR 07-13-2009 1 07-13-2009 0 1 CR CR CR CR CR 100.00
48 174761D 48 Female 01-11-2006 12,000 Minor Yes No 9                        Minor Dapsone 01-22-2008 25 NR 01-09-1900 NR NR NR NR NR 100.00
49 460115D 45 Female 07-10-2009 5,000 Other Yes No 9                        Other Azathioprine 08-11-2009 1 PR 09-20-2009 1 02-10-2010 5 6 NR PR CR PR PR 1.50
50 467358D 25 Male 04-01-2008 6,000 Minor Yes No 9                        Minor Dapsone 05-26-2009 14 CR 08-25-2009 3 08-25-2009 0 3 CR CR CR Relapse NR 100.00
51 471709D 6 Male 04-01-2009 28,000 Minor Yes No 9                        Minor Dapsone 06-12-2009 2 NR 01-09-1900 NR NR NR NR NR 2.50
52 488330D 13 Female 07-06-2009 12,000 Minor Yes No 9                        Minor Dapsone 07-31-2009 1 PR 09-04-2009 1 02-12-2010 5 7 CR CR CR CR CR 2.00
53 489009D 40 Female 07-17-2009 28,000 Minor No Yes 8/11/11                  Minor Azathioprine 11-08-2009 4 CR 01-10-2010 2 01-10-2010 0 2 CR CR CR PR NA 1.50
54 489958D 27 Female 06-05-2009 9,000 Other Yes No 9                        Minor Dapsone 07-14-2009 1 PR 08-18-2009 1 PR PR PR Relapse NR 100.00
55 227554F 40 Female 01-01-1993 15,000 Minor No Yes 15/06/2012               Minor Dapsone 06-22-2012 237 NR 01-09-1900 NR NR NR NR NA 100.00
56 490294D 42 Female 04-07-2009 15,000 Other No Yes 3/10/09                  Minor Azathioprine 10-30-2009 7 NR 01-09-1900 NR NR NA NA NA 1.00
57 501501D 25 Female 04-01-2008 10,000 Other No Yes 15/07/2009               Minor Dapsone 08-04-2009 16 CR 09-15-2009 1 09-15-2009 0 1 CR CR NA CR Relapse 100.00
58 504523D 2 Female 04-13-2009 28,000 Minor No Yes 4/8/09                   Minor Dapsone 08-04-2009 4 NR 01-09-1900 NR NR NR NR NA 2.00
59 506883D 30 Female 08-07-2009 7,000 Minor No Yes 8/9/09                   None Azathioprine 09-08-2009 1 NR 01-09-1900 NR NR NR NA NA 1.50
60 508414D 38 Female 04-08-2009 10,000 Minor Yes No 9                        Minor Dapsone 09-04-2009 5 CR 09-22-2009 1 09-22-2009 0 1 CR CR CR CR CR 100.00
61 512158D 12 Female 01-01-2009 10,000 Minor Yes No 9                        Minor Azathioprine 08-10-2009 7 NR 01-09-1900 NR NR NR NA NA 1.50
62 512167D 23 Female 07-31-2009 15,000 Other Yes No 9                        Other Azathioprine 09-01-2009 1 PR 09-29-2009 1 PR PR NA PR Relapse 1.80
63 513818D 30 Male 04-08-2009 5,000 Other Yes No 9                        Minor Dapsone 08-21-2009 5 NR 01-09-1900 NR NR NR NR NR 100.00
64 473552D 13 Female 06-01-2008 12,000 Minor No Yes 5/6/09                   Minor Dapsone 06-05-2009 12 CR 09-08-2009 3 09-08-2009 0 3 CR PR Relapse PR PR 1.50
65 522969D 12 Female 06-26-2004 12,000 Minor No Yes 15/09/2009               Minor Azathioprine 10-23-2009 65 PR 11-24-2009 1 PR PR NA NA NA 2.00
66 520990D 5 Female 06-24-2008 26,000 Minor No Yes 10/8/09                  Minor Dapsone 08-10-2009 14 CR 09-08-2009 1 09-08-2009 0 1 CR CR CR CR NA 1.50
67 529139D 12 Male 07-01-2009 6,000 Minor No Yes 29/09/2009               Minor Dapsone 09-20-2009 3 CR 01-08-2010 4 01-08-2010 0 4 CR CR NA CR CR 1.00
68 526235D 47 Female 07-24-2009 3,000 Other Yes No 9                        Minor Dapsone 08-28-2009 1 NR 01-09-1900 NR NR NR CR NA 100.00
69 533079D 13 Male 01-09-2009 3,000 Minor Yes No 9                        Minor Azathioprine 11-28-2009 11 PR 01-29-2010 2 11-26-2010 10 12 PR CR NA Relapse CR 1.50
70 542911D 11 Female 11-01-2007 7,000 Minor No Yes 25/09/2009               Minor Azathioprine 09-25-2009 23 NR 01-09-1900 NR NR NR PR CR 2.00
71 551530D 21 Female 09-08-2009 12,000 Other Yes No 9                        Minor Dapsone 10-10-2009 1 NR 01-09-1900 NR NR NR PR NR 100.00
72 591232D 23 Female 11-29-2009 2,000 Other No Yes 7/2/10                   Other Azathioprine 02-07-2010 2 CR 03-09-2010 1 03-09-2010 0 1 NR CR CR CR NA 2.00
73 576872D 41 Female 06-27-2005 40,000 Minor No Yes 9/3/10                   Minor Azathioprine 03-09-2010 57 PR 08-31-2010 6 NR PR PR PR CR 1.50
74 581502D 58 Female 09-16-2009 12,000 Minor No Yes 29/12/2009               Minor Azathioprine 12-29-2009 3 NR 01-09-1900 NR NR NR NR NR 1.50
75 605490D 8 Male 12-19-2009 12,000 Minor Yes No 9                        Minor Azathioprine 02-02-2010 2 NR 01-09-1900 NR NR NR NA NA 1.50
76 602635D 7 Female 07-01-2008 12,000 Minor Yes No 9                        Minor Dapsone 08-01-2008 1 NR 01-09-1900 NR NR NR NR NR 1.50
77 603222D 23 Female 06-25-2003 7,000 Minor No Yes 15/12/2009               Minor Azathioprine 12-15-2009 79 CR 01-22-2010 1 01-22-2010 0 1 CR CR CR CR CR 1.00
78 396890C 16 Female 08-01-2002 24,000 Minor Yes No 9                        Minor Dapsone 11-28-2003 16 PR 02-22-2004 3 PR PR PR PR PR 100.00
79 566617D 21 Female 10-23-2007 4,000 Other Yes No 9                        Minor Azathioprine 09-20-2009 23 NR 01-09-1900 NR NR NA NA NA 1.50
80 570820D 53 Female 04-20-2009 15,000 Minor No Yes 27/10/2009               Minor Azathioprine 10-27-2009 6 NR 01-09-1900 NR NR NA NA NA 1.30
81 563327D 28 Male 06-01-2008 12,000 Minor Yes No 9                        Minor Dapsone 10-30-2009 17 NR 01-09-1900 NR NR NA NA NA 100.00
82 570984D 27 Male 09-01-2005 2,000 Minor No Yes 30/10/2009               Minor Dapsone 11-03-2009 51 PR 02-12-2010 3 PR Relapse NR NR NA 100.00
83 577112D 38 Male 09-11-2009 8,000 Minor Yes No 9                        Minor Dapsone 01-08-2010 4 CR 06-11-2010 5 06-11-2010 0 5 NR CR CR Relapse CR 100.00
84 562095D 4 Male 08-01-2008 30,000 Minor Yes No 9                        Minor Dapsone 11-24-2009 16 NR 01-09-1900 NR NR NR NR NR 1.50
85 614194D 38 Female 01-08-2010 5,000 Minor No Yes 30/03/2010               Minor Azathioprine 03-30-2010 3 CR 09-24-2010 6 09-24-2010 0 6 NR CR CR CR CR 2.00
86 614923D 33 Female 04-01-2008 20,000 Minor Yes No 9                        Minor Dapsone 01-15-2010 22 PR 04-23-2010 3 PR PR Relapse NR NA 100.00
87 614587D 18 Female 09-01-2009 12,000 Minor Yes No 9                        Minor Dapsone 01-15-2010 5 NR 01-09-1900 NR NR NR NR NA 100.00
88 178672D 35 Female 01-01-2000 20,000 Minor No Yes 30/01/2008               Minor Dapsone 02-15-2008 99 PR 08-11-2008 6 11-06-2008 3 9 NR PR CR CR Relapse 100.00
89 622482D 1 Female 01-01-2010 7,000 Minor No Yes 19/02/2010               Minor Dapsone 02-19-2010 2 PR 04-20-2010 2 05-20-2010 1 3 CR CR CR CR NA 1.30
90 623817D 25 Male 04-01-2006 16,000 Minor No Yes 29/01/2010               Minor Dapsone 01-29-2010 47 CR 02-26-2010 1 02-26-2010 0 1 CR CR NA NA NA 100.00
91 624638D 28 Female 12-01-2009 25,000 Minor Yes No 9                        Minor Dapsone 01-29-2010 2 PR 03-10-2010 1 PR PR NA NA NA 100.00
92 609615D 8 Male 12-30-2009 10,000 Minor Yes No 9                        Minor Dapsone 01-29-2010 1 PR 04-27-2010 3 07-23-2010 3 6 PR CR CR NA CR 1.00
93 625203D 32 Male 01-01-2010 6,000 Minor Yes No 9                        Minor Dapsone 03-05-2010 2 CR 04-13-2010 1 04-13-2010 0 1 CR CR CR CR CR 100.00
94 625032D 33 Female 12-01-2009 5,000 Minor Yes No 9                        Minor Dapsone 02-03-2010 2 NR 01-09-1900 NR NR NR NR NA 100.00
95 628004D 5 Female 08-01-2008 12,000 Minor No Yes 12/2/10                  Minor Dapsone 02-12-2010 19 CR 04-16-2010 2 04-16-2010 0 2 CR CR NA Relapse NA 2.00
96 630089D 18 Female 05-02-2010 7,000 Minor No Yes 18/06/2010               Minor Azathioprine 07-02-2010 2 CR 08-03-2010 1 08-03-2010 0 1 CR CR CR Relapse CR 2.00
97 563678D 25 Female 09-17-2009 7,000 Minor No Yes 25/01/2010               Minor Dapsone 01-29-2010 4 NR 01-09-1900 NR NR NA NA NA 100.00
98 638916D 28 Male 05-01-2009 10,000 Minor Yes No 9                        Minor Dapsone 03-26-2010 11 NR 01-09-1900 NR NR NR NR NR 100.00
99 665562D 9 Male 01-01-2010 15,000 Minor No Yes 20/04/2010               Minor Azathioprine 04-23-2010 4 PR 10-12-2010 6 06-30-2011 9 14 NR PR PR PR CR 1.50
100 678002D 34 Female 06-27-2005 19,000 Minor No Yes 3/8/10                   Minor Azathioprine 08-03-2010 62 PR 10-29-2010 3 02-15-2011 4 7 PR CR CR CR Relapse 1.50
101 686040D 2 Female 01-01-2010 12,000 Minor No Yes 30/04/2010               Minor Dapsone 05-04-2010 4 NR 01-09-1900 NR NR NR NR NR 1.50
102 690414D 5 Female 09-20-2009 10,000 Minor No Yes 5/4/10                   Minor Azathioprine 04-05-2010 7 NR 01-09-1900 NR NR NR PR PR 1.50
103 639226D 29 Female 02-08-2006 18,000 Minor No Yes 15/10/2010               Other Dapsone 10-19-2010 57 NR 01-09-1900 NR PR PR CR NA 100.00
104 660077D 47 Female 01-18-2010 9,000 Minor Yes No 9                        Minor Dapsone 03-10-2010 2 NR 01-09-1900 NR NR NR NR NA 100.00
105 669143D 25 Female 05-12-2010 12,000 Minor Yes No 9                        Minor Dapsone 06-22-2010 1 CR 07-21-2010 1 07-21-2010 0 1 CR CR NA NA NA 100.00
106 677658D 24 Female 06-01-2004 20,000 Minor No Yes 25/05/2010               Minor Dapsone 06-08-2010 73 NR 01-09-1900 NR NR NR NR NA 100.00
107 715761D 22 Female 06-01-2010 2,000 Minor Yes No 9                        Minor Dapsone 07-02-2010 1 CR 08-17-2010 2 08-17-2010 0 2 CR CR CR CR CR 75.00
108 700713D 52 Male 03-01-2010 11,000 Minor Yes No 9                        Minor Azathioprine 05-11-2010 2 NR 01-09-1900 NR NR NR PR PR 1.50
109 704000D 4 Female 06-01-2010 15,000 Minor Yes No 9                        Minor Azathioprine 07-01-2010 1 NR 01-09-1900 NR NR NR NA NA 1.30
110 729514D 39 Female 06-19-2010 8,000 Minor Yes No 9                        Minor Dapsone 07-21-2010 1 NR 01-09-1900 NR NR NR NR NR 100.00
111 727200D 20 Female 12-01-2009 30,000 Minor No Yes 2/7/10                   Minor Dapsone 07-06-2010 7 PR 08-03-2010 1 09-27-2011 14 15 PR PR NA CR Relapse 100.00
112 724141D 33 Male 06-29-2010 4,000 Minor Yes No 9                        Other Dapsone 08-03-2010 1 NR 01-09-1900 NR NR NR NR CR 100.00
113 724146D 54 Female 06-28-2010 14,000 Minor Yes No 9                        None Dapsone 07-30-2010 1 CR 09-07-2010 1 09-07-2010 0 1 CR CR CR NA NA 100.00
114 738332D 5 Female 07-20-2010 9,000 Minor Yes No 9                        Minor Azathioprine 09-14-2010 2 NR 01-09-1900 NR NR NR NR NR 1.50
115 719141D 18 Female 06-10-2010 4,000 Other No Yes 6/10/11                  Minor Dapsone 10-06-2011 16 CR 11-07-2011 1 11-07-2011 0 1 CR CR CR CR NA 100.00
116 741942D 6 Male 05-01-2010 16,000 Minor Yes No 9                        Minor Dapsone 07-23-2010 3 CR 08-23-2010 1 08-23-2010 0 1 CR CR NA CR CR 2.00
117 723806D 14 Male 06-01-2010 23,000 Minor Yes No 9                        Minor Dapsone 07-02-2010 1 PR 11-09-2010 4 PR PR Relapse NR NA 1.50
118 707237d 30 Female 03-01-2009 9,000 Minor No Yes 7/6/10                   Minor Azathioprine 07-06-2010 16 NR 01-09-1900 NR NR NR NR NR 1.50
119 741241D 21 Female 02-01-2009 8,000 Minor Yes No 9                        Minor Azathioprine 10-19-2009 9 PR 02-11-2010 4 09-22-2011 20 23 NR PR CR CR CR 2.00
120 743773D 8 Female 05-01-2010 20,000 Minor Yes No 9                        Minor Dapsone 07-24-2010 3 CR 11-16-2010 4 11-16-2010 0 4 NR CR PR CR CR 1.50
121 749621D 49 Female 03-01-2010 5,000 Minor Yes No 9                        Minor Azathioprine 08-03-2010 5 PR 02-08-2011 6 NR PR Relapse PR PR 1.00
122 762296D 33 Female 08-01-2010 9,000 Minor No Yes 28/01/2011               Minor Dapsone 01-28-2011 6 PR 02-25-2011 1 PR Relapse NR NR NA 100.00
123 762703D 3 Female 05-01-2010 20,000 Minor Yes No 9                        None Dapsone 08-24-2010 4 CR 09-24-2010 1 09-24-2010 0 1 CR CR CR CR NA 1.50
124 723910D 45 Female 12-01-2009 14,000 Minor No Yes 28/07/2010               Minor Dapsone 07-30-2010 8 NR 01-09-1900 NR NR NR NR NR 100.00
125 753057D 17 Female 08-01-2010 14,000 Minor Yes No 9                        Minor Azathioprine 09-10-2010 1 PR 10-08-2010 1 01-04-2011 3 4 CR CR CR CR CR 1.50
126 762785D 10 Female 08-01-2010 15,000 Minor Yes No 9                        None Dapsone 08-30-2010 1 NR 01-09-1900 NR NR NR NR NA 1.50
127 738509D 6 Female 03-01-2010 30,000 Minor No Yes 20/08/2010               Minor Dapsone 08-20-2010 6 PR 09-07-2010 1 10-05-2010 1 2 CR CR CR CR PR 1.50
128 779737D 34 Female 10-01-2010 15,000 Other No Yes 26/07/2011               Minor Azathioprine 07-29-2011 10 CR 01-03-2012 5 01-03-2012 0 5 NR CR PR CR Relapse 1.50
129 770237D 38 Female 08-01-2010 4,000 Other No Yes 26/07/2011               Minor Azathioprine 05-29-2011 10 PR 08-26-2011 3 05-08-2012 9 PR PR PR CR NA 1.50
130 000460D 29 Male 01-01-2007 32,000 Minor No Yes 19/06/2007               Minor Dapsone 06-19-2007 6 CR 07-17-2007 1 07-17-2007 0 1 CR CR CR CR Relapse 100.00
131 805953D 35 Male 06-01-2010 14,000 Minor No Yes 2/10/10                  Minor Dapsone 11-09-2010 5 PR 12-07-2010 1 PR Relapse NR CR CR 100.00
132 832646D 27 Female 11-01-2009 16,000 Minor No Yes 11/2/10                  Minor Azathioprine 02-11-2011 16 NR 01-09-1900 NR NR NR NA NA 1.50
133 396494F 26 Female 01-01-2013 8,000 Minor Yes No 9                        Minor Azathioprine 02-26-2013 2 NR 01-09-1900 NR NR NR NA NA 1.50
134 828678D 13 Female 10-01-2010 5,000 Minor Yes No 9                        Minor Azathioprine 03-04-2011 5 CR 07-01-2011 4 07-01-2011 0 4 NR CR CR CR CR 1.50
135 845908D 39 Male 10-01-2010 25,000 Minor Yes No 9                        Minor Dapsone 12-17-2010 3 NR 01-09-1900 NR NR NR NR NA 100.00
136 785849D 16 Female 05-01-2010 5,000 Minor No Yes 15/10/2010               Minor Dapsone 10-26-2010 6 NR 01-09-1900 NR NR NR NR NR 75.00
137 788474D 35 Female 09-01-2010 19,000 Minor No Yes 9/11/10                  Minor Azathioprine 11-09-2010 2 NR 01-09-1900 NR NR PR CR CR 1.50
138 811449D 25 Male 06-01-2010 13,000 Minor No Yes 29/10/2010               None Dapsone 10-29-2010 5 NR 01-09-1900 NR NR NR NR NA 100.00
139 807280D 10 Female 01-01-2010 12,000 Minor Yes No 9                        Minor Dapsone 11-09-2010 10 CR 05-27-2011 7 05-27-2011 0 7 NR CR CR CR NA 1.50
140 801656D 27 Male 01-01-2004 4,000 Minor No Yes 8/10/10                  Minor Azathioprine 10-08-2010 82 CR 11-09-2010 1 11-09-2010 0 1 CR CR CR CR NA 1.50
141 503114A 30 Male 01-01-2005 10,000 Minor No Yes 2/8/10                   Intracranial hemoAzathioprine 08-13-2010 68 NR 01-09-1900 NR NR NR NR NR 1.50
142 754092D 43 Female 01-01-1993 26,000 Minor No Yes 10/8/10                  Minor Dapsone 08-17-2010 215 NR 01-09-1900 NR NR NR NA NA 100.00
143 750605D 2 Male 08-01-2010 15,000 Minor No Yes 14/12/2010               None Dapsone 01-11-2011 5 PR 03-08-2011 2 12-28-2011 10 12 PR PR CR CR NA 1.50
144 812256D 65 Female 10-01-2010 12,000 Minor No Yes 29/04/2011               Minor Dapsone 04-26-2011 7 CR 08-26-2011 4 08-26-2011 0 4 NR CR CR Relapse CR 100.00
145 913107D 20 Female 11-01-2010 10,000 Other No Yes 15/04/2011               Minor Azathioprine 04-15-2011 6 CR 07-06-2011 3 07-06-2011 0 3 CR CR CR CR CR 1.50
146 036594D 34 Female 01-01-2012 10,000 Minor Yes No 9                        None Dapsone 03-02-2012 2 PR 06-05-2012 3 11-30-2012 6 9 PR PR CR PR NA 100.00
147 887624B 42 Male 05-01-2000 7,000 Minor No Yes 6/11/10                  Minor Azathioprine 01-07-2011 130 CR 02-01-2011 1 02-01-2011 0 1 CR CR CR CR CR 1.50
148 645591D 37 Male 06-01-2009 6,000 Other No Yes 2/3/10                   Minor Azathioprine 03-06-2010 9 CR 04-07-2010 1 04-07-2010 0 1 CR CR CR CR CR 1.50
149 894944D 31 Female 12-01-2010 10,000 Minor No Yes 18/03/2011               Minor Azathioprine 03-18-2011 4 NR 01-09-1900 NR NR NR NR NR 1.50
150 893349D 12 Female 12-01-2010 32,000 Minor Yes No 9                        Minor Azathioprine 03-15-2011 3 NR 01-09-1900 NR NR NR NR NA 1.50
151 876086D 5 Female 03-01-2010 34,000 Minor Yes No 9                        Minor Azathioprine 02-04-2011 11 NR 01-09-1900 NR NR NR NR NR 1.50
152 876665D 20 Female 01-01-2011 6,000 Minor Yes No 9                        Minor Dapsone 03-04-2011 2 NR 01-09-1900 NR NR NR NA NA 100.00
153 887616D 2 Female 10-01-2010 30,000 Minor No Yes 4/3/11                   Minor Azathioprine 03-04-2011 5 NR 01-09-1900 NR NR NR NA NA 1.50
154 837756D 11 Male 09-01-2010 2,000 Minor No Yes 20/12/2010               Minor Azathioprine 01-04-2011 4 NR 01-09-1900 NR NR NR PR PR 1.50
155 839790D 50 Male 01-27-2005 10,000 Minor No Yes 24/2/2011                Minor Azathioprine 02-24-2011 74 CR 06-03-2011 3 NR CR PR Relapse NR 1.50
156 831684D 14 Female 09-01-2010 15,000 Other Yes No 9                        Minor Dapsone 12-21-2010 4 NR 01-09-1900 NR NR NR NR NA 1.50
157 982308D 19 Male 05-24-2011 3,000 Minor Yes No 9                        Minor Dapsone 06-29-2011 1 PR 07-29-2011 1 08-28-2011 1 2 CR CR CR CR Relapse 100.00
158 983685D 40 Female 07-01-2011 6,000 Minor Yes No 9                        Minor Azathioprine 08-26-2011 2 PR 12-15-2011 4 03-08-2012 3 7 CR CR CR CR CR 1.50
159 976267D 42 Female 06-27-2005 5,000 Minor No Yes 10/10/11                 Minor Dapsone 10-10-2011 77 CR 06-15-2012 8 06-15-2012 0 8 NR NR CR Relapse NR 100.00
160 966868D 13 Female 06-01-2011 15,000 Minor No Yes 16/08/2011               Minor Azathioprine 08-16-2011 3 PR 09-13-2011 1 06-29-2012 10 11 PR PR PR CR CR 1.50
161 948992D 27 Female 03-01-2011 15,000 Minor No Yes 5/5/12                   Minor Dapsone 05-18-2012 15 CR 07-23-2012 2 07-23-2012 0 2 CR Relapse CR CR NA 100.00
162 965503D 9 Female 06-01-2009 30,000 Minor No Yes 17/06/2011               Minor Azathioprine 06-17-2011 25 NR 01-09-1900 NR NR NR NR NR 1.50
163 957608D 35 Female 05-01-2011 5,000 Minor Yes No 9                        Minor Dapsone 06-01-2011 1 PR 07-15-2011 1 PR PR PR PR PR 100.00
164 891924D 36 Female 07-01-2010 35,000 Minor No Yes 25/02/2011               Minor Dapsone 02-25-2011 8 NR 01-09-1900 NR NR NR NR NR 75.00
165 878510D 20 Female 02-01-2011 10,000 Minor Yes No 9                        Minor Dapsone 03-04-2011 1 NR 01-09-1900 NR NR CR CR NA 75.00
166 875179D 50 Male 09-01-2010 15,000 Minor Yes No 9                        Minor Azathioprine 02-11-2011 5 NR 01-09-1900 NR NR PR PR Relapse 1.50
167 992739D 18 Male 07-01-2011 3,000 Minor Yes No 9                        Minor Dapsone 08-23-2011 2 PR 09-20-2011 1 11-18-2011 2 3 CR CR CR NA NA 100.00
168 972642D 19 Female 04-01-2011 9,000 Minor No Yes 3/4/12                   Minor Azathioprine 04-03-2012 12 PR 06-29-2012 3 07-05-2013 12 15 PR PR NA CR NA 1.50
169 993073D 23 Male 07-01-2011 15,000 Minor Yes No 9                        Minor Dapsone 12-27-2011 6 NR 01-09-1900 NR NR NR NR NA 100.00
170 987743D 7 Female 07-01-2011 18,000 Minor No Yes 10/1/12                  Minor Dapsone 01-10-2012 6 CR 04-13-2012 3 04-13-2012 0 3 CR CR NA NA NA 1.50
171 997196D 29 Female 07-01-2011 17,000 Minor Yes No 9                        Minor Azathioprine 08-05-2011 1 NR 01-09-1900 NR NR NA NA NA 1.50
172 974879D 2 Female 07-01-2011 7,000 Minor Yes No 9                        Minor Azathioprine 12-01-2011 5 NR 01-09-1900 NR NR NR NR NA 1.50
173 968245D 27 Male 07-01-2011 3,000 Minor Yes No 9                        Minor Azathioprine 08-02-2011 1 NR 01-09-1900 NR NR NR CR CR 1.50
174 907224D 63 Female 03-01-2011 9,000 Intracranial Yes No 9                        None Dapsone 04-26-2011 2 NR 01-09-1900 NR NR NR NR NR 100.00
175 795296D 32 Female 10-01-2010 8,000 Minor Yes No 9                        Minor Dapsone 11-04-2010 1 CR 02-08-2011 3 02-08-2011 0 3 CR CR Relapse NR NR 100.00
176 901294D 33 Male 03-01-2011 10,000 Minor Yes No 9                        Minor Dapsone 04-29-2011 2 CR 08-02-2011 3 08-02-2011 0 3 NR CR PR CR Relapse 100.00
177 902917D 27 Female 03-01-2011 35,000 Minor Yes No 9                        Minor Azathioprine 03-25-2011 1 CR 08-02-2011 4 08-02-2011 0 4 NR NR NR NR NA 1.50
178 911136D 58 Female 01-01-2013 7,000 Minor No Yes 22/03/2013               Minor Azathioprine 03-22-2013 3 NR 01-09-1900 NR NR NR NA NA 1.50
179 911843D 33 Male 03-01-2011 19,000 Minor Yes No 9                        Minor Azathioprine 05-17-2011 3 PR 06-17-2011 1 07-01-2011 0 2 CR CR CR CR NA 1.50
180 916437D 9 Male 04-27-2006 15,000 Minor No Yes 1/4/11                   Minor Dapsone 04-14-2011 60 NR 01-09-1900 NR NR NR NR NA 1.50
181 916749D 62 Female 04-01-2010 7,000 Intracranial No Yes 1/4/11                   Minor Dapsone 04-12-2011 13 NR 01-09-1900 NR NR NR NR NA 100.00
182 918567D 9 Male 03-01-2010 21,000 Minor Yes No 9                        Minor Azathioprine 04-05-2011 13 NR 01-09-1900 NR NR NR NR NA 1.50
183 929985D 45 Female 03-01-2011 20,000 Minor Yes No 9                        Minor Azathioprine 04-19-2011 2 CR 06-10-2011 2 06-10-2011 0 2 CR CR CR CR CR 1.50
184 983742D 21 Female 07-01-2011 17,000 Minor Yes No 9                        Minor Dapsone 08-04-2011 1 NR 01-09-1900 NR NR NR NR PR 100.00
185 947089B 24 Female 08-01-2011 15,000 Minor Yes No 9                        Minor Azathioprine 10-18-2011 3 PR 11-18-2011 1 CR PR Relapse PR NA 1.50
186 017743F 50 Female 09-01-2008 5,000 Minor No Yes 24/01/2012               Minor Azathioprine 01-24-2012 41 NR 01-09-1900 NR PR CR CR CR 1.00
187 047165F 7 Female 07-01-2011 25,000 Minor Yes No 9                        Minor Dapsone 10-07-2011 3 CR 05-01-2012 7 NR CR PR NR NR 1.50
188 041716F 27 Female 07-01-2011 20,000 Minor No Yes 10/1/12                  None Azathioprine 01-10-2012 6 NR 01-09-1900 NR NR NR NR NR 1.50
189 094844F 37 Female 01-01-2012 10,000 Minor No Yes 12/7/12                  Minor Azathioprine 07-12-2012 6 NR 01-09-1900 NR NR NR CR NA 1.50
190 096193F 39 Female 01-01-2000 25,000 Minor No Yes 16/12/2011               Minor Azathioprine 12-16-2011 146 PR 01-17-2012 1 06-11-2012 5 6 PR PR PR CR NA 1.50
191 089949F 18 Female 12-01-2011 6,000 Other Yes No 9                        Minor Dapsone 01-13-2012 1 CR 09-21-2012 8 09-21-2012 0 8 NR NR CR CR NA 100.00
192 072095F 22 Female 05-01-2011 10,000 Minor No Yes 14/02/2012               Minor Azathioprine 02-14-2012 10 CR 03-16-2012 1 03-16-2012 0 1 CR CR CR CR NA 1.50
193 086134F 40 Male 11-01-2011 32,000 Minor No Yes 21/02/2012               Minor Azathioprine 04-21-2012 6 PR 07-06-2012 3 09-28-2012 3 5 PR CR CR Relapse NA 1.50
194 043392F 12 Female 10-01-2011 8,000 Minor Yes No 9                        Minor Azathioprine 11-04-2011 1 NR 01-09-1900 NR NR NR NR NA 2.00
195 003575F 3 Male 11-01-2010 18,000 Minor No Yes 06/08 2011               Minor Dapsone 08-12-2011 9 CR 09-16-2011 1 09-16-2011 0 1 CR Relapse NR PR NA 1.50
196 031122F 13 Female 10-24-2010 15,000 Minor Yes No 9                        Minor Azathioprine 09-16-2011 11 PR 02-10-2012 5 05-04-2012 3 8 NR PR CR CR Relapse 1.50
197 002121F 4 Male 05-01-2011 20,000 Minor Yes No 9                        Minor Dapsone 08-16-2011 4 CR 11-11-2011 3 11-11-2011 0 3 CR Relapse PR CR CR 1.50
198 034590f 75 Male 06-25-1994 50,000 Minor No Yes 17/09/2011               Minor Dapsone 09-20-2011 210 PR 11-04-2011 2 02-14-2012 3 5 PR PR NA NA NA 100.00
199 025411F 28 Male 10-01-2009 22,000 Minor No Yes 6/9/11                   Minor Azathioprine 09-06-2011 24 NR 01-09-1900 NR NR NA NA NA 1.50
200 022605F 9 Female 12-01-2008 15,000 Minor Yes No 9                        Minor Azathioprine 10-04-2011 35 NR 01-09-1900 NR NR NR NR NA 1.50
201 086834F 4 Male 06-01-2011 13,000 Minor No Yes 16/12/2011               Minor Dapsone 12-16-2011 7 NR 01-09-1900 NR NR NR NR NA 1.50
202 024875F 44 Male 03-01-2010 30,000 Minor No Yes 4/10/11                  Minor Dapsone 10-04-2011 19 PR 11-01-2011 1 PR PR PR PR NA 100.00
203 036330F 3 Male 02-01-2011 15,000 Minor Yes No 9                        Minor Azathioprine 10-25-2011 9 NR 01-09-1900 NR NR NR NA NA 1.50
204 053058F 50 Female 07-01-2011 5,000 Minor No Yes 17/01/2012               Minor Azathioprine 01-17-2012 7 PR 04-03-2012 3 06-26-2012 3 5 CR CR CR CR NA 2.00
205 052213F 41 Male 08-01-2010 4,000 Minor No Yes 18/10/2011               Minor Azathioprine 10-19-2011 15 NR 01-09-1900 NR NR NR NR NA 1.50
206 094490F 17 Female 12-01-2011 13,000 Epistaxis re     Yes No 9                        Minor Dapsone 01-31-2012 2 PR 02-28-2012 1 PR PR PR PR NA 100.00
207 098684F 31 Female 12-23-2011 20,000 Other Yes No 9                        Other Azathioprine 01-27-2012 1 CR 03-23-2012 2 03-23-2012 0 2 CR CR CR CR NA 1.00
208 122899F 16 Female 06-27-2005 30,000 Minor No Yes 26/06/2012               Minor Dapsone 06-20-2012 85 PR 09-21-2012 3 PR PR PR PR NA 100.00
209 124137F 17 Male 02-01-2012 12,000 Minor Yes No 9                        Minor Dapsone 02-24-2012 1 CR 06-05-2012 3 06-05-2012 0 3 NR CR CR NA NA 100.00
210 116505F 31 Male 12-01-2011 15,000 Minor Yes No 9                        None Azathioprine 02-10-2012 2 CR 03-13-2012 1 03-13-2012 0 1 CR CR CR CR NA 1.50
211 117332F 36 Female 06-01-2010 40,000 None No Yes 31/01/2012               None Azathioprine 01-31-2012 20 PR 03-30-2012 2 PR PR PR PR NA 1.50
212 132241F 21 Female 01-01-2012 20,000 None Yes No 9                        None Azathioprine 02-07-2012 1 PR 03-02-2012 1 PR Relapse NR NR NR 1.00
213 129647F 45 Female 12-01-2011 12,000 Intracranial Yes No 9                        None Azathioprine 02-14-2013 15 PR 03-13-2013 1 PR PR PR PR NA 1.50
214 125718F 17 Female 02-01-2012 35,000 Other Yes No 9                        None Azathioprine 05-11-2013 16 NR 01-09-1900 NR NR NA NR NA 1.50
215 140570F 20 Female 01-01-2012 48,000 Minor Yes No 9                        None Azathioprine 02-21-2013 14 CR 03-23-2013 1 03-23-2013 0 1 CR CR PR NA NA 1.50
216 129797F 30 Female 02-01-2012 10,000 Minor Yes No 9                        Minor Azathioprine 02-24-2012 1 NR 01-09-1900 NR NR NR CR NA 1.50
217 154795F 35 Female 11-01-2011 9,000 Intracranial Yes No 9                        Minor Azathioprine 03-16-2012 5 PR 05-04-2012 2 09-07-2012 4 6 CR CR NA NA NA 1.50
218 144598F 28 Female 01-01-2012 12,000 Other Yes No 9                        Minor Azathioprine 03-20-2012 3 PR 06-14-2012 3 PR PR PR PR NA 1.50
219 147939F 38 Female 05-01-2009 9,000 Other No Yes 13/03/2012               Minor Azathioprine 04-13-2012 36 CR 07-20-2012 3 07-20-2012 0 3 CR CR CR CR NA 1.50
220 159063F 2 Female 01-01-2012 9,000 Minor No Yes 8/5/12                   Minor Dapsone 05-08-2012 4 NR 01-09-1900 NR NR NR NA NA 1.50
221 168948F 10 Female 02-01-2012 10,000 Minor No Yes 24/04/2012               Minor Azathioprine 05-01-2012 3 PR 08-03-2012 3 PR PR PR PR NA 1.50
222 291076F 2 Male 04-01-2012 12,000 Minor No Yes 08/02/2013               Minor Azathioprine 02-08-2013 10 NR 01-09-1900 NR NR NR NA NA 2.00
223 139722F 11 Female 10-01-2010 40,000 Minor No Yes 27/03/2012               Minor Azathioprine 03-30-2012 18 NR 01-09-1900 NR PR PR Relapse NA 1.50
224 175081F 58 Male 03-01-2012 10,000 Minor Yes No 9                        Minor Azathioprine 04-10-2012 1 NR 01-09-1900 NR PR CR CR NA 1.50
225 173367F 22 Female 04-01-2010 15,000 Intracranial No Yes 15/06/2012               Minor Azathioprine 06-15-2012 27 CR 07-06-2012 1 07-06-2012 0 1 CR CR NA NA NA 1.50
226 183420F 3 Male 03-01-2012 12,000 Minor Yes No 9                        Minor Azathioprine 05-25-2012 3 NR 01-09-1900 NR NR NR NR NA 1.50
227 122973F 32 Female 11-01-2011 5,000 Intracranial No Yes 31/01/2012               Minor Azathioprine 01-31-2012 3 CR 04-23-2012 3 04-23-2012 0 3 CR CR NA NA NA 1.50
228 188965F 5 Male 05-01-2011 14,000 Minor No Yes 25/05/2012               Minor Azathioprine 05-25-2012 13 NR 01-09-1900 NR NR NR NR NA 1.50
229 178149F 32 Female 03-01-2012 5,000 Minor Yes No 9                        Minor Dapsone 05-04-2012 2 CR 07-31-2012 3 07-31-2012 0 3 CR CR NA Relapse NA 100.00
230 180007F 5 Female 04-01-2012 15,000 Minor Yes No 9                        Minor Azathioprine 06-15-2012 3 CR 11-20-2012 5 11-20-2012 0 5 NR CR CR Relapse NA 1.50
231 235925F 10 Female 05-01-2012 30,000 Minor Yes No 9                        Minor Azathioprine 06-26-2012 2 NR 01-09-1900 NR NR NR NR NA 1.50
232 390133F 10 Male 03-01-2009 13,000 Minor No Yes 15/01/2013               Minor Azathioprine 01-18-2013 47 PR 04-12-2013 3 PR PR PR NA NA 1.50
233 243066F 5 Male 03-01-2011 7,000 Minor Yes No 9                        Minor Dapsone 07-13-2012 17 NR 01-09-1900 NR NR NR NR NA 1.50
234 198753F 48 Female 03-01-2012 34,000 Minor No Yes 24/08/2012               Minor Azathioprine 08-24-2012 6 PR 09-25-2012 1 04-05-2013 6 7 PR PR PR CR NA 1.50
235 200873F 4 Male 08-01-2009 56,000 Minor No Yes 21/05/2012               Minor Azathioprine 06-28-2012 35 CR 09-25-2012 3 09-25-2012 0 3 CR CR CR CR NA 1.50
236 206235f 21 Male 03-01-2000 32,000 Minor No Yes 18/05/2012               Minor Dapsone 05-18-2012 149 PR 07-17-2012 2 10-09-2012 3 5 CR CR Relapse PR NA 100.00
237 199805F 36 Female 05-12-2012 4,000 Other Yes No 9                        Other Azathioprine 06-12-2012 1 CR 07-10-2012 1 07-10-2012 0 1 PR PR PR Relapse NA 1.50
238 201616f 18 Female 05-01-2010 19,000 Minor No Yes 15/05/2012               Minor Dapsone 05-15-2012 25 CR 08-17-2012 3 08-17-2012 0 3 CR CR CR CR NA 100.00
239 190459F 18 Female 03-01-2012 22,000 Minor No Yes 22/05/2012               Minor Azathioprine 09-18-2012 7 PR 12-11-2012 3 PR PR NA PR NA 2.50
240 199941F 11 Male 10-01-2011 19,000 Minor No Yes 12/05/2012               Minor Dapsone 05-12-2012 7 NR 01-09-1900 NR NR NR NR NA 2.30
241 474777C 13 Male 04-30-2004 10,000 Minor Yes No 9                        None Dapsone 05-31-2004 1 CR 07-06-2004 1 07-06-2004 0 1 CR CR CR CR Relapse 1.50
242 433937C 1 Male 05-01-2002 30,000 Minor No Yes February 2    Other Azathioprine 05-07-2004 25 CR 08-10-2004 3 08-10-2004 0 3 CR CR CR Relapse CR 1.50
243 034777D 18 Female 06-01-2007 30,000 Minor No Yes 05/10/2007               Minor Dapsone 07-05-2007 1 NR 01-09-1900 NR NR NR NR NR 100.00
244 616549C 9 Female 03-01-2002 30,000 Minor No Yes 23/08/2005               Minor Azathioprine 08-23-2005 42 CR 06-06-2006 10 06-06-2006 0 10 NR NR NR CR PR 1.50
245 625986C 10 Male 10-01-2004 21,000 Minor No Yes 19/04/2005               None Azathioprine 04-19-2005 7 CR 05-24-2005 1 05-24-2005 0 1 CR CR CR NA NA 1.50
246 659581C 5 Female 06-01-2005 15,000 Minor No Yes 02/08/2005               Minor Dapsone 08-02-2005 2 NR 01-09-1900 NR NR NR NR NR 1.50
247 680715C 45 Female 09-08-2005 13,000 Minor No Yes 25/10/2005               None Dapsone 10-25-2005 2 NR 01-09-1900 NR PR CR NA NA 100.00
248 690693C 20 Female 01-01-2003 13,000 Other No Yes 26/08/2005               Minor Dapsone 08-27-2005 32 PR 09-30-2005 1 05-19-2006 8 9 CR CR CR Relapse Relapse 50.00
249 313299C 10 Male 05-01-2003 2,000 Minor Yes No 9                        Minor Dapsone 05-28-2004 13 CR 08-31-2004 3 08-31-2004 0 3 CR CR CR CR NA 1.50
250 434497C 14 Female 02-04-2004 8,000 Minor No Yes 01/02/2008               Minor Dapsone 02-02-2008 49 NR 01-09-1900 NR NR NR NR NR 2.00
251 675900C 38 Male 03-01-2005 10,000 Minor Yes No 9                        Minor Azathioprine 07-29-2005 5 PR 10-25-2005 3 PR PR PR Relapse CR 1.50
252 410413C 45 Female 12-01-2003 5,000 Minor No Yes 14/09/2007               Minor Dapsone 09-18-2007 46 PR 01-10-2008 4 NR PR PR Relapse PR 100.00
253 900582C 5 Male 09-01-2006 5,000 Minor No Yes 01/12/2006               Minor Dapsone 12-01-2006 3 NR 01-09-1900 NR NR NR NR CR 1.50
254 095045D 19 Female 09-01-2007 12,000 Minor No Yes 22/2/2009                Minor Azathioprine 02-24-2009 18 CR 05-19-2009 3 05-19-2009 0 3 CR CR NA CR NA 2.30
255 096379D 61 Male 06-01-2007 15,000 Minor No Yes 07/09/2007               Minor Azathioprine 09-07-2007 3 CR 12-07-2007 3 12-07-2007 0 3 CR CR CR CR CR 1.50
256 081880D 3 Male 09-01-2007 8,000 Minor Yes No 9                        None Dapsone 11-13-2007 2 CR 05-30-2008 7 05-30-2008 0 7 NR NR CR Relapse NR 1.50
257 083998D 7 Female 11-01-2004 3,000 Other Yes No 9                        Minor Dapsone 08-17-2007 34 NR 01-09-1900 NR NR NR NR NA 1.50
258 104189D 41 Female 03-01-2007 19,000 Minor No Yes 18/09/2007               Minor Dapsone 09-18-2007 7 NR 01-09-1900 NR NR NR CR CR 100.00
259 105580D 5 Male 06-01-2007 15,000 Minor No Yes 29/9/2009                Minor Dapsone 10-02-2009 28 CR 12-15-2009 2 12-15-2009 0 2 CR CR NA CR CR 1.50
260 105618D 20 Male 04-01-2005 20,000 Minor No Yes 23/11/2007               None Azathioprine 11-23-2007 32 PR 01-11-2008 2 11-12-2008 10 12 PR PR NA CR CR 1.50
261 105987D 38 Female 09-01-2007 3,000 Other No Yes 11/03/2008               Minor Azathioprine 03-11-2008 6 CR 07-25-2008 5 07-25-2008 0 5 NR CR CR CR CR 1.50
262 359596C 16 Female 09-01-2003 35,000 Minor No Yes 19/12/2003               Minor Dapsone 12-19-2003 4 CR 01-27-2004 1 01-27-2004 0 1 CR CR CR CR CR 100.00
263 619910C 80 Female 10-01-2005 5,000 Minor No Yes 31/12/2007               None Azathioprine 01-25-2008 28 CR 02-29-2008 1 02-29-2008 0 1 CR CR NA NA NA 1.00
264 150715D 12 Female 05-01-2007 12,000 Minor No Yes 14/12/2007               Minor Dapsone 12-14-2007 8 NR 01-09-1900 NR NR NR NR NR 1.50
265 153147D 28 Female 12-01-2007 4,000 Other No Yes 14/02/2008               None Azathioprine 02-15-2008 3 CR 04-11-2008 2 04-11-2008 0 2 CR CR Relapse CR CR 1.50
266 161816D 7 Male 03-01-2005 4,000 Minor Yes No 9                        Minor Dapsone 01-08-2008 35 CR 02-08-2008 1 02-08-2008 0 1 CR CR CR CR CR 1.50
267 215005D 9 Male 04-01-2008 9,000 Minor Yes No 9                        None Dapsone 05-27-2008 2 NR 01-09-1900 NR NR NR NR CR 2.00
268 214816D 14 Male 12-01-2007 7,000 Minor Yes No 9                        Minor Dapsone 04-08-2008 4 PR 08-12-2008 4 11-09-2008 3 7 NR PR NA CR CR 1.50
269 208741d 5 Male 04-01-2008 25,000 Minor No Yes 25/11/2009               None Dapsone 11-25-2009 20 NR 01-09-1900 NR NR NA NA NA 1.50
270 208794D 20 Female 01-01-2008 6,000 Minor Yes No 9                        None Azathioprine 03-28-2008 3 NR 01-09-1900 NR NR CR CR NA 1.50
271 206332D 8 Female 03-01-2008 7,000 Minor No Yes 14/5/2010                Minor Dapsone 05-14-2010 27 CR 08-06-2010 3 08-06-2010 0 3 CR CR CR CR Relapse 1.50
272 202501D 28 Female 03-01-2008 6,000 Minor No Yes 13/10/2009               Minor Dapsone 10-13-2009 20 CR 11-17-2009 1 11-17-2009 0 1 CR CR NA NA NA 100.00
273 202502D 30 Male 03-01-2006 15,000 Minor No Yes 03/02/2009               Minor Azathioprine 02-03-2009 36 PR 05-01-2009 3 07-28-2009 3 6 CR CR PR PR PR 1.50
274 201429D 45 Female 03-01-2008 15,000 Minor Yes No 9                        Minor Dapsone 03-28-2008 1 NR 01-09-1900 NR NR NR NA NA 100.00
275 203501D 12 Female 02-01-2004 18,000 Minor No Yes 14/03/2008               Minor Azathioprine 03-14-2008 50 CR 05-18-2008 2 05-18-2008 0 2 CR CR CR CR NA 1.50
276 232037D 24 Female 05-08-2008 5,000 Other Yes No 9                        Minor Dapsone 06-10-2008 1 NR 01-09-1900 NR NR NR NR CR 100.00
277 230700D 9 Female 04-01-2008 17,000 Minor Yes No 9                        Minor Dapsone 05-02-2008 1 CR 09-19-2008 5 09-19-2008 0 5 NR CR CR CR CR 1.50
278 235359D 18 Female 05-01-2008 13,000 Minor No Yes 05/08/2008               Minor Dapsone 08-05-2008 3 NR 01-09-1900 NR NR CR Relapse NA 100.00
279 235113D 22 Male 04-01-2008 22,000 Minor Yes No 9                        Minor Dapsone 05-20-2008 2 NR 01-09-1900 NR NR NR NR NR 100.00
280 515953B 23 Female 07-01-2008 16,000 Minor No Yes 24/04/2012               Minor Azathioprine 05-29-2012 48 CR 06-12-2012 0 06-12-2012 0 0 CR CR CR CR NA 1.50
281 589125A 30 Male 11-01-1986 8,000 Minor No Yes 09/05/2008               Minor Dapsone 05-09-2008 262 NR 01-09-1900 NR CR NR NR NR 100.00
282 235058D 4 Male 03-01-2007 28,000 Minor No Yes 13/05/2008               Minor Dapsone 05-16-2008 15 PR 09-28-2008 5 NR PR PR NA NA 1.50
283 236543D 3 Female 04-01-2008 11,000 Minor Yes No 9                        Minor Dapsone 05-16-2008 2 PR 08-12-2008 3 08-11-2009 12 15 PR PR PR PR CR 1.50
284 240123D 3 Male 03-01-2008 12,000 Minor Yes No 9                        Minor Dapsone 05-27-2008 3 CR 08-12-2008 3 08-12-2008 0 3 CR CR NA CR CR 1.50
285 242168D 52 Male 03-01-2007 40,000 Minor No Yes 20/05/2008               Minor Dapsone 05-20-2008 15 NR 01-09-1900 NR NR NR NR NR 100.00
286 258498D 18 Male 12-01-2007 5,000 Minor No Yes 16/09/2008               Minor Dapsone 09-16-2008 10 NR 01-09-1900 NR NR NR NR NR 100.00
287 267827d 30 Male 07-01-2008 5,000 Minor No Yes 08/08/2008               Minor Dapsone 08-08-2008 1 NR 01-09-1900 NR NR NR NA NA 100.00
288 268591D 21 Female 04-01-2008 17,000 Minor No Yes 12/09/2008               Minor Dapsone 09-12-2008 5 PR 12-09-2008 3 PR CR CR NA NA 100.00
289 257313D 8 Male 01-01-2008 4,000 Minor No Yes 20/06/2008               Minor Azathioprine 06-20-2008 6 PR 03-17-2009 9 NR NR PR PR CR 1.50
290 266200D 74 Male 06-01-2008 10,000 Minor Yes No 9                        Minor Dapsone 06-27-2008 1 CR 09-23-2008 3 09-23-2008 0 3 CR CR CR CR CR 100.00
291 271112D 48 Male 06-01-2007 40,000 Minor No Yes 08/07/2008               Minor Dapsone 07-08-2008 13 NR 01-09-1900 NR NR NR NR NA 100.00
292 274901D 45 Male 07-01-2007 22,000 Minor No Yes 07/05/2010               Minor Dapsone 05-07-2010 35 PR 01-04-2011 8 06-24-2011 6 14 NR PR PR CR CR 100.00
293 274429D 7 Female 01-01-2008 10,000 Minor Yes No 9                        Minor Dapsone 09-09-2008 8 NR 01-09-1900 NR NR NR NR NA 1.50
294 279795D 6 Female 06-01-2006 5,000 Minor No Yes 05/07/2008               Minor Dapsone 07-08-2008 26 NR 01-09-1900 NR NR NA NA NA 1.00
295 279151D 37 Female 07-01-2008 6,000 Minor Yes No 9                        Minor Dapsone 09-02-2008 2 CR 11-05-2008 2 11-05-2008 0 2 CR CR NA NA NA 100.00
296 292586F 21 Female 06-01-2012 15,000 Minor No Yes 11/09/2012               Minor Azathioprine 09-11-2012 3 NR 01-09-1900 NR NR NR NR NA 1.50
297 132145D 22 Male 11-01-2007 25,000 Minor No Yes 21/01/2008               Minor Azathioprine 01-21-2008 3 NR 01-09-1900 NR NR NR NR NR 1.30
298 136777D 11 Male 04-01-2007 24,000 Minor Yes No 9                        Minor Dapsone 09-13-2007 6 NR 01-09-1900 NR NR CR CR CR 1.00
299 178298D 2 Female 08-01-2007 10,000 Minor Yes No 9                        Minor Azathioprine 09-22-2007 2 NR 01-09-1900 NR NR NR NR NR 1.50
300 177684D 49 Female 10-01-2004 14,000 Minor No Yes 01/02/2008               Minor Azathioprine 02-01-2008 41 PR 04-29-2008 3 09-29-2008 5 8 PR CR CR CR CR 1.5
Maximum_ mgkgday Side_Effec Refractory Best_Resp Duration_o Relapse_w THIRD_LINthirdlineres THIRD_AGStopping_date_ stopdate Time from     LFD Best_susta DURATIONRelapse_A SplenectomSplen date Time from sta     Time from dat     PRESENT_splenres startingdate LFUdate osstatus
2.00 none No CR 30 No NA None 19/07/2011                    07-19-2011 29 03-26-2013 CR 20 No No Remission 03-03-2009 03-26-2013 Alive/LFU
2.00 none No CR 18 No NA None 08/10/2011                    08-10-2011 30 07-17-2012 PR 11 No No Persistent 02-13-2009 07-17-2012 Alive/LFU
2.00 none No CR 12 No NA none Not known(Lost to followup)   08-17-2010 NA NA NA No Remission 02-03-2009 08-17-2010 Alive/LFU
100.00 none No CR 19 No NA none 04/15/2009                    04-15-2009 3 11-22-2010 CR 19 No No Remission 01-13-2009 11-22-2010 Alive/LFU
1.50 none Yes NR NA NA NA None NA                            06-16-2009 NA NA NA No Chronic ITP 01-20-2009 06-16-2009 Alive/LFU
1.50 none No PR 9 No NA none NA                            11-17-2009 NA NA NA No Persistent 01-16-2009 11-17-2009 Alive/LFU
100.00 none No CR 39 No NA none NA                            07-31-2012 NA NA NA No Remission 03-06-2009 07-31-2012 Alive/LFU
1.50 none No CR 42 No NA none 08/17/2010                    08-17-2010 15 09-02-2011 CR 12 No No Remission 06-05-2009 09-02-2011 Alive/LFU
2.00 none No CR 5 No NA none NA                            09-10-2009 NA NA NA No Remission 01-27-2009 09-10-2009 Alive/LFU
100.00 none No CR 9 No Other NA none (Rest  02/15/2012                    02-15-2012 37 07-10-2012 NR NA Yes No Remission 02-13-2009 07-10-2012 Alive/LFU
100.00 none Yes NR NA NA AZA NA Azathioprin   08/25/2009                    08-25-2009 5 08-25-2009 NA NA NA No Chronic ITP 03-20-2009 08-25-2009 Alive/LFU
1.50 none Yes NR NA NA AZA No Azathioprin   18/06/2010                    06-18-2010 13 01-17-2012 NR NA NA Yes 11-01-12 32 0 Remission CR 06-02-2009 01-17-2012 Alive/LFU
100.00 none No CR 9 No NA NA(ReRx D   Ist - 9/4/2010, II   04-09-2010 14 05-22-2013 CR 1 Yes No Remission 02-17-2009 05-22-2013 Alive/LFU
100.00 none No PR 9 Yes DDS No Re- Daps. X     20/10/2009                   10-20-2009 8 07-04-2011 NA NA NA Yes 9999 Remission CR 02-17-2009 07-04-2011 Alive/LFU
1.50 none No CR 21 No NA none 09/02/2010                    09-02-2010 11 11-04-2011 CR 19 No No Remission 10-09-2009 11-04-2011 Alive/LFU
1.50 none(Reint No CR 12 No DDS No Re- Daps.(  10/02/2010                    02-10-2010 12 02-22-2013 CR 2 Yes No Remission 02-20-2009 02-22-2013 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA X 6 m 29/1/2010                     01-29-2010 10 06-03-2011 NR NA NA No Chronic ITP 03-27-2009 06-03-2011 Alive/LFU
1.50 Cytopenia x    No CR 9 No DDS NA Dapsonex 2   10/07/2009                    07-10-2009 4 09-29-2009 CR 3 No No Remission 03-03-2009 09-29-2009 Alive/LFU
2.00 none Yes NR NA NA Splenect Yes (splenectomNA(20/1/12)                   01-20-2010 11 05-04-2010 NA NA NA Yes 21-09-09 7 8 Remission CR 03-03-2009 05-04-2010 Alive/LFU
100.00 none No PR 6 Yes AZA No Azoran(21/ 21/09/2010                    09-21-2010 18 12-13-2010 NA NA NA No Chronic ITP 03-24-2009 12-13-2010 Alive/LFU
1.50 none No PR 12 Yes AZA No AZA X 3mt        NA(1/06/2012)                06-01-2012 39 06-01-2012 NR NA NA No Chronic ITP 03-13-2009 06-01-2012 Alive/LFU
100.00 none Yes NR NA NA NA none NA                            07-14-2009 NR NA NA No Chronic ITP 03-27-2009 07-14-2009 Alive/LFU
1.50 none No CR 9 No NA none 15/1/2010(9 mts               01-15-2010 9 03-28-2010 CR 2 No No Remission 05-05-2009 03-28-2010 Alive/LFU
1.50 mild compe  No CR 9 Yes DDS Yes Re - DDS X    20/4/2012                     04-20-2012 38 07-06-2012 NR NA NA No Chronic ITP 03-13-2009 07-06-2012 Alive/LFU
2.30 cytopenia o   Yes NR NA NA DDS NA DDS(18/02 18/02/2011                    02-18-2011 24 02-18-2011 NR NA NA No Chronic ITP 03-13-2009 02-18-2011 Alive/LFU
100.00 Dapsone -  Yes NR NA NA AZA Yes AZA X 3 M       09/06/2009                    06-09-2009 2 11-10-2009 CR 2 NA No Remission 04-16-2009 11-10-2009 Alive/LFU
75.00 none No CR 12 No NA none May-10                        05-07-2010 13 04-13-2012 PR 24 No No Persistent 04-03-2009 04-13-2012 Alive/LFU
1.00 none No CR 7 No NA none 26/05/2009                    05-26-2009 11 05-26-2009 NA NA NA No Remission 06-20-2008 05-26-2009 Alive/LFU
150.00 1.90 none No CR 34 No NA none NA                            01-03-2012 NA NA NA No Remission 03-20-2009 01-03-2012 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA(1/06/0    27/05/2011                    05-27-2011 22 03-18-2013 NR NA NA No Persistent 08-04-2009 03-18-2013 Alive/LFU
100.00 none Yes NR NA NA AZA Yes AZA(11/09/     11/09/2009                  09-11-2009 4 11-03-2009 NA NA NA No Persistent 05-15-2009 11-03-2009 Alive/LFU
2.00 none Yes NR NA NA AZA No AZA(10/11/   10/11/2009                    11-10-2009 6 04-23-2013 NR NA NA No Chronic ITP 05-08-2009 04-23-2013 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA(14/05/    October 2009(s    10-04-2009 3 03-26-2013 NR NA NA No Chronic ITP 07-21-2009 03-26-2013 Alive/LFU
1.50 none No CR 9 Yes AZA Yes AZA(19/02/  19/02/09                     02-19-2010 11 03-26-2013 NA NA NA No Chronic ITP 03-20-2009 03-26-2013 Alive/LFU
125.00 2.00 none No PR 4 Yes AZA No AZA- 6 mts    18/09/09                      09-18-2009 6 08-17-2010 NA NA NA Yes 16-04-10 13 4 Remission CR 03-25-2009 08-17-2010 Alive/LFU
2.00 none No CR 24 No NA none 14/01/2011                    01-14-2011 21 01-14-2011 NA NA NA No Remission 04-24-2009 01-14-2011 Alive/LFU
2.50 none Yes NR NA NA DDS Yes DDS(30/06 30/06/2009                    06-30-2009 7 11-18-2011 NA NA NA No Remission 12-01-2008 11-18-2011 Alive/LFU
100.00 none No CR 24 No AZA Yes AZA AFTE   Jul-10                       05-21-2010 13 05-24-2013 PR 12 Yes No Remission 04-21-2009 05-24-2013 Alive/LFU
50.00 none No PR 5 NA NA NA 9                             09-29-2009 NA NA NA No Persistent 05-01-2009 09-29-2009 Alive/LFU
100.00 none No CR 24 No AZA No AZA+Pred( 25/02/2011                    02-25-2011 22 04-12-2013 NR NA Yes No Remission 05-05-2009 04-12-2013 Alive/LFU
100.00 none No CR 12 No NA none NA                            02-02-2010 NA NA NA No Remission 06-02-2009 02-02-2010 Alive/LFU
2.00 none No CR 24 No NA None NA                            06-07-2011 NA NA NA No Remission 05-15-2009 06-07-2011 Alive/LFU
100.00 none No CR 9 Yes AZA No AZAX 2 ye   18/03/2011                    03-18-2011 16 03-19-2013 NA NA NA No Chronic ITP 11-09-2009 03-19-2013 Alive/LFU
1.50 none Yes NR NA NA DDS No DDSX1 yea   12/06/2009                    12-06-2009 6 07-30-2010 NA NA NA No Chronic ITP 06-12-2009 07-30-2010 Alive/LFU
1.50 none No CR 12 No NA NA 01/09/1900                    10-25-2013 NA NA NA No Remission 10-09-2012 10-25-2013 Alive/LFU
100.00 none No CR 4 NA NA NA NA                            11-13-2009 NA NA NA No Remission 06-30-2009 11-13-2009 Alive/LFU
100.00 none No CR 36 No NA none 27/7/2012                     07-27-2012 38 07-27-2012 NA NA NA No Remission 06-12-2009 07-27-2012 Alive/LFU
100.00 none Yes NR NA NA NA None 19/06/2009                    06-19-2009 17 09-23-2009 NR NA NA Yes 15-09-09 20 0 Remission CR 01-22-2008 09-23-2009 Alive/LFU
1.50 none No CR 48 No NA none NA                            04-30-2013 NA NA NA No Remission 08-11-2009 04-30-2013 Alive/LFU
100.00 none No CR 12 Yes AZA No AZAX 1 ye   09/03/2010                    03-09-2010 10 04-01-2011 NA NA NA Yes 23-03-11 22 0 Remission CR 05-26-2009 04-01-2011 Alive/LFU
2.50 none Yes NR NA NA AZA No AZA X 1 ye   12/01/2010                    01-12-2010 7 08-18-2012 NA NA NA Yes 16-04-12 35 4 Remission CR 06-12-2009 08-18-2012 Alive/LFU
2.00 none No CR 36 No NA None 12/11/2009                    11-12-2009 3 10-05-2012 CR 12 No No Remission 07-31-2009 10-05-2012 Alive/LFU
1.50 none No CR 17 No NA none NA                            05-24-2013 NA NA NA No Remission 11-08-2009 05-24-2013 Alive/LFU
100.00 none No PR 11 Yes AZA No AZAx6mts,  19/02/2010                    02-19-2010 7 04-10-2013 NA NA NA Yes 09-08-10 13 33 Chronic ITPNR 07-14-2009 04-10-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6 M   22/02/2013                    02-22-2013 8 07-05-2013 NA NA NA Yes 03-07-13 13 0 Remission CR 06-22-2012 07-05-2013 Alive/LFU
1.80 none Yes NR NA NA NA NONE NA                            05-24-2010 NA NA NA No Chronic ITP 10-30-2009 05-24-2010 Alive/LFU
100.00 none No CR 11 No NA NA 07/09/2010                    07-09-2010 11 04-05-2013 CR 24 Yes No Remission 08-04-2009 04-05-2013 Alive/LFU
2.00 none Yes NR NA NA AZA No AZA(3mts)     NA                          01-08-2013 NA NA NA No Persistent 08-04-2009 01-08-2013 Alive/LFU
1.50 none Yes NR NA NA NA NA NA                            03-02-2010 NA NA NA No Chronic ITP 09-08-2009 03-02-2010 Alive/LFU
100.00 none No CR 24 No NA none 13/04/13                      04-13-2013 44 04-13-2013 NA NA NA No Remission 09-04-2009 04-13-2013 Alive/LFU
2.00 none Yes NR NA No DDS No DDS(09/04 09/04/2010                    04-09-2010 8 04-09-2010 NA NA NA No Chronic ITP 08-10-2009 04-09-2010 Alive/LFU
1.80 none No PR 16 Yes NA none Jan-11                        05-17-2013 NA NA NA No Chronic ITP 09-01-2009 05-17-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA(09/11  29/09/2011                    09-29-2011 26 04-19-2013 NA NA NA Yes 30-07-12 36 9 Remission CR 08-21-2009 04-19-2013 Alive/LFU
2.00 none No CR 6 Yes DDS Yes DDS X 1 Y      24/09/2010                    09-24-2010 16 06-14-2011 NA NA NA No Persistent 06-05-2009 06-14-2011 Alive/LFU
2.80 DDS RASH   No PR 5 No NA NONE NA                            03-30-2010 NA NA NA No Persistent 10-23-2009 03-30-2010 Alive/LFU
1.50 none No CR 15 No NA NONE NA                            01-21-2011 NA NA NA No Remission 08-10-2009 01-21-2011 Alive/LFU
1.00 none No CR 12 No NA none 17/09/2010                    09-17-2010 12 07-17-2011 CR 12 No No Remission 09-20-2009 07-17-2011 Alive/LFU
100.00 Agranulocy    Yes NR NA NA AZA No AZAX9 mn   29/10/2009                    10-29-2009 2 08-24-2010 NA NA NA Yes 26-05-10 9 3 Remission CR 08-28-2009 08-24-2010 Alive/LFU
2.00 Skin rash x    No CR 24 Yes NA NA 04/10/2013                    10-04-2013 47 10-04-2013 NA NA NA No Remission 11-28-2009 10-04-2013 Alive/LFU
2.50 none Yes NR NA NA DDS Yes DDSX 1 1/2    20/04/2010                    04-20-2010 7 05-25-2012 NA NA NA No Chronic ITP 09-25-2009 05-25-2012 Alive/LFU
100.00 none Yes NR NA NA AZA No AZAX 9 mt     13/07/2010                   07-13-2010 9 04-12-2013 NR NA NA Yes 28-03-11 18 25 Chronic ITPNR 10-10-2009 04-12-2013 Alive/LFU
2.00 Borderline No CR 12 No NA none NA                            03-22-2011 NA NA NA No Remission 02-07-2010 03-22-2011 Alive/LFU
2.50 Borderline No PR 6 No DDS Yes DDS X 1 Y   13/05/2011                    05-13-2011 14 01-25-2012 NA NA NA No Remission 03-09-2010 01-25-2012 Alive/LFU
1.50 none Yes NR NA NA DDS No DDS x 1 ye  13/04/2010                    04-13-2010 4 02-29-2012 NR NA NA No Chronic ITP 12-29-2009 02-29-2012 Alive/LFU
1.50 none Yes NR NA NA DDS No DDS X 3 m   30/08/2011                    08-30-2011 19 11-01-2011 NA NA NA No Chronic ITP 02-02-2010 11-01-2011 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA X 1 ye   22/1/2010                     01-22-2010 18 12-24-2010 NA NA NA No Chronic ITP 08-01-2008 12-24-2010 Alive/LFU
2.50 none No CR 36 No NA None NA                            12-13-2012 NA NA NA No Remission 12-15-2009 12-13-2012 Alive/LFU
100.00 none No PR 3 No NA none 20/02/2004                    02-20-2004 3 01-05-2010 PR 72 NA NA Persistent NA 11-28-2003 01-05-2010 Alive/LFU
2.00 none Yes NR NA NA NA none NA(lost to f/up)              03-09-2010 NA NA NA No Persistent 09-20-2009 03-09-2010 Alive/LFU
1.50 none Yes NR NA NA NA none 9                             03-09-2010 NA NA NA No Chronic ITP 10-27-2009 03-09-2010 Alive/LFU
100.00 none Yes NR NA NA AZA NA AZA X 1 m   30/03/2010                    03-30-2010 5 04-13-2010 NA NA NA No Chronic ITP 10-30-2009 04-13-2010 Alive/LFU
100.00 none No PR 3 Yes AZA NA AZA X 1 m   12/02/2010                    11-02-2010 12 11-02-2010 NR NA NA No Chronic ITP 11-03-2009 11-02-2010 Alive/LFU
100.00 none No CR 6 Yes AZA Yes Aza x1 yR- 01/03/2011                    03-01-2011 14 06-04-2013 NA NA NA No Remission 01-08-2010 06-04-2013 Alive/LFU
3.00 DDS HemoYes NR NA NA AZA Yes AZA X 2 1/    02/07/2010                    07-02-2010 7 05-30-2013 NA NA NA No Persistent 11-24-2009 05-30-2013 Alive/LFU
2.00 none No CR 36 No NA NA 11/06/2013                    06-11-2013 39 06-11-2013 NA NA NA No Persistent 03-30-2010 06-11-2013 Alive/LFU
100.00 subclinical No PR 3 Yes AZA No AZA X 1 yr  20/07/2010                    07-20-2010 6 06-28-2011 NA NA NA No Chronic ITP 01-15-2010 06-28-2011 Alive/LFU
100.00 none Yes NR NA NA Splenect No Splenectom       05/04/2010                   05-04-2010 4 04-26-2012 NA NA NA Yes 05-04-10 3 25 Chronic ITPNR 01-15-2010 04-26-2012 Alive/LFU
100.00 none No CR 12 No DDS Yes Re Rx DDS      11/09/2009                  09-11-2011 43 12-03-2013 CR 6 Yes No Persistent 02-15-2008 12-03-2013 Alive/LFU
2.50 none No CR 12 No NA none 17/05/2011                    05-17-2011 15 10-04-2011 CR 6 No No Remission 02-19-2010 10-04-2011 Alive/LFU
100.00 none No CR 5 No NA none NA                            06-22-2010 NA NA NA No Remission 01-29-2010 06-22-2010 Alive/LFU
100.00 none No PR 4 No NA none NA                            06-28-2010 NA NA NA No Persistent 01-29-2010 06-28-2010 Alive/LFU
2.00 none No CR 6 Yes AZA No ct DDS-CR   29/05/2012                   05-29-2012 28 02-26-2013 NR NA NA Yes 19-11-12 34 3 Remission CR 01-29-2010 02-26-2013 Alive/LFU
100.00 none No CR 24 No NA none 30/03/2012                    03-30-2012 25 06-28-2012 CR 3 No No Remission 03-05-2010 06-28-2012 Alive/LFU
100.00 Hemolysis Yes NR NA NA AZA No AZA X 9 m   NA                           02-11-2011 NA NA NA No Chronic ITP 02-03-2010 02-11-2011 Alive/LFU
2.00 none No CR 10 Yes AZA Yes AZA X 6 m   11/02/2011                    02-11-2011 12 08-05-2011 NA NA NA No Remission 02-12-2010 08-05-2011 Alive/LFU
2.00 none No CR 12 No NA none 07/06/2010                    06-07-2011 11 03-26-2013 CR 2 Yes No Remission 07-02-2010 03-26-2013 Alive/LFU
100.00 none Yes NR NA NA AZA NA AZA @ LF 14/05/2010                    05-14-2010 4 05-14-2010 NA NA NA No Chronic ITP 01-29-2010 05-14-2010 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6mt  NA                            12-21-2010 NA NA NA No Chronic ITP 03-26-2010 12-21-2010 Alive/LFU
2.50 none No CR 30 No NA NA 05/03/2013                    03-05-2013 35 03-05-2013 NA NA NA No Remission 04-23-2010 03-05-2013 Alive/LFU
1.50 none No CR 16 No NA none 24/02/2012                    02-24-2012 19 07-05-2013 CR 7 Yes No Remission 08-03-2010 07-05-2013 Alive/LFU
1.50 none Yes NR NA NA AZA Yes AZA X 2 1/       07/09/2010                   09-07-2010 4 07-02-2013 NA NA NA No Persistent 05-04-2010 07-02-2013 Alive/LFU
1.50 none Yes NR NA NA DDS Yes DDS X 1/2      18/01/2011                    01-18-2011 10 05-28-2013 NA NA NA No Chronic ITP 04-05-2010 05-28-2013 Alive/LFU
100.00 none Yes NR NA NA Other Yes DEX+AZAF        25/01/2011                    01-25-2011 3 08-21-2011 NA NA NA No Remission 10-19-2010 08-21-2011 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 1 yr  01/06/2010                    10-08-2010 7 05-17-2011 NA NA NA No Chronic ITP 03-10-2010 05-17-2011 Alive/LFU
100.00 DAPSONE No CR 5 No NA NA 21/07/2010                    07-21-2010 1 09-16-2010 CR 2 No No Remission 06-22-2010 09-16-2010 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6mt  14/09/2010                    09-14-2010 3 04-05-2011 NA NA NA No Chronic ITP 06-08-2010 04-05-2011 Alive/LFU
75.00 none No CR 24 No NA NA 11/05/2012                    05-11-2012 23 05-11-2012 NA NA NA No Remission 07-02-2010 05-11-2012 Alive/LFU
1.50 none Yes NR NA NA DDS Yes DDS X 1 Y       03/09/2010                   09-03-2010 4 10-01-2013 NA NA NA No Remission 05-11-2010 10-01-2013 Alive/LFU
2.50 none Yes NR NA NA NA NA NA                            09-14-2010 NA NA NA No Chronic ITP 07-01-2010 09-14-2010 Alive/LFU
100.00 none Yes NR NA NA AZA Yes AZA X 21 m09/11/2010                    11-09-2010 4 06-25-2013 NR NA NA No Chronic ITP 07-21-2010 06-25-2013 Alive/LFU
150.00 3.00 none No CR 12 Yes AZA NA AZA @ LF 16/03/2012                    03-16-2012 21 03-16-2012 NR NA NA No Chronic ITP 07-06-2010 03-16-2012 Alive/LFU
100.00 none Yes NR NA NA AZA Yes AZA @ 6 m14/12/2010                    12-14-2010 4 04-12-2012 NA NA NA Yes 06-10-11 14 6 Persistent PR 08-03-2010 04-12-2012 Alive/LFU
100.00 none No CR 6 No NA NA NA                            05-10-2011 NA NA NA No Remission 07-30-2010 05-10-2011 Alive/LFU
1.50 none Yes NR NA NA DDS No DDS - NR 09/02/2011                    02-09-2011 5 09-21-2012 NA NA NA No Chronic ITP 09-14-2010 09-21-2012 Alive/LFU
100.00 none No CR 24 No NA NA NA                            11-21-2012 NA NA NA No Remission 10-06-2011 11-21-2012 Alive/LFU
2.00 none No CR 24 No NA NA 01/06/2012                    06-01-2012 23 06-01-2012 NA NA NA No Remission 07-23-2010 06-01-2012 Alive/LFU
2.00 none No PR 5 Yes AZA No AZA X 6 m   17/06/2011                    06-17-2011 12 01-02-2012 NR NA NA No Chronic ITP 07-02-2010 01-02-2012 Alive/LFU
3.00 none Yes NR NA NA NA NA NA                            01-03-2012 NA NA NA No Chronic ITP 07-06-2010 01-03-2012 Alive/LFU
2.50 none No CR 24 No NA NA 26/03/2013                    03-26-2013 42 03-26-2013 NA NA NA No Remission 10-19-2009 03-26-2013 Alive/LFU
2.50 none No CR 24 No NA NA 07/05/2013                    05-07-2013 34 05-07-2013 NA NA NA No Remission 07-24-2010 05-07-2013 Alive/LFU
2.00 none No PR 18 No NA NA NA                            08-20-2013 NA NA NA No Persistent 08-03-2010 08-20-2013 Alive/LFU
100.00 none No PR 4 Yes AZA No AZA X 6 m   24/05/2011                    05-24-2011 4 09-23-2011 NR NA NA No Chronic ITP 01-28-2011 09-23-2011 Alive/LFU
1.50 none No CR 12 No NA NA 16/12/2011                    12-16-2011 16 12-16-2011 NA NA NA No Remission 08-24-2010 12-16-2011 Alive/LFU
100.00 none Yes NR NA NA AZA No aZA X 1 ye   18/03/2011                    03-18-2011 8 05-29-2012 NA NA NA No Chronic ITP 07-30-2010 05-29-2012 Alive/LFU
1.50 none No CR 24 No NA na 30/10/2012                    10-30-2012 26 08-20-2013 CR 12 No No Remission 09-10-2010 08-20-2013 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA X 6 m   11/03/2011                    03-11-2011 6 09-02-2011 NA NA No No Chronic ITP 08-30-2010 09-02-2011 Alive/LFU
1.50 none No CR 18 No AZA No AZAX 4 Mo   26/06/2012                    06-26-2012 23 07-09-2013 NA NA NA No Chronic ITP 08-20-2010 07-09-2013 Alive/LFU
2.50 none No CR 12 Yes NA NA NA                            07-05-2013 NA NA NA No Chronic ITP 07-29-2011 07-05-2013 Alive/LFU
2.00 none No CR 9 No NA na na                            08-03-2012 NA NA NA No Remission 05-29-2011 08-03-2012 Alive/LFU
100.00 none No CR 9 No NA NA 04/03/2008                    03-04-2008 9 10-22-2013 CR 18 Yes No Persistent 06-19-2007 10-22-2013 Alive/LFU
100.00 none No PR 6 Yes AZA No AZA X 6 m      31/05/2011                  05-31-2011 7 06-25-2013 NA NA NA No Remission 11-09-2010 06-25-2013 Alive/LFU
2.50 none Yes NR NA NA NA NA 26/08/2011                    08-26-2011 7 08-26-2011 NA NA NA No Chronic ITP 02-11-2011 08-26-2011 Alive/LFU
2.50 none Yes NR NA NA NA NA 01/09/1900                    10-25-2013 NA NA NA No Chronic ITP 02-26-2013 10-25-2013 Alive/LFU
2.50 hair loss No CR 24 No NA NA 18/09/2012                    09-18-2012 19 05-31-2013 CR 6 No No Remission 03-04-2011 05-31-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6 M   13/05/2011                    05-13-2011 5 11-18-2011 NA NA NA No Chronic ITP 12-17-2010 11-18-2011 Alive/LFU
75.00 1.50 none Yes NR NA NA AZA No AZA X 6 M   01/05/2012                    05-01-2012 18 01-15-2013 NA NA NA No Chronic ITP 10-26-2010 01-15-2013 Alive/LFU
1.50 none Yes NR NA NA DDS Yes DDS X 2 Y  08/04/2011                    04-08-2011 5 07-05-2013 NA NA NA No Remission 11-09-2010 07-05-2013 Alive/LFU
100.00 none Yes NR NA NA Other No CYCLOSP  27/05/2011                    05-27-2011 7 10-07-2011 NA NA NA No Chronic ITP 10-29-2010 10-07-2011 Alive/LFU
1.50 none No CR 18 No NA NA 27/06/2011                    06-27-2011 8 06-27-2011 NA NA NA No Chronic ITP 11-09-2010 06-27-2011 Alive/LFU
1.50 none No CR 27 No DDS No DDS @ RL  04/01/2013                    04-01-2013 30 07-05-2013 NR NA Yes No Remission 10-08-2010 07-05-2013 Alive/LFU
1.50 none Yes NR NA NA Other No Eltrombopa    21/01/2011                    01-21-2011 5 08-13-2013 NA NA NA No Chronic ITP 08-13-2010 08-13-2013 Alive/LFU
150.00 2.50 Meth-hemoYes NR NA NA NA NA 05/04/2011                    05-04-2011 9 11-08-2011 NA NA NA NA Chronic ITPNA 08-17-2010 11-08-2011 Alive/LFU
1.50 none No CR 18 No NA NA 07/10/2012                    07-10-2012 18 11-06-2012 CR 3 NA No Remission 01-11-2011 11-06-2012 Alive/LFU
100.00 none No CR 8 Yes DDS Yes ReRx DDS   NA                            10-08-2013 NA NA NA No Remission 04-26-2011 10-08-2013 Alive/LFU
1.50 none No CR 24 No NA NA 04/10/2013                    04-10-2013 24 10-04-2013 NA NA NA No Remission 04-15-2011 10-04-2013 Alive/LFU
100.00 none No CR 15 No NA NA 11/05/2013                    05-11-2013 15 10-11-2013 PR 5 Yes No Chronic ITP 03-02-2012 10-11-2013 Alive/LFU
2.50 Grade I cyt    No CR 18 No NA NA 12/04/2013                    04-12-2013 28 10-11-2013 CR 6 No No Remission 01-07-2011 10-11-2013 Alive/LFU
2.00 none No CR 24 No NA NA 01/07/2011                    07-01-2011 16 10-14-2013 CR 28 No No Remission 03-06-2010 10-14-2013 Alive/LFU
2.50 none Yes NR NA NA AZA No dds x 2 wks    NA                          10-12-2012 NA NA NA No Chronic ITP 03-18-2011 10-12-2012 Alive/LFU
2.00 Grade I cyt Yes NR NA NA Other No Mycept x 6   20/09/2011                    09-20-2011 6 07-20-2012 NA NA NA No Chronic ITP 03-15-2011 07-20-2012 Alive/LFU
2.50 none Yes NR NA NA DDS No DDS X 6 m   08/07/2011                    07-08-2011 5 12-04-2012 NA NA NA No Chronic ITP 02-04-2011 12-04-2012 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 3 M   02/08/2011                    08-02-2011 5 10-04-2012 NA NA NA No Chronic ITP 03-04-2011 10-04-2012 Alive/LFU
2.00 none Yes NR NA NA DDS No DDS X 5 m   29/07/2011                    07-29-2011 5 12-23-2011 NA NA NA No Chronic ITP 03-04-2011 12-23-2011 Alive/LFU
2.50 none Yes NR NA NA DDS Yes DDS X 1 1/   17/1/2012                     01-17-2012 13 08-09-2013 NA NA NA No Persistent 01-04-2011 08-09-2013 Alive/LFU
2.50 none No PR 5 Yes DDS Yes DDS X 1 1/    25/12/2011                    12-25-2011 10 08-30-2013 NA NA NA No Chronic ITP 02-24-2011 08-30-2013 Alive/LFU
2.00 none Yes NR NA NA AZA No AZA X 1 YE     17/05/2011                    05-17-2011 5 09-30-2013 NA NA NA Yes 08-08-12 20 14 Chronic ITPNR 12-21-2010 09-30-2013 Alive/LFU
100.00 none No CR 12 Yes DDS Yes Re Rx DDS     21/06/2013(AZA        06-21-2013 24 10-15-2013 NA NA NA No Remission 06-29-2011 10-15-2013 Alive/LFU
2.50 none No CR 24 No NA NA NA                            08-16-2013 NA NA NA No Remission 08-26-2011 08-16-2013 Alive/LFU
100.00 none No CR 4 Yes AZA No AZA X 6 m   NA                           10-25-2013 NA NA NA No Chronic ITP 10-10-2011 10-25-2013 Alive/LFU
1.50 none No CR 12 No NA NA 21/12/12                      12-21-2012 16 09-03-2013 CR 9 No No Remission 08-16-2011 09-03-2013 Alive/LFU
150.00 2.50 NONE No CR 3 Yes AZA Yes AZA X   6 m  25/01/2013                    01-25-2013 8 07-23-2013 NA NA NA No Remission 05-18-2012 07-23-2013 Alive/LFU
2.50 none Yes NR NA NA DDS Yes DDS X 9 m     04/08/2012                   04-08-2012 10 10-04-2013 NA NA NA No Chronic ITP 06-17-2011 10-04-2013 Alive/LFU
150.00 1.70 none No PR 22 No NA NA NA                            07-19-2013 NA NA NA No Persistent 06-01-2011 07-19-2013 Alive/LFU
150.00 2.00 none Yes NR NA NA NA NA NA                            07-24-2013 NA NA NA No Remission 02-25-2011 07-24-2013 Alive/LFU
150.00 2.00 none Yes NR NA NA AZA No AZA X 1 YE   27/08/2013                    08-27-2013 30 08-27-2013 NA NA NA No Remission 03-04-2011 08-27-2013 Alive/LFU
2.00 none Yes NR NA NA DDS Yes DDS X 1 Y     06/05/2011                   05-06-2011 3 07-16-2013 NA NA NA Yes 07-07-13 29 0 Remission CR 02-11-2011 07-16-2013 Alive/LFU
100.00 none No CR 9 No NA NA NA                            05-06-2012 NA NA NA No Remission 08-23-2011 05-06-2012 Alive/LFU
2.00 none No CR 12 No NA NA NA                            07-07-2013 NA NA NA No Remission 04-03-2012 07-07-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA x 9 mo  01/05/2012                    05-01-2012 4 03-26-2013 NA NA NA No Chronic ITP 12-27-2011 03-26-2013 Alive/LFU
1.50 none No CR 3 No NA NA NA                            07-10-2012 NA NA NA No Remission 01-10-2012 07-10-2012 Alive/LFU
2.50 none Yes NR NA NA NA NA NA                            12-20-2011 NA NA NA No Chronic ITP 08-05-2011 12-20-2011 Alive/LFU
1.50 none Yes NR NA NA DDS No DDS X 1 Y  20/03/2012                    03-20-2012 4 07-05-2013 NA NA NA No Chronic ITP 12-01-2011 07-05-2013 Alive/LFU
2.50 none Yes NR NA NA Splenect No Post splene  NA                           03-15-2013 NA NA NA Yes 15-05-12 10 10 Remission CR 08-02-2011 03-15-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 1 1/    02/12/2011                    12-02-2011 7 08-30-2013 NA NA NA No Chronic ITP 04-26-2011 08-30-2013 Alive/LFU
100.00 DDS Induc   No CR 6 Yes AZA No AZAX 6 mt    05/06/2011                   06-05-2011 7 09-27-2013 NA NA NA Yes 03-06-13 31 4 Persistent PR 11-04-2010 09-27-2013 Alive/LFU
125.00 2.00 none No CR 12 Yes AZA Yes AZAX 1 ye   16/10/2012                    10-16-2012 18 07-19-2013 NA NA NA No Remission 04-29-2011 07-19-2013 Alive/LFU
1.50 none No CR 8 Yes DDS No DDS X 1 m   01/05/2012                    01-05-2012 10 09-25-2012 NA NA NA No Chronic ITP 03-25-2011 09-25-2012 Alive/LFU
2.50 none Yes NR NA NA Other No Added Puls    NA                            08-23-2013 NA NA NA No Chronic ITP 03-22-2013 08-23-2013 Alive/LFU
2.00 none No CR 12 No NA na na                            03-16-2012 NA NA NA No Chronic ITP 05-17-2011 03-16-2012 Alive/LFU
2.00 none Yes NR NA NA AZA No AZA X 6 m   09/09/2011                    09-09-2011 5 03-13-2012 NA NA NA No Chronic ITP 04-14-2011 03-13-2012 Alive/LFU
150.00 3.00 none Yes NR NA NA NA NA NA                            07-12-2012 NA NA NA No Chronic ITP 04-12-2011 07-12-2012 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA X 1 ye   09/08/2011                    09-08-2011 5 06-19-2012 NA NA NA No Chronic ITP 04-05-2011 06-19-2012 Alive/LFU
2.50 none No CR 18 No NA NA 22/01/2013                    01-22-2013 21 08-19-2013 CR 8 No No Remission 04-19-2011 08-19-2013 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6 m   13/01/2012                    01-13-2012 5 04-23-2013 NA NA NA Yes 01-10-12 14 7 Persistent PR 08-04-2011 04-23-2013 Alive/LFU
2.50 none No PR 7 Yes DDS Yes dds X 4 mn   19/06/2012                    06-19-2012 8 10-09-2012 NA NA NA No Remission 10-18-2011 10-09-2012 Alive/LFU
2.00 none Yes NR NA NA DDS Yes DDS X 1 1/   24/03/2011                    03-24-2012 2 08-16-2013 NA NA NA No Remission 01-24-2012 08-16-2013 Alive/LFU
1.50 Hemolysis No PR 2 No AZA No AZA X 1 YE   01/05/2012                    07-27-2012 10 07-26-2013 NA NA NA No Chronic ITP 10-07-2011 07-26-2013 Alive/LFU
1.50 NONE Yes NR NA NA NA NA NA                            10-01-2012 NA NA NA Yes 23-11-12 11 5 Remission CR 01-10-2012 04-26-2013 Alive/LFU
1.50 none Yes NR NA NA Splenect No Splenectom     02/10/2012                   10-02-2012 3 08-30-2013 NA NA NA Yes 06-02-13 7 7 Remission CR 07-12-2012 08-30-2013 Alive/LFU
2.50 none No CR 18 No NA NA NA                            07-09-2013 NA NA NA No Remission 12-16-2011 07-09-2013 Alive/LFU
100.00 none No CR 18 No NA NA NA                            09-20-2013 NA NA NA No Remission 01-13-2012 09-20-2013 Alive/LFU
1.50 none No CR 18 No NA NA NA                            08-23-2013 NA NA NA No Remission 02-14-2012 08-23-2013 Alive/LFU
2.00 none No CR 6 Yes NA NA(ReRx A   NA                           09-27-2013 NA NA NA No Remission 04-21-2012 09-27-2013 Alive/LFU
2.50 none Yes NR NA NA Splenect No Splenectom       NA                           07-09-2013 NA NA NA Yes 07-01-13 14 6 Chronic ITPNR 11-04-2011 07-09-2013 Alive/LFU
2.00 none No CR 4 Yes AZA Yes AZA X 1 YE   09/12/2011                    12-09-2011 4 12-28-2012 NA NA NA No Persistent 08-12-2011 12-28-2012 Alive/LFU
2.50 none No CR 18 Yes DDS NA DDS @ LF 04/10/2013                    10-04-2013 25 12-06-2013 NA NA NA No Chronic ITP 09-16-2011 12-06-2013 Alive/LFU
1.50 none No CR 3 Yes NA NA 9                             10-04-2013 NA NA NA No Remission 08-16-2011 10-04-2013 Alive/LFU
100.00 none No CR 5 No NA NA 9                             02-14-2012 NA NA NA No Persistent 09-20-2011 02-14-2012 Alive/LFU
2.50 none Yes NR NA NA NA NA 9                             02-16-2012 NA NA NA No Chronic ITP 09-06-2011 02-16-2012 Alive/LFU
1.50 none Yes NR NA NA NA NA 9                             09-04-2012 NA NA NA No Chronic ITP 10-04-2011 09-04-2012 Alive/LFU
1.50 none Yes NR NA NA AZA No AZA X 9 m   04/01/2013                    01-04-2013 13 10-01-2013 NA NA NA No Chronic ITP 12-16-2011 10-01-2013 Alive/LFU
100.00 none No PR 18 No NA NA 9                             10-01-2013 NA NA NA No Chronic ITP 10-04-2011 10-01-2013 Alive/LFU
2.00 none Yes NR NA NA NA NA 9                             09-10-2012 NA NA NA No Chronic ITP 10-25-2011 09-10-2012 Alive/LFU
2.50 none No CR 18 No NA NA 9                             06-20-2013 NA NA NA No Remission 01-17-2012 06-20-2013 Alive/LFU
2.50 none Yes NR NA NA NA NA 9                             08-17-2012 NA NA NA No Chronic ITP 10-19-2011 08-17-2012 Alive/LFU
100.00 none No PR 18 Yes NA NA 9                             10-15-2013 NA NA NA No Chronic ITP 01-31-2012 10-15-2013 Alive/LFU
1.00 none No CR 18 No NA NA 9                             10-27-2013 NA NA NA No Remission 01-27-2012 10-27-2013 Alive/LFU
100.00 none No PR 12 No NA NA NA                            10-08-2013 NA NA NA No Persistent 06-20-2012 10-08-2013 Alive/LFU
100.00 none No CR 5 No NA NA NA                            08-03-2012 NA NA NA No Remission 02-24-2012 08-03-2012 Alive/LFU
1.50 none No CR 12 No NA na na                            05-10-2013 NA NA NA No Remission 02-10-2012 05-10-2013 Alive/LFU
2.00 none No PR 1 No NA NA NA                            07-02-2013 NA NA NA No Persistent 01-31-2012 07-02-2013 Alive/LFU
2.00 none No PR 3 Yes DDS No DDS X 5 m   26/03/2013                    03-26-2013 14 08-13-2013 NA NA NA Yes 18-09-13 20 1 Remission CR 02-07-2012 10-11-2013 Alive/LFU
1.50 Grade 1 cy No PR 1 No NA NA NA                            08-30-2013 NA NA NA No Persistent 02-14-2013 08-30-2013 Alive/LFU
2.50 Grade 1 cy Yes NR NA NA DDS No DDS X 1 ye   04/09/2012                    09-04-2012 -8 08-23-2013 NA NA NA No Chronic ITP 05-11-2013 08-23-2013 Alive/LFU
1.50 none No CR 7 No NA NA NA                            10-04-2013 NA NA NA No Remission 02-21-2013 10-04-2013 Alive/LFU
2.50 none Yes NR NA NA DDS Yes DDS X 1 ye   10/07/2012                    07-10-2012 5 07-06-2013 NA NA NA No Remission 02-24-2012 07-06-2013 Alive/LFU
2.50 none No CR 5 No NA NA NA                            09-11-2012 NA NA NA No Remission 03-16-2012 09-11-2012 Alive/LFU
2.50 None No PR 12 No NA NA NA                            06-07-2013 NA NA NA No Persistent 03-20-2012 06-07-2013 Alive/LFU
1.50 none No CR 12 No NA NA NA                            10-01-2013 NA NA NA No Remission 04-13-2012 10-01-2013 Alive/LFU
1.50 NONE Yes NR NA NA AZA NA AZA @LFD14/09/2012                    09-14-2012 4 09-14-2012 NA NA NA No Chronic ITP 05-08-2012 09-14-2012 Alive/LFU
1.50 none No PR 12 No NA NA NA                            07-12-2013 NA NA NA No Chronic ITP 05-01-2012 07-12-2013 Alive/LFU
2.00 none Yes NR NA NA NA NA 9                             10-29-2013 NA NA NA No Chronic ITP 02-08-2013 10-29-2013 Alive/LFU
1.50 none Yes NR NA No DDS No DDS X 9 m   14/06/2012                    06-14-2012 3 02-12-2013 NA NA NA No Chronic ITP 03-30-2012 02-12-2013 Alive/LFU
1.50 none Yes NR NA NA DDS Yes DDS X 1 Y    20/07/2012                    07-20-2012 3 09-27-2013 NA NA NA No Remission 04-10-2012 09-27-2013 Alive/LFU
1.50 none No CR 6 No NA NA NA                            12-11-2012 NA NA NA No Remission 06-15-2012 12-11-2012 Alive/LFU
3.00 none Yes NR NA NA NA NA NA                            09-30-2013 NA NA NA No Chronic ITP 05-25-2012 09-30-2013 Alive/LFU
2.00 none No CR 3 No NA NA NA                            07-23-2012 NA NA NA No Remission 01-31-2012 07-23-2012 Alive/LFU
2.50 none Yes NR NA NA DDS No DDS X 9 m   02/10/2012                    10-02-2012 4 09-24-2013 NA NA NA Yes 27-07-13 14 2 Remission CR 05-25-2012 09-24-2013 Alive/LFU
100.00 none No CR 14 Yes AZA NA AZA @LFD06/09/2013                    09-06-2013 16 10-04-2013 NA NA NA No Chronic ITP 05-04-2012 10-04-2013 Alive/LFU
2.50 none No CR 12 Yes DDS Yes DDS+Pred   06/09/2013                    09-06-2013 15 10-04-2013 NA NA NA No Persistent 06-15-2012 10-04-2013 Alive/LFU
1.50 none Yes NR NA NA DDS No DDS X 6 m   11/27/2012                    11-27-2012 5 04-10-2013 NA NA NA Yes 22-07-13 13 2 Remission CR 06-26-2012 10-04-2013 Alive/LFU
1.50 none No PR 6 No NA NA NA                            10-01-2013 NA NA NA No Persistent 01-18-2013 10-01-2013 Alive/LFU
2.00 none Yes NR NA NA AZA No aza x 6 mts  05/04/2013                    04-05-2013 9 07-12-2013 NA NA NA No Chronic ITP 07-13-2012 07-12-2013 Alive/LFU
2.00 none No CR 11 No NA NA NA                            08-02-2013 NA NA NA No Remission 08-24-2012 08-02-2013 Alive/LFU
1.50 none No CR 9 No NA NA 05/02/2013                    05-03-2013 10 05-03-2013 CR 3 No No Remission 06-28-2012 05-03-2013 Alive/LFU
100.00 none No CR 7 Yes NA NA (Contin    NA                           07-26-2013 NA NA NA No Persistent 05-18-2012 07-26-2013 Alive/LFU
2.50 none No CR 9 Yes DDS Yes DDS + PRe      17/05/2013                    05-17-2013 11 09-20-2013 NA NA NA No Persistent 06-12-2012 09-20-2013 Alive/LFU
100.00 none No CR 12 No NA NA NA                            07-05-2013 NA NA NA No Remission 05-15-2012 07-05-2013 Alive/LFU
2.50 none No PR 9 No NA NA NA                            09-06-2013 NA NA NA No Persistent 09-18-2012 09-06-2013 Alive/LFU
2.30 none Yes NR NA NA AZA No aza x 6 mts  14/08/2012                    08-14-2012 3 06-07-2013 NA NA NA No Chronic ITP 05-12-2012 06-07-2013 Alive/LFU
1.50 none No CR 4 Yes Other No Predni + DA24/07/2006                    07-24-2006 26 10-09-2009 NR NA NA Yes 24-07-06 26 39 Remission CR 05-31-2004 10-09-2009 Alive/LFU
1.50 none No CR 12 Yes DDS Yes DAPSONE  AZO - 08/11/20    08-11-2005 15 09-10-2007 NR NA NA No Remission 05-07-2004 09-10-2007 Alive/LFU
100.00 none Yes NR NA NA AZA Yes AZAX9mnt         19/06/2009                    06-19-2009 24 10-22-2013 NA NA NA No Remission 07-05-2007 10-22-2013 Alive/LFU
3.00 none No CR 18 No NA none 08/01/2008                    01-08-2008 29 08-29-2008 CR 8 No No Remission 08-23-2005 08-29-2008 Alive/LFU
1.50 Dapsone in  No CR 5 No NA none 18/11/2005                    11-18-2005 7 01-20-2006 CR 3 No No Remission 04-19-2005 01-20-2006 Alive/LFU
2.50 none Yes NR NA NA AZA Yes azathioprin    DDS-21/3/06 , A      03-21-2006 8 07-06-2010 NA NA NA No Remission 08-02-2005 07-06-2010 Alive/LFU
100.00 none Yes NR NA NA AZA Yes azathioprin    DDS-24/1/06 , A     01-24-2006 3 06-26-2007 NA NA NA No Remission 10-25-2005 06-26-2007 Alive/LFU
100.00 none No CR 24 Yes DDS Yes ReRX DDS     20/4/2006,                    04-20-2006 8 10-24-2008 NA NA NA No Persistent 08-27-2005 10-24-2008 Alive/LFU
2.00 none No CR 16 No AZA Yes Azoran(Ma     14/6/2005                  06-14-2005 13 01-16-2007 CR 16 Yes No Remission 05-28-2004 01-16-2007 Alive/LFU
2.00 none Yes NR NA NA AZA No AZA X 6 m  22/05/2009                    05-22-2009 16 03-12-2010 NA NA NA No Chronic ITP 02-02-2008 03-12-2010 Alive/LFU
2.00 none No PR 12 Yes DDS No DDS X 1 ye   03/02/2007                    02-03-2007 18 11-20-2012 NA NA NA Yes 23-04-08 33 56 Remission CR 07-29-2005 11-20-2012 Alive/LFU
100.00 none No PR 6 Yes DDS Yes ReRX DDS       10/05/2011                  05-10-2011 44 05-10-2011 NR NA NA No Chronic ITP 09-18-2007 05-10-2011 Alive/LFU
1.50 none Yes NR NA No AZA No AZA X 9 M    05/10/2007                    05-10-2007 5 08-13-2013 NA NA NA Yes 23-07-08 20 62 Remission CR 12-01-2006 08-13-2013 Alive/LFU
2.30 none No CR 12 No NA NA NA                            07-06-2010 NA NA NA No Remission 02-24-2009 07-06-2010 Alive/LFU
1.50 none No CR 24 No NA NA 11/12/2009                    12-11-2009 28 08-06-2010 PR 9 No No Persistent 09-07-2007 08-06-2010 Alive/LFU
1.50 none No CR 4 Yes AZA No AZA X 1 1/       07/12/2008                   12-07-2008 13 07-07-2012 NA NA NA No Persistent 11-13-2007 07-07-2012 Alive/LFU
1.50 NONE Yes NR NA NA AZA No AZA X 8 m   19/02/2008                    02-19-2008 6 10-28-2008 NA NA NA No Chronic ITP 08-17-2007 10-28-2008 Alive/LFU
100.00 none Yes NR NA NA NA NA 14/03/2008                    03-14-2008 6 05-29-2012 NR NA NA Yes 15-04-08 7 50 Remission CR 09-18-2007 05-29-2012 Alive/LFU
1.50 NONE No CR 24 No NA none 29/07/2011                    07-29-2011 22 07-29-2011 NA NA NA No Remission 10-02-2009 07-29-2011 Alive/LFU
1.50 none No CR 24 No NA NA 16/09/2010                    09-16-2010 34 06-14-2013 PR 24 Yes No Remission 11-23-2007 06-14-2013 Alive/LFU
1.50 alopecia No CR 12 Yes DDS Yes DDS X 5 m 17/07/2009                    07-17-2009 16 08-24-2012 NA NA NA No Remission 03-11-2008 08-24-2012 Alive/LFU
100.00 none No CR 12 No NA NA 19/11/2004                    11-19-2004 11 08-03-2007 CR 36 Yes No Remission 12-19-2003 08-03-2007 Alive/LFU
1.50 AZA dermaNo CR 6 No DDS Yes DDS x 2 ye11/03/2008                    03-11-2008 2 07-08-2011 CR 48 No No Remission 01-25-2008 07-08-2011 Alive/LFU
2.00 none Yes NR NA NA NA NA 11/09/2012                    09-11-2012 58 06-04-2013 NA NA NA Yes 30-04-13 65 1 Remission CR 12-14-2007 06-04-2013 Alive/LFU
2.00 Grade I Cy No CR 9 Yes Other Yes Pred x 2 ye    08/08/2008                   08-08-2008 6 02-14-2013 NA NA NA No Remission 02-15-2008 02-14-2013 Alive/LFU
2.00 none No CR 24 No Splenect Yes Splenectom      21/08/2009                    08-21-2009 20 10-11-2013 CR 1 Yes Yes 10-11-11 47 23 Remission CR 01-08-2008 10-11-2013 Alive/LFU
3.00 none Yes NR NA NA AZA No AZA X 6 m     13/04/2009                    04-13-2009 11 07-27-2012 NA NA NA Yes 17-06-09 13 38 Remission CR 05-27-2008 07-27-2012 Alive/LFU
2.00 none No CR 12 No NA NA 21/10/2011                    10-21-2011 43 07-12-2013 CR 21 No No Remission 04-08-2008 07-12-2013 Alive/LFU
1.50 none Yes NR NA NA NA NA NA                            03-30-2010 NA NA NA No Chronic ITP 11-25-2009 03-30-2010 Alive/LFU
1.50 none Yes NR NA NA NA NA 03/01/2009                    01-03-2009 9 05-01-2009 NA NA NA Yes 06-01-09 9 4 Remission CR 03-28-2008 05-01-2009 Alive/LFU
1.50 none No CR 21 Yes DDS Yes CT RX DDS     NA                          07-02-2013 NA NA NA No Remission 05-14-2010 07-02-2013 Alive/LFU
100.00 none No CR 5 No NA NA NA                            12-08-2009 NA NA NA No Remission 10-13-2009 12-08-2009 Alive/LFU
1.50 none No PR 24 No NA NA NA                            04-09-2013 NA NA NA No Remission 02-03-2009 04-09-2013 Alive/LFU
100.00 none Yes NR NA NA NA NA NA                            10-24-2008 NA NA NA No Chronic ITP 03-28-2008 10-24-2008 Alive/LFU
1.50 none No CR 10 No NA na NA                            03-14-2009 NA NA NA No Remission 03-14-2008 03-14-2009 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6 m     28/04/2009                    04-28-2009 11 01-10-2012 NA NA NA Yes 09-10-09 16 27 Remission CR 06-10-2008 01-10-2012 Alive/LFU
2.00 none No CR 24 No NA NA 23/03/2010                    03-23-2010 23 01-04-2013 CR 18 Yes No Persistent 05-02-2008 01-04-2013 Alive/LFU
100.00 none Yes NR NA NA AZA Yes AZA X 6 m       27/01/2009                   01-27-2009 6 06-26-2009 NA NA NA No Chronic ITP 08-05-2008 06-26-2009 Alive/LFU
125.00 1.60 Dermatitis Yes NR NA NA AZA No AZA X 2 ye   27/03/2009                    03-27-2009 10 12-21-2012 NA NA NA Yes 01-08-11 39 17 Persistent PR 05-20-2008 12-21-2012 Alive/LFU
1.50 none No CR 12 No NA NA NA                            09-20-2013 NA NA NA No Remission 05-29-2012 09-20-2013 Alive/LFU
100.00 none Yes NR NA NA DDS NA DDS @ LF      26/08/2008                   08-26-2008 4 06-12-2012 NA NA NA Yes 30-07-08 3 47 Chronic ITPNR 05-09-2008 06-12-2012 Alive/LFU
1.50 none No PR 5 No NA NA 27/02/2009                    02-27-2009 10 02-27-2009 NA NA NA No Chronic ITP 05-16-2008 02-27-2009 Alive/LFU
1.50 none No CR 24 No NA NA NA                            10-19-2010 NA NA NA No Remission 05-16-2008 10-19-2010 Alive/LFU
2.00 none No CR 24 No NA NA 14/06/2009                    06-14-2009 13 12-14-2010 CR 18 No No Remission 05-27-2008 12-14-2010 Alive/LFU
100.00 none Yes NR NA No Splenect Yes CR (POST 30/05/2013                    05-30-2013 61 06-06-2013 NA NA NA Yes 30-05-13 61 0 Remission CR 05-20-2008 06-06-2013 Alive/LFU
100.00 none Yes NR NA No Splenect No SPLENECT   15/07/2009                    07-15-2009 10 02-07-2012 NA NA NA Yes 20-07-09 10 31 Chronic ITPNR 09-16-2008 02-07-2012 Alive/LFU
100.00 none Yes NR NA NA NA NA NA                            03-17-2009 NA NA NA No Chronic ITP 08-08-2008 03-17-2009 Alive/LFU
100.00 none No PR 6 No NA NA NA                            03-06-2009 NA NA NA No Remission 09-12-2008 03-06-2009 Alive/LFU
2.00 none No PR 3 No DDS Yes DDS X 1 Y   12/06/2009                    06-12-2009 12 05-03-2013 NA NA NA No Remission 06-20-2008 05-03-2013 Alive/LFU
100.00 none No CR 24 No NA NA NA                            07-13-2010 NA NA NA No Remission 06-27-2008 07-13-2010 Alive/LFU
100.00 none Yes NR NA NA AZA No AZA X 6 M   06/01/2009                    01-06-2009 6 05-05-2009 NA NA NA No Chronic ITP 07-08-2008 05-05-2009 Alive/LFU
100.00 none No CR 24 No NA none NA                            05-21-2013 NA NA NA No Remission 05-07-2010 05-21-2013 Alive/LFU
1.50 none Yes NR NA NA NA NA 06/03/2009                    03-06-2009 6 06-16-2009 NA NA NA No Chronic ITP 09-09-2008 06-16-2009 Alive/LFU
1.50 none Yes NR NA NA NA NA NA                            12-03-2008 NA NA NA No Chronic ITP 07-08-2008 12-03-2008 Alive/LFU
100.00 none No CR 4 NA NA NA NA                            02-05-2009 NA NA NA No Remission 09-02-2008 02-05-2009 Alive/LFU
2.00 none Yes NR NA NA NA NA 9                             10-29-2013 NA NA NA No Chronic ITP 09-11-2012 10-29-2013 Alive/LFU
1.50 none Yes NR NA NA AZA No AZANX 1 Y   06/01/2009                    01-06-2009 12 09-23-2012 NA NA NA Yes 9999 Persistent PR 01-21-2008 09-23-2012 Alive/LFU
2.00 none Yes NR NA NA Splenect No SPLENECT   03/03/2008                    03-03-2008 6 04-08-2011 NA NA NA Yes 25-02-08 6 38 Remission CR 09-13-2007 04-08-2011 Alive/LFU
2.50 none Yes NR NA NA DDS No DDS X 3 M   10/07/2010                    07-10-2010 34 07-03-2012 NA NA NA No Chronic ITP 09-22-2007 07-03-2012 Alive/LFU
2 none No CR 31 No NA NA 01/08/2010                    01-08-2010 24 09-12-2011 NR NA Yes No Persistent 02-01-2008 09-12-2011 Alive/LFU
ostimem efsdate efsstatus efstimem Time from 1st response to relapse/response date (months)
49 No event 49 45
42 No event 42 41
19 No event 19 17
23 No event 23 21
5 06-16-2009 event 5
10 No event 10 6
41 No event 41 38
27 No event 27 24
8 No event 8 4
41 02-15-2012 event 37 39
5 08-25-2009 event 5
32 12-01-2009 event 6
52 04-30-2010 event 15 44
29 06-30-2010 event 17 26
25 No event 25 22
49 04-09-2010 event 14 11
27 08-04-2009 event 4
7 No event 7 3
14 09-08-2009 event 6
21 09-20-2010 event 18 9
39 05-14-2010 event 14 37
4 07-14-2009 event 4
11 No event 11 10
40 03-12-2010 event 12 38
24 07-01-2009 event 4
7 07-19-2009 event 3
37 No event 37 36
11 No event 11 6
34 No event 34 33
44 01-01-2010 event 5
6 11-03-2009 event 6
48 11-17-2009 event 6
45 10-04-2009 event 3
49 12-18-2009 event 9 46
17 09-18-2009 event 6 14
21 No event 21 19
36 05-15-2009 event 6
50 08-12-2011 event 28 43
5 No event 5 4
48 03-25-2011 event 23 45
8 No event 8 8
25 No event 25 14
41 01-04-2011 event 14 35
14 12-10-2009 event 6
13 No event 13 12
5 No event 5 3
38 No event 38 37
20 06-19-2008 event 5
45 No event 45 44
23 03-09-2010 event 10 19
39 12-02-2009 event 6
39 No event 39 38
43 No event 43 41
46 05-18-2010 event 10 44
13 11-23-2012 event 5
7 03-24-2010 event 5
45 06-20-2012 event 35 43
42 01-01-2010 event 5
6 03-02-2010 event 6
44 No event 44 43
8 01-11-2010 event 5
45 01-21-2011 event 17 44
45 01-04-2010 event 5
25 03-30-2010 event 10 21
5 No event 5 4
18 No event 18 17
22 No event 22 19
12 10-27-2009 event 2
47 11-19-2010 event 12 45
32 03-20-2010 event 6
43 04-16-2010 event 6
14 No event 14 13
23 05-13-2011 event 14 17
26 06-08-2010 event 5
21 07-19-2010 event 6
29 01-28-2009 event 6
36 No event 36 35
74 No event 74 71
6 03-09-2010 event 6
4 03-09-2010 event 4
6 04-13-2010 event 6
12 05-11-2010 event 6 9
41 03-01-2011 event 14 36
43 06-02-2010 event 6
39 No event 39 33
18 05-24-2011 event 16 14
28 07-08-2010 event 6
71 05-15-2010 event 27 65
20 No event 20 18
5 No event 5 4
5 No event 5 4
37 05-29-2012 event 28 35
28 No event 28 27
12 08-10-2010 event 6
18 02-11-2011 event 12 16
33 08-05-2011 event 13 32
4 05-14-2010 event 4
9 09-23-2010 event 6
35 No event 35 29
36 09-28-2012 event 26 33
39 11-02-2010 event 6
38 09-22-2010 event 6
10 01-24-2011 event 3
14 08-31-2010 event 6
3 No event 3 2
10 12-11-2010 event 6
23 No event 23 21
41 09-03-2010 event 4
3 09-14-2010 event 3
36 01-31-2011 event 6
21 03-16-2012 event 21 20
21 12-03-2010 event 4
9 No event 9 8
25 03-25-2011 event 6
14 No event 14 13
23 No event 23 22
18 06-16-2011 event 12 14
18 12-14-2010 event 5
42 No event 42 38
34 No event 34 30
37 No event 37 31
8 09-23-2011 event 8 7
16 No event 16 15
22 10-28-2010 event 3
36 No event 36 35
12 03-11-2011 event 6
35 06-26-2012 event 23 35
24 04-19-2013 event 21 18
14 No event 14 11
77 10-13-2009 event 28 76
32 08-23-2011 event 10 31
7 07-26-2011 event 6
8 08-27-2013 event 6
27 No event 27 23
11 05-13-2011 event 5
27 04-29-2011 event 6
32 04-15-2011 event 5
11 03-27-2011 event 5
8 No event 8 1
33 07-05-2013 event 33 32
37 01-21-2011 event 5
15 01-01-2011 event 5
22 No event 22 20
30 06-20-2012 event 14 26
30 No event 30 27
20 10-11-2013 event 20 18
34 No event 34 33
44 No event 44 43
19 09-14-2011 event 6
16 09-22-2011 event 6
22 08-12-2011 event 6
19 09-08-2011 event 6
10 08-15-2011 event 5
32 06-03-2011 event 5
31 01-17-2012 event 11 27
34 05-17-2011 event 5
28 06-18-2013 event 24 27
24 No event 24 20
25 03-30-2013 event 18 17
25 No event 25 24
14 10-08-2012 event 5 12
28 12-20-2011 event 6
26 No event 26 25
29 08-16-2011 event 6
30 07-08-2011 event 4
30 08-01-2011 event 6
9 No event 9 8
15 No event 15 12
15 05-01-2012 event 4
6 No event 6 3
5 12-20-2011 event 5
19 04-17-2012 event 5
20 01-24-2012 event 6
29 11-04-2011 event 6
35 06-04-2011 event 7 32
27 04-27-2013 event 24 24
18 05-01-2012 event 13 14
5 08-23-2013 event 5
10 No event 10 9
11 10-06-2011 event 6
15 07-12-2011 event 3
15 09-06-2011 event 5
28 No event 28 27
21 02-09-2012 event 6
12 06-18-2012 event 8 11
19 03-23-2012 event 2
22 No event 22 15
16 06-29-2012 event 6
14 01-08-2013 event 6
19 No event 19 18
21 No event 21 12
19 No event 19 18
17 06-18-2013 event 14 15
20 04-03-2012 event 5
17 02-07-2012 event 6 16
27 10-04-2013 event 25 22
26 02-02-2012 event 6 23
5 No event 5 3
5 02-16-2012 event 5
11 03-18-2012 event 6
22 06-15-2012 event 6
24 No event 24 23
11 04-25-2012 event 6
17 No event 17 15
10 04-13-2012 event 6
21 10-01-2013 event 20 20
21 No event 21 19
16 No event 16 13
5 No event 5 2
15 No event 15 14
17 No event 17 15
20 08-24-2013 event 19 18
7 No event 7 6
3 08-23-2013 event 3
8 No event 8 7
17 07-09-2012 event 5
6 No event 6 4
15 No event 15 12
18 No event 18 15
4 09-14-2012 event 4
15 No event 15 11
9 08-02-2013 event 6
11 06-22-2012 event 3
18 07-20-2012 event 3
6 No event 6 5
16 11-30-2012 event 6
6 No event 6 3
16 11-28-2012 event 6
17 09-06-2013 event 16 14
16 09-06-2013 event 15 11
16 11-27-2012 event 5
9 No event 9 6
12 01-03-2013 event 6
11 No event 11 10
10 No event 10 7
14 02-05-2013 event 9 12
16 09-21-2012 event 3 15
14 No event 14 11
12 No event 12 9
13 11-09-2012 event 6
65 07-18-2006 event 26 64
41 11-08-2005 event 18 38
77 01-04-2008 event 6
37 No event 37 27
9 No event 9 8
60 12-16-2005 event 5
20 01-24-2006 event 3
38 08-21-2008 event 36 37
32 06-02-2006 event 25 29
26 07-11-2008 event 5
89 06-13-2006 event 11 86
44 05-07-2011 event 44 41
82 05-15-2007 event 6
17 No event 17 14
35 No event 35 32
57 02-26-2009 event 16 9
15 02-18-2008 event 6
57 03-14-2008 event 6
22 No event 22 20
68 10-23-2012 event 60 58
54 07-17-2009 event 16 12
44 08-03-2007 event 44 43
42 03-11-2008 event 2 0
67 03-28-2008 event 4
61 12-18-2008 event 10 8
70 09-29-2009 event 21 20
51 11-16-2008 event 6
64 No event 64 60
4 03-30-2010 event 4
13 08-26-2008 event 5
38 04-03-2012 event 23 35
2 No event 2 1
51 No event 51 48
7 09-10-2008 event 6
12 No event 12 10
44 11-11-2008 event 5
57 07-22-2011 event 39 52
11 02-03-2009 event 6
56 09-24-2008 event 4
16 No event 16 16
50 08-26-2008 event 4
10 No event 10 5
30 No event 30 27
31 No event 31 28
61 11-17-2008 event 6
41 02-23-2009 event 5
7 02-17-2009 event 6
6 No event 6 3
59 No event 59 50
25 No event 25 22
10 01-12-2009 event 6
37 No event 37 29
9 03-06-2009 event 6
5 12-03-2008 event 5
5 No event 5 3
14 01-21-2013 event 4
57 04-04-2008 event 2
43 02-14-2008 event 5
58 02-03-2008 event 4
44 09-12-2011 event 44 41
